

Contents

1	Experimental	4
1.1	Methyl 3-oxodecanoate 21	4
1.2	Methyl (<i>E</i>)-3-((4-((<i>tert</i> -butoxycarbonyl)amino)phenyl)amino)dec-2-enoate 24	5
1.3	6-Amino-2-heptylquinolin-4-ol 25	5
1.4	6-Azido-2-heptylquinolin-4-ol 26	6
1.5	Heptyl magnesium bromide 28	7
1.6	2-Chloro- <i>N</i> -methoxy- <i>N</i> -methylacetamide 30	7
1.7	1-Chlorononan-2-one 31	8
1.8	2-Oxononyl 2-amino-5-nitrobenzoate 33	8
1.9	6-Nitro-2-heptyl-3-hydroxyquinolin-4(1 <i>H</i>)-one 34	9
1.10	(<i>S</i>)-3-Aminodihydrofuran-2(3 <i>H</i>)-one hydrobromide 38	10
1.11	(<i>S</i>)-2-Bromo- <i>N</i> -(2-oxotetrahydrofuran-3-yl)acetamide 40	10
1.12	(<i>S</i>)-2-Azido- <i>N</i> -(2-oxotetrahydrofuran-3-yl)acetamide 41	11
1.13	(<i>S</i>)-4-Bromo- <i>N</i> -(2-oxotetrahydrofuran-3-yl)butanamide 44	12
1.14	(<i>S</i>)-6-Bromo- <i>N</i> -(2-oxotetrahydrofuran-3-yl)hexanamide 45	12
1.15	(<i>S</i>)-6-Azido- <i>N</i> -(2-oxotetrahydrofuran-3-yl)hexanamide 47	13
1.16	Hex-5-ynal 49	14
1.17	<i>tert</i> -Butyl 4-(hex-5-yn-1-yl)piperazine-1-carboxylate 51	14
1.18	1-(Hex-5-yn-1-yl)piperazine 52	15
1.19	1-Cyclopropyl-6-fluoro-7-(4-(hex-5-yn-1-yl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 54	16
1.20	4-((2,4-Diaminopyrimidin-5-yl)methyl)-2,6-dimethoxyphenol 124	17
1.21	5-(4-(Hex-5-yn-1-yloxy)-3,5-dimethoxybenzyl)pyrimidine-2,4-diamine 125	17
1.22	(<i>S</i>)-1-Cyclopropyl-6-fluoro-4-oxo-7-(4-(4-(1-(2-oxo-2-((2-oxotetrahydrofuran-3-yl)amino)ethyl)-1 <i>H</i> -1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid 126	18
1.23	(<i>S</i>)-1-Cyclopropyl-6-fluoro-4-oxo-7-(4-(4-(1-(4-oxo-4-((2-oxotetrahydrofuran-3-yl)amino)butyl)-1 <i>H</i> -1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid 127	19
1.24	(<i>S</i>)-1-Cyclopropyl-6-fluoro-4-oxo-7-(4-(4-(1-(6-oxo-6-((2-oxotetrahydrofuran-3-yl)amino)hexyl)-1 <i>H</i> -1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid 128	21
1.25	1-Cyclopropyl-6-fluoro-7-(4-(4-(1-(2-heptyl-4-oxo-1,4-dihydroquinolin-6-yl)-1 <i>H</i> -1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 129	22
1.26	(<i>S</i>)-4-(4-(4-(4-((2,4-Diaminopyrimidin-5-yl)methyl)-2,6-dimethoxyphenoxy)butyl)-1 <i>H</i> -1,2,3-triazol-1-yl)- <i>N</i> -(2-oxotetrahydrofuran-3-yl)butanamide 130	23
1.27	(<i>S</i>)-6-(4-(4-(4-((2,4-Diaminopyrimidin-5-yl)methyl)-2,6-dimethoxyphenoxy)butyl)-1 <i>H</i> -1,2,3-triazol-1-yl)- <i>N</i> -(2-oxotetrahydrofuran-3-yl)hexanamide 131	23
1.28	6-(4-(4-(4-((2,4-Diaminopyrimidin-5-yl)methyl)-2,6-dimethoxyphenoxy)butyl)-1 <i>H</i> -1,2,3-triazol-1-yl)-2-heptylquinolin-4(1 <i>H</i>)-one 132	24
1.29	2-(6-(4-(4-(4-((2,4-Diaminopyrimidin-5-yl)methyl)-2,6-dimethoxyphenoxy)butyl)-1 <i>H</i> -1,2,3-triazol-1-yl)hexyl)-3-hydroxyquinolin-4(1 <i>H</i>)-one 133	25
1.30	Methyl 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate 134	27
1.31	4-Bromo- <i>N</i> -(2-oxotetrahydrothiophen-3-yl)butanamide 135	27
1.32	4-Azido- <i>N</i> -(2-oxotetrahydrothiophen-3-yl)butanamide 136	28

1.33	Methyl 1-cyclopropyl-6-fluoro-4-oxo-7-(4-(4-oxo-4-((2-oxotetrahydrothiophen-3-yl)amino)butyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate 137	29
1.34	1-Cyclopropyl-6-fluoro-4-oxo-7-(4-(4-(1-(4-oxo-4-((2-oxotetrahydrothiophen-3-yl)amino)butyl)-1H-1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid 138	30
1.35	1-Cyclopropyl-6-fluoro-4-oxo-7-(4-(((4-(1-(4-oxo-4-((2-oxotetrahydrothiophen-3-yl)amino)butyl)-1H-1,2,3-triazol-4-yl)butanoyl)oxy)methoxy)carbonyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid 139	31
1.36	1-Cyclopropyl-6-fluoro-4-oxo-7-(4-(((1-((4-(1-(4-oxo-4-((2-oxotetrahydrothiophen-3-yl)amino)butyl)-1H-1,2,3-triazol-4-yl)butanoyl)oxy)ethoxy)carbonyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid 140	32
1.37	4-Bromo- <i>N</i> -(2-methoxyphenyl)butanamide 141	32
1.38	4-Bromo- <i>N</i> -(3-methoxyphenyl)butanamide 142	33
1.39	4-Azido- <i>N</i> -(2-methoxyphenyl)butanamide 143	34
1.40	4-Azido- <i>N</i> -(3-methoxyphenyl)butanamide 144	34
1.41	Methyl 1-cyclopropyl-6-fluoro-7-(4-(4-((2-methoxyphenyl)amino)-4-oxobutyl)-piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate 145	35
1.42	Methyl 1-cyclopropyl-6-fluoro-7-(4-(4-((3-methoxyphenyl)amino)-4-oxobutyl)-piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate 146	36
1.43	1-Cyclopropyl-6-fluoro-7-(4-(4-(1-(4-((2-methoxyphenyl)amino)-4-oxobutyl)-1H-1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 147	37
1.44	1-Cyclopropyl-6-fluoro-7-(4-(4-(1-(4-((3-methoxyphenyl)amino)-4-oxobutyl)-1H-1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 148	38
1.45	Methyl 7-(4-(4-(<i>tert</i> -butoxy)-4-oxobutyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate 149	40
1.46	4-(4-(1-Cyclopropyl-6-fluoro-3-(methoxycarbonyl)-4-oxo-1,4-dihydroquinolin-7-yl)piperazin-1-yl)butanoic acid, trifluoroacetic acid salt 150	41
1.47	(1 <i>S</i> ,2 <i>S</i>)-2-(((<i>S</i>)-1-Phenylethyl)amino)cyclopentan-1-ol 151 and (1 <i>R</i> ,2 <i>R</i>)-2-(((<i>S</i>)-1-phenylethyl)amino)cyclopentan-1-ol 152	42
1.48	(1 <i>S</i> ,2 <i>S</i>)-2-Aminocyclopentan-1-ol 153	43
1.49	(1 <i>R</i> ,2 <i>R</i>)-2-Aminocyclopentan-1-ol 154	44
1.50	(1 <i>R</i> ,2 <i>R</i>)-2-((<i>tert</i> -butyldimethylsilyl)oxy)cyclopentan-1-amine 155	44
1.51	4-Chloro- <i>N</i> -((1 <i>S</i> ,2 <i>S</i>)-2-hydroxycyclopentyl)butanamide 156	45
1.52	4-Chloro- <i>N</i> -((1 <i>R</i> ,2 <i>R</i>)-2-hydroxycyclopentyl)butanamide 157	46
1.53	4-Azido- <i>N</i> -((1 <i>R</i> ,2 <i>R</i>)-2-((<i>tert</i> -butyldimethylsilyl)oxy)cyclopentyl)butanamide 158	46
1.54	4-Azido- <i>N</i> -((1 <i>S</i> ,2 <i>S</i>)-2-hydroxycyclopentyl)butanamide 159	47
1.55	4-Azido- <i>N</i> -((1 <i>R</i> ,2 <i>R</i>)-2-hydroxycyclopentyl)butanamide 160	48
1.56	Methyl 1-cyclopropyl-6-fluoro-7-(4-(4-(((1 <i>S</i> ,2 <i>S</i>)-2-hydroxycyclopentyl)amino)-4-oxobutyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate 161	49
1.57	Methyl 1-cyclopropyl-6-fluoro-7-(4-(4-(((1 <i>R</i> ,2 <i>R</i>)-2-hydroxycyclopentyl)amino)-4-oxobutyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate 162	50
1.58	Methyl (<i>R</i>)-1-cyclopropyl-6-fluoro-4-oxo-7-(4-(4-oxo-4-((2-oxocyclopentyl)amino)butyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate 163	51
1.59	7-(4-(4-(1-(4-(((1 <i>R</i> ,2 <i>R</i>)-2-((<i>tert</i> -butyldimethylsilyl)oxy)cyclopentyl)amino)-4-oxobutyl)-1H-1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 164	52
1.60	1-Cyclopropyl-6-fluoro-7-(4-(4-(1-(4-(((1 <i>S</i> ,2 <i>S</i>)-2-hydroxycyclopentyl)amino)-4-oxobutyl)-1H-1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 165	53

1.61	1-Cyclopropyl-6-fluoro-7-(4-(4-(1-(4-(((1 <i>R</i> ,2 <i>R</i>)-2-hydroxycyclopentyl)amino)-4-oxobutyl)-1 <i>H</i> -1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 166	54
1.62	(<i>trans</i>)-2-Aminocyclohexan-1-ol 167	55
1.63	4-Chloro- <i>N</i> -(((<i>trans</i>)-2-hydroxycyclohexyl)butanamide 168	55
1.64	4-Azido- <i>N</i> -(((<i>trans</i>)-2-hydroxycyclohexyl)butanamide 169	56
1.65	Methyl 1-cyclopropyl-6-fluoro-7-(4-(4-(((<i>trans</i>)-2-hydroxycyclohexyl)amino)-4-oxobutyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate 170	57
1.66	Methyl 1-cyclopropyl-6-fluoro-4-oxo-7-(4-(4-oxo-4-((2-oxocyclohexyl)amino)-butyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate 171	58
1.67	1-Cyclopropyl-6-fluoro-7-(4-(4-(1-(4-(((<i>trans</i>)-2-hydroxycyclohexyl)amino)-4-oxobutyl)-1 <i>H</i> -1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 172	59
1.68	1-Cyclopropyl-6-fluoro-4-oxo-7-(4-(4-(1-(4-oxo-4-((2-oxocyclohexyl)amino)butyl)-1 <i>H</i> -1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid 173	60


2 References

62

1 Experimental

1.1 Methyl 3-oxodecanoate **21**

fix eps



Meldrum's acid (9.0 g, 63 mmol, 1 eq.) was dissolved in anhydrous CH_2Cl_2 (150 mL) and cooled to 0 °C. Pyridine (10.2 mL, 126 mmol, 2 eq.) was added dropwise over 20 min. Octanoyl chloride (11.7 mL, 69 mmol, 1.1 eq.) was then added and the mixture was stirred at 0 °C for a further 4 h. The mixture was allowed to warm to r.t., diluted with CH_2Cl_2 (20 mL) and poured into a mixture of ice (~ 30 g) and HCl (2 N, 90 mL). The solution was washed with NaCl (sat., aq., 150 mL) and dried over MgSO_4 . The solvent was removed under vacuum to give an orange-brown oil. The oil was refluxed in anhydrous MeOH (150 mL) for 5 h and the solvent was removed under vacuum. The resulting residue was purified by column chromatography (SiO_2 , 5 % Et_2O /40-60 P.E.) to give a tautomeric mixture of **21** and **22** as a colourless oil (8.34 g, 41.6 mmol, 66 %, 92 % **21** as determined by NMR).

Keto form **21**

TLC R_f = 0.12 (5 % EtO_2 /PE)

IR (neat) ν_{max} / cm^{-1} = 2927.84 (C-H), 2856.26 (C-H), 1746.86 (ester C=O), 1716.70 (ketone C=O)

^1H NMR (400 MHz, CDCl_3) δ / ppm = 3.74 (s, 3 H, OCH_3), 3.45 (s, 2 H, $\text{C}(=\text{O})\text{CH}_2\text{C}(=\text{O})$), 2.53 (t, J = 7.4 Hz, 2 H, $\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$), 1.60 (quin, J = 7.1 Hz, 2 H, $\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$), 1.39 - 1.19 (m, 8 H, $\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$), 0.88 (t, J = 6.8 Hz, 3 H, $\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$)

^{13}C NMR (101 MHz, CDCl_3) δ / ppm = 202.3 ($\text{CH}_3\text{OC}(=\text{O})\text{CH}_2\text{C}(=\text{O})$), 167.3 ($\text{CH}_3\text{OC}(=\text{O})\text{CH}_2\text{C}(=\text{O})$), 51.7 (OCH_3), 48.5 ($\text{CH}_3\text{OC}(=\text{O})\text{CH}_2\text{C}(=\text{O})$), 42.5 (CH_2), 31.3 (CH_2), 28.7 (CH_2), 28.6 (CH_2), 23.1 (CH_2), 22.2 (CH_2), 13.6 (CH_3)

Enol form **22**

TLC R_f = 0.12 (5 % EtO_2 /PE)


IR (neat) ν_{max} / cm^{-1} = 2927.84 (C-H), 2856.26 (C-H), 1653.80 (C=C), 1629.21 (α,β unsaturated C=O)

^1H NMR (400 MHz, CDCl_3) δ / ppm = 12.02 (s, 1 H, COH), 4.99 (s, 1 H, $\text{C}(=\text{O})\text{CH}=\text{COH}$), 3.73 (s, 3 H, OCH_3), 2.20 (t, J = 7.4 Hz, 2 H, $\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$), 1.76 - 1.72 (m, 2 H, $\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$), 1.39 - 1.19 (m, 8 H, $\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$), 0.88 (t, J = 6.8 Hz, 3 H, $\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$)

^{13}C NMR (101 MHz, CDCl_3) δ / ppm = 178.7 ($\text{CH}_3\text{OC}(=\text{O})\text{CH}=\underline{\text{C}}\text{OH}$), 172.7 ($\text{CH}_3\text{OC}(=\text{O})\text{CH}=\text{COH}$), 88.2 ($\text{CH}_3\text{OC}(=\text{O})\underline{\text{C}}\text{H}=\text{COH}$), 50.5 ($\text{OC}\underline{\text{H}}_3$), 37.9 ($\underline{\text{C}}\text{H}_2$), 34.6 ($\underline{\text{C}}\text{H}_2$), 31.2 ($\underline{\text{C}}\text{H}_2$), 29.0 ($\underline{\text{C}}\text{H}_2$), 25.9 ($\underline{\text{C}}\text{H}_2$), 22.3 ($\underline{\text{C}}\text{H}_2$), 13.6 ($\underline{\text{C}}\text{H}_3$)

Spectroscopic data are consistent with the literature.^{1,2}

1.2 Methyl (*E*)-3-((4-((*tert*-butoxycarbonyl)amino)phenyl)amino)dec-2-enoate **24**



Methyl 3-oxodecanoate **21** (500 mg, 2.50 mmol, 1.00 eq.) and *tert*-butyl (4-aminophenyl)carbamate **174** (520 mg, 2.50 mmol, 1.00 eq.) were dissolved in MeOH (10 mL) and refluxed for 18 h. The solvent was removed under vacuum and the resulting residue was purified by column chromatography (SiO_2 , gradient of 0 to 20 % $\text{Et}_2\text{O}/40\text{-}60$ P.E.) to give a white powder (0.169 mg, 0.480 mmol, 19 %).

TLC R_f = 0.30 (30 % $\text{Et}_2\text{O}/40\text{-}60$ P.E.)

mp T / $^\circ\text{C}$ = 78.8 ($\text{Et}_2\text{O}/40\text{-}60$ P.E.)

IR (neat) ν_{max} / cm^{-1} = 3336.97 (N-H), 2927.71 (C-H), 2857.14 (C-H), 1723.71 (carbamate C=O), 1634.49 (α,β unsaturated C=O), 1610.73 (C=C), 1580.85 (N-H bend)


^1H NMR (400 MHz, CDCl_3) δ / ppm = 10.16 (s, 1 H, $\text{NH}\underline{\text{C}}(\text{C}_7\text{H}_{15})=\text{C}$), 7.35 (d, J = 8.6 Hz, 2 H, *meta* to NHBoc), 7.02 (d, J = 8.7 Hz, 2 H, *meta* to enamine), 6.60 (br s, 1 H, $\text{NH}\underline{\text{Boc}}$), 4.71 (s, 1 H, $\text{C}=\underline{\text{C}}\text{H}$), 3.70 (s, 3 H, $\text{OC}\underline{\text{H}}_3$), 2.23 (t, J = 7.7 Hz, 2 H, $\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$), 1.54 (s, 9 H, $\text{C}(\underline{\text{C}}\text{H}_3)_3$), 1.40 (quin, J = 7.3 Hz, 2 H, $\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$), 1.33 - 1.16 (m, 8 H, $\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$), 0.86 (t, J = 7.1 Hz, 3 H, $\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$)

^{13}C NMR (101 MHz, CDCl_3) δ / ppm = 171.1 ($\underline{\text{C}}(=\text{O})\text{CH}=\text{C}$), 164.3 ($\text{C}(=\text{O})\text{CH}=\underline{\text{C}}$), 152.7 ($\text{OC}(=\text{O})\text{NH}$), 136.0 (*para* to NHBoc), 134.1 ($\underline{\text{C}}\text{NHBoc}$), 126.3 (*meta* to NHBoc), 119.1 (*ortho* to NHBoc), 83.8 ($\text{C}(=\text{O})\underline{\text{C}}\text{H}=\text{C}$), 80.7 ($\underline{\text{C}}(\text{CH}_3)_3$), 50.2 ($\text{OC}\underline{\text{H}}_3$), 32.2 ($\underline{\text{C}}\text{H}_2$), 31.6 ($\underline{\text{C}}\text{H}_2$), 29.1 ($\underline{\text{C}}\text{H}_2$), 28.8 ($\underline{\text{C}}\text{H}_2$), 28.3 ($\text{C}(\underline{\text{C}}\text{H}_3)_3$), 28.0 ($\underline{\text{C}}\text{H}_2$), 22.6 ($\underline{\text{C}}\text{H}_2$), 14.0 ($\underline{\text{C}}\text{H}_3$)

HRMS (ESI^+) m/z / Da = 391.2589, $[\text{M}+\text{H}]^+$, $[\text{C}_{22}\text{H}_{35}\text{N}_2\text{O}_4]^+$ requires 391.2591

1.3 6-Amino-2-heptylquinolin-4-ol **25**

NMR
wrong?
not
tau-
tomer?



Methyl (*E*)-3-((4-((tert-butoxycarbonyl)amino)phenyl)amino)dec-2-enoate **24** (168 mg, 0.649 mmol, 1 eq.) and polyphosphoric acid (5 g) were heated to 90 °C for 1 h. The reaction mixture was then poured into NaHCO₃ (sat., aq., 50 mL) cooled with ice. The precipitate was collected by vacuum filtration, washed with water (50 mL) and dried under high vacuum to give a pale yellow powder (121 mg, 0.468 mmol, 72 %).

mp *T* / °C = 249 (H₂O)


IR (neat) ν_{max} / cm⁻¹ = 3336.52 (N-H), 2926.47 (C-H), 2856.89 (C-H), 1723.88 (aromatic), 1634.48 (aromatic), 1610.84 (aromatic), 1583.26 (aromatic), 1519.06 (aromatic)

¹H NMR (400 MHz, DMSO-d₆) δ / ppm = 7.26 (d, *J* = 8.7 Hz, 1 H, *meta* to NH₂), 7.15 (d, *J* = 2.6 Hz, 1 H, *para* to COH), 6.95 (dd, *J* = 2.7, 8.8 Hz, 1 H, *ortho* to COH), 5.74 (s, 1 H, *ortho* to OH), 5.16 (s, 2 H, NH₂), 2.52 (t, *J* = 7.4 Hz, 2 H, CH₂CH₂CH₂CH₂CH₂CH₂CH₃), 1.64 (quin, *J* = 7.6 Hz, 2 H, CH₂CH₂CH₂CH₂CH₂CH₂CH₃), 1.36 - 1.19 (m, 8 H, CH₂CH₂CH₂CH₂CH₂CH₂CH₃), 0.86 (t, *J* = 7.0 Hz, 3 H, CH₂CH₂CH₂CH₂CH₂CH₂CH₃)

¹³C NMR (101 MHz, DMSO-d₆) δ / ppm = 176.7 (C=O), 151.7 (CCH₂CH₂CH₂CH₂CH₂CH₂CH₃), 145.1 (C=NH₂), 132.4 (*para* to NH₂), 126.6 (*para* to CH₂CH₂CH₂CH₂CH₂CH₂CH₃), 121.1 (*ortho* to NH₂ and *para* to COH), 119.0 (*meta* to NH₂ and *meta* to COH), 106.2 (*ortho* to NH₂ and *ortho* to COH), 105.9 (*ortho* to CH₂CH₂CH₂CH₂CH₂CH₂CH₃ and *ortho* to OH), 33.6 (CH₂), 31.6 (CH₂), 29.0 (CH₂), 29.0 (CH₂), 28.9 (CH₂), 22.5 (CH₂), 14.4 (CH₃)

HRMS (ESI⁺) *m/z* / Da = 259.1810, [M+H]⁺, [C₁₆H₂₃N₂O]⁺ requires 259.1803

1.4 6-Azido-2-heptylquinolin-4-ol **26**



6-Amino-2-heptylquinolin-4-ol **25** (50 mg, 0.194 mmol, 1 eq) was dissolved in HCl (conc., aq., 1.20 ml), water (1.80 ml) and MeOH (2.00 ml) and cooled to 0 °C. A solution of NaNO₂ (16.0 mg, 0.232 mmol, 1.2 eq.) in water (0.300 ml) was added dropwise over 10 min and the mixture was stirred for 1 h. A solution of NaN₃ (15.1 mg, 0.232 mmol, 1.2 eq.) in water (0.300 ml) was then added. The mixture was warmed to room temperature and stirred for a further 4 h. The resultant precipitate was filtered off and dried under reduced pressure. **26** was obtained as a pale cream amorphous solid (25.6 mg, 0.0900 mmol, 46.5 %).

TLC *R_f* = 0.40 (5 % MeOH/CH₂Cl₂)

check
for con-
sistent
prod
report-
ing

mp $T / ^\circ\text{C} = ??$ (??)


IR (neat) $\nu_{\text{max}} / \text{cm}^{-1} = ??$

^1H NMR (400 MHz, MeOD) $\delta / \text{ppm} = 7.73$ (d, $J = 8.6$ Hz, 1 H, *ortho* to NH), 7.71 (d, $J = 2.8$ Hz, 1 H, *ortho* to N_3 and *ortho* to $\text{C}(=\text{O})$), 7.47 (dd, $J = 8.9, 2.7$ Hz, 1 H, *para* to $\text{C}(=\text{O})$), 6.24 (s, 1 H, $\text{C}(=\text{O})\text{CH}$), 2.69 (t, $J = 7.7$ Hz, 2 H, NHCCH_2), 1.68 (quin, $J = 7.6$ Hz, 2 H, $\text{NHCCH}_2\text{CH}_2$), 1.28 - 1.39 (m, 4 H, $\text{NHCCH}_2\text{CH}_2\text{CH}_2\text{CH}_2$), 1.18 - 1.28 (m, 4 H, $\text{CH}_2\text{CH}_2\text{CH}_3$), 0.85 (t, $J = 6.8$ Hz, 3 H, CH_3)

^{13}C NMR (101 MHz, MeOD) $\delta / \text{ppm} = 172.3$ ($\text{C}(=\text{O})$), 155.5 (NHCCH_2), 137.4 (CN_3), 135.6 (*para* to N_3), 124.6 (*para* to $\text{C}(=\text{O})$), 124.1 (*ipso* to $\text{C}(=\text{O})$), 120.7 (*meta* to N_3 and *meta* to $\text{C}(=\text{O})$), 112.8 (*ortho* to N_3 and *ortho* to $\text{C}(=\text{O})$), 107.0 ($\text{C}(=\text{O})\text{CH}$), 33.3 (NHCCH_2), 31.2 ($\text{CH}_2\text{CH}_2\text{CH}_3$), 28.3 - 28.5 ($\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$), 22.1 (CH_2CH_3), 14.0 (CH_3)


HRMS (ESI^+) $m/z / \text{Da} = ??$, $[\text{M}+\text{H}]^+$ found, $[??]^+$ requires ??

1.5 Heptyl magnesium bromide 28



Magnesium turnings (352 mg, 14.5 mmol, 1 eq.) were added to a dry flask under argon. THF (15 mL) was added, followed by bromoheptane (2.40 mL, 14.5 mmol, 1 eq.) dropwise. The mixture was stirred at r.t. for 2 h followed by heating to reflux for 2 h to give the Grignard reagent as a pale grey suspension (15 mL, ~ 1 M) which was used without further purification.

1.6 2-Chloro-*N*-methoxy-*N*-methylacetamide 30



N,*O*-Dimethylhydroxyl amine hydrochloride (6.00 g, 61.5 mmol, 1 eq.) and toluene (75 mL) were added successively to a solution of potassium carbonate (22.4 g, 162 mmol, 2.63 eq.) in water (75 mL) at 0°C under argon. The mixture was cooled to -5°C and chloroacetyl chloride (5.88 mL, 73.8 mmol, 1.20 eq.) was added dropwise over 5 min. The mixture was allowed to warm to r.t. over 30 min, then the organic layer was separated and the aqueous layer was extracted with toluene (3×20 mL). The four combined organic extracts were dried with MgSO_4 and the solvent was removed by rotary evaporation followed by high vacuum to give white, prism-like crystals (7.24 g, 52.6 mmol, 71 %).

mp $T / ^\circ\text{C} = 38.8$ (toluene)


IR (neat) $\nu_{\text{max}} / \text{cm}^{-1} = 3016.69$ (C-H), 2966.38 (C-H), 2946.75 (C-H), 2827.73 (C-H), 1666.20 ($\text{C}=\text{O}$)

^1H NMR (400 MHz, CDCl_3) $\delta / \text{ppm} = 4.20$ (s, 2 H, $\text{ClCH}_2\text{C}=\text{O}$), 3.71 (m, 3 H, OCH_3), 3.18 (s, 3 H, NCH_3)

^{13}C NMR (101 MHz, CDCl_3) δ / ppm = 167.4 (C=O), 61.6 (OCH_3), 40.9 ($\text{ClCH}_2\text{C=O}$), 32.6 (NCH_3)

Spectroscopic data are consistent with the literature.³

1.7 1-Chlorononan-2-one **31**



2-Chloro-*N*-methoxy-*N*-methylacetamide (1.00 g, 7.26 mmol, 1 eq.) was added to a dry flask under argon. THF (20 mL) was added and the flask cooled to 0 °C. Heptyl magnesium bromide (~ 1 M, 15.0 mL, 15.0 mmol, 2.07 eq.) was added dropwise over 5 min, then the mixture was allowed to warm to r.t. and stirred for 15 h. The reaction mixture was then poured into HCl (aq., 2 N, 60 mL) at 0 °C and stirred for 10 min. The mixture was extracted with toluene (30 mL) and the aqueous layer discarded. The organic layer was washed with brine and dried with MgSO_4 . The solvent was removed by rotary evaporation to give a colourless oil (1.23 g, 6.96 mmol, 96 %).


IR (neat) ν_{max} / cm^{-1} = 2951.65 (C-H), 2924.99 (C-H), 2855.46 (C-H), 1720.39 (C=O)

^1H NMR (400 MHz, CDCl_3) δ / ppm = 4.05 (s, 2 H, $\text{ClCH}_2\text{C(=O)}$), 2.54 (t, J = 7.4 Hz, 2 H, $\text{C(=O)CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$), 1.59 (quin, J = 7.0 Hz, 2 H, $\text{C(=O)CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$), 1.34 - 1.21 (m, 8 H, $\text{C(=O)CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$), 0.87 (t, J = 6.8 Hz, 3 H, $\text{C(=O)CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$)

^{13}C NMR (101 MHz, CDCl_3) δ / ppm = 202.6 (C=O), 48.1 (CH_2Cl), 39.6 (C(=O)CH_2), 31.5 ($\text{CH}_2\text{CH}_2\text{CH}_3$), 28.9 (CH_2), 28.9 (CH_2), 23.5 ($\text{C(=O)CH}_2\text{CH}_2$), 22.5 (CH_2CH_3), 13.9 (CH_3)

Spectroscopic data are consistent with the literature.³

1.8 2-Oxononyl 2-amino-5-nitrobenzoate **33**



5-Nitroanthranilic acid (500 mg, 2.75 mmol, 1.38 eq.) and potassium carbonate (270 mg, 2.00 mmol, 1 eq.) were dissolved in DMF (5 ml). The mixture was heated under argon to 90 °C and stirred for 1 h then cooled to r.t.. 1-chlorononan-2-one **31** (353 mg, 2.00 mmol, 1 eq.) was added and the mixture was stirred for 15 h. The solution was poured into Na_2HCO_3 (aq., 10 %, 50 ml) and ice (~ 20 g). The precipitate was collected by vacuum filtration, washed with water and dried under high vacuum to give a yellow powder (0.674 g, 2.00 mmol, 100 %).

mp T / °C = 135 (H_2O)

IR (neat) ν_{max} / cm^{-1} = 3453.32 (N-H), 3350.52 (N-H), 2924.93 (C-H), 2853.87 (C-H), 1720.10 (ester C=O)


1703.91 (ketone C=O) 1626.14 (N-H bend) 1602.74 (aromatic) 1572.48 (N-O) 1506.58 (N-O)

¹H NMR (400 MHz, DMSO-d₆) δ / ppm = 8.66 (d, J = 2.8 Hz, 1 H, *ortho* to C(=O)), 8.12 (dd, J = 2.8, 9.4 Hz, 1 H, *para* to C(=O)), 6.93 (d, J = 9.4 Hz, 1 H, *meta* to C(=O)), 5.05 (s, 2 H, OCH₂C(=O)), 2.49 (t, J = 7.4 Hz, 2 H, C(=O)CH₂CH₂CH₂CH₂CH₂CH₂CH₃), 1.52 (quin, J = 7.2 Hz, 2 H, C(=O)CH₂CH₂CH₂CH₂CH₂CH₂CH₃), 1.32 - 1.20 (m, 8 H, C(=O)CH₂CH₂CH₂CH₂CH₂CH₂CH₃), 0.86 (t, J = 6.8 Hz, 3 H, C(=O)CH₂CH₂CH₂CH₂CH₂CH₂CH₃)

¹³C NMR (101 MHz, DMSO-d₆) δ / ppm = 204.4 (OCH₂C(=O)), 165.6 (C(=O)O), 156.3 (C(NH₂)), 135.7 (CNO₂), 129.6 (*para* to C=O), 128.9 (*ortho* to C=O), 117.4 (*meta* to C=O), 107.5 (CC(=O)O), 68.8 (OCH₂C(=O)), 38.3 (CH₂), 31.6 (CH₂), 28.9 (CH₂), 28.9 (CH₂), 23.2 (CH₂), 22.5 (CH₂), 14.4 (CH₃)

HRMS (ESI⁺) m/z / Da = 323.1610, [M+H]⁺, [C₁₆H₂₃N₂O₅]⁺ requires 323.1607

1.9 6-Nitro-2-heptyl-3-hydroxyquinolin-4(1H)-one 34



2-Oxononyl 2-amino-5-nitrobenzoate (100 mg, 0.340 mmol, 1 eq.) and polyphosphoric acid (300 mg) were stirred for 5.5 h at 90 °C under argon. The mixture was then poured into NaHCO₃ (sat., aq., 50 mL) cooled on ice. The precipitate was collected by vacuum filtration, washed with water (50 mL) and dried under high vacuum to give a yellow-brown powder (44 mg, 0.145 mmol, 43 %) which could be recrystallised from EtOAc to give yellow-brown plate-like crystals.

mp T / °C = 223 (H₂O)


IR (neat) ν_{max} / cm⁻¹ = 3436.01 (N-H), 3000.00 (O-H, br), 2955.37 (C-H), 2925.76 (C-H), 2850.93 (C-H), 1648.18 (aromatic), 1606.05 (aromatic), 1570.67 (N-O), 1536.35 (N-O)

¹H NMR (400 MHz, DMSO-d₆) δ / ppm = 12.00 (s, 1 H, NH), 8.91 (d, J = 2.8 Hz, 1 H, *ortho* to C=O), 8.29 (dd, J = 2.7, 9.2 Hz, 1 H, *para* to C=O), 7.70 (d, J = 9.3 Hz, 1 H, *meta* to C=O), 2.75 (t, J = 7.7 Hz, 2 H, CH₂CH₂CH₂CH₂CH₂CH₂CH₃), 1.67 (quin, J = 7.3 Hz, 2 H, CH₂CH₂CH₂CH₂CH₂CH₂CH₃), 1.36 - 1.23 (m, 8 H, CH₂CH₂CH₂CH₂CH₂CH₂CH₃), 0.85 (t, J = 7.0 Hz, 3 H, CH₂CH₂CH₂CH₂CH₂CH₂CH₃)

¹³C NMR (101 MHz, DMSO-d₆) δ / ppm = 169.7 (C=O), 141.9 (COH), 140.7 (*para* to NO₂), 139.6 (CNO₂), 137.3 (CHCC=O), 124.3 (*ortho* to NO₂ and *ortho* to C=O), 122.3 (*ortho* to NO₂ and *para* to C=O), 121.5 (CCH₂CH₂CH₂CH₂CH₂CH₂CH₃), 120.0 (*meta* to NO₂ and *meta* to C=O), 31.6 (CH₂), 29.2 (CH₂), 28.9 (CH₂), 28.5 (CH₂), 28.1 (CH₂), 22.5 (CH₂), 14.4 (CH₃)

HRMS (ESI⁺) m/z / Da = 305.1501, [M+H]⁺, [C₁₆H₂₁N₂O₄]⁺ requires 305.1500

1.10 (*S*)-3-Aminodihydrofuran-2(3*H*)-one hydrobromide **38**



L-Methionine (3.04 g, 20.4 mmol, 1 eq.) and bromoacetic acid (3.08 g, 22.2 mmol, 1.09 eq.) were dissolved in *i*-PrOH (12.5 mL), H₂O (12.5 mL) and AcOH (5 mL). The reaction was refluxed for 15 h then concentrated under vacuum. The resulting brown oil was added to a mixture of *i*-PrOH (16 mL) and HBr (33 % in AcOH, 4 mL), causing the precipitation of a pale pink powder. The precipitate was collected by filtration and washed with *i*-PrOH (20 mL). The filtrate was concentrated under vacuum and precipitated again using the same procedure. The two crops of precipitate were combined to give a pale pink powder (1.73 g, 9.50 mmol, 41 % yield).

mp $T / ^\circ\text{C} = 242$ (*i*-PrOH/AcOH, gas evolved)

IR (neat) $\nu_{\max} / \text{cm}^{-1} = 2972.09$ (N-H), 2877.54 (N-H), 1771.77 (C=O), 1585.05 (N-H bend), 1572.24 (N-H bend)


¹H NMR (400 MHz, DMSO-*d*₆) $\delta / \text{ppm} = 8.59$ (br s, 3 H, NH_3^+), 4.46 (dt, $J = 1.3, 8.9$ Hz, 1 H, OCH_2), 4.37 (dd, $J = 8.8, 11.4$ Hz, 1 H, CHNH_3^+), 4.29 (ddd, $J = 6.1, 8.8, 10.9$ Hz, 1 H, OCH_2), 2.57 (dddd, $J = 1.2, 6.1, 8.9, 12.3$ Hz, 1 H, OCH_2CH_2), 2.26 (dtd, $J = 9.0, 11.2, 12.2$ Hz, 1 H, OCH_2CH_2)

¹³C NMR (101 MHz, DMSO-*d*₆) $\delta / \text{ppm} = 173.3$ ($\text{C}=\text{O}$), 66.2 (OCH_2), 47.8 (CHNH_3^+), 27.0 (OCH_2CH_2)

$[\alpha]_D^{20} / ^\circ 10^{-1} \text{cm}^2 \text{g}^{-1} = -30.0$ ($c / \text{g}(100 \text{ mL})^{-1} = 0.02$, DMSO)

The data are consistent with the literature.⁴

1.11 (*S*)-2-Bromo-*N*-(2-oxotetrahydrofuran-3-yl)acetamide **40**



(*S*)-3-Aminodihydrofuran-2(3*H*)-one hydrobromide **38** (100 mg, 0.549 mmol, 1.08 eq.) and NaHCO₃ (84.9 mg, 1.01 mmol, 2.00 eq.) were dissolved in CH₂Cl₂ (2 mL) and H₂O (2 mL). Bromoacetyl bromide (44.0 μL , 102 mg, 0.505 mmol, 1.00 eq.) was then added dropwise. The reaction mixture was stirred for 24 h, after which the CH₂Cl₂ was removed under vacuum. The aqueous phase was extracted with EtOAc (4 \times 10 mL) and the combined organic layers were dried with MgSO₄. The solvent was removed under vacuum to give white, needle-like crystals (88.0 mg, 0.396 mmol, 74 %).

mp $T / ^\circ\text{C} = 132$ (EtOAc)

IR (neat) $\nu_{\max} / \text{cm}^{-1} = 3255.69$ (N-H), 3066.58 (C-H), 1763.02 (lactone C=O), 1657.99 (amide C=O), 1552.67

(N-H bend)


¹H NMR (400 MHz, CDCl₃) δ / ppm = 6.95 (br d, 1 H, NH), 4.58 (ddd, J = 5.9, 8.6, 11.7 Hz, 1 H, CHNHC=O), 4.53 (dt, J = 1.0, 9.2 Hz, 1 H, OCH₂), 4.33 (ddd, J = 5.9, 9.4, 11.3 Hz, 1 H, OCH₂), 3.95 (d, J = 1.3 Hz, 2 H, C(=O)CH₂Br), 2.88 (dddd, J = 1.3, 5.9, 8.6, 12.6 Hz, 1 H, OCH₂CH₂), 2.24 (dtd, J = 8.9, 11.5, 12.6 Hz, 1 H, OCH₂CH₂)

¹³C NMR (101 MHz, CDCl₃) δ / ppm = 174.6 (OC=O), 166.4 (C(=O)NH), 66.1 (OCH₂), 49.8 (CHNHC=O), 29.9 (OCH₂CH₂), 28.2 (O=CCH₂Br)

$[\alpha]_D^{20}$ / °10⁻¹cm²g⁻¹ = 27.0 (c / g(100 mL)⁻¹ = 0.0074, CHCl₃)

The data are consistent with the literature.^{4,5}

1.12 (*S*)-2-Azido-*N*-(2-oxotetrahydrofuran-3-yl)acetamide **41**



(3*S*)-2-Oxotetrahydrofuran-3-aminium bromide **38** (100 mg, 0.552 mmol, 1.08 eq.), NaN₃ (85.7 mg, 1.32 mmol, 2.61 eq.) and NaHCO₃ (84.9 mg, 1.01 mmol, 2.00 eq.) were dissolved in CH₂Cl₂ (2 mL) and H₂O (2 mL). Bromoacetyl bromide (44.0 μ L, 102 mg, 0.505 mmol, 1.00 eq.) was then added dropwise. The reaction mixture was stirred for 48 h, after which the CH₂Cl₂ was removed under vacuum. The aqueous phase was extracted with EtOAc (4 \times 10 mL) and the combined organic layers were dried with MgSO₄. The solvent was removed under vacuum to give white, needle-like crystals (38.4 mg, 0.209 mmol, 41 %).

mp T / °C = 87 (EtOAc)

IR (neat) ν_{max} / cm⁻¹ = 3283.47 (N-H), 2923.28 (C-H), 2852.99 (C-H), 2129.69 (N₃), 1782.86 (lactone C=O), 1661.40 (amide C=O), 1536.81 (N-H bend)


¹H NMR (400 MHz, CDCl₃) δ / ppm = 7.07 (br d, J = 5.1 Hz, 1 H, NH), 4.65 (ddd, J = 6.8, 8.7, 11.6 Hz, 1 H, CHNHC=O), 4.49 (dt, J = 1.3, 9.1 Hz, 1 H, OCH₂), 4.31 (ddd, J = 6.0, 9.2, 11.2 Hz, 1 H, OCH₂), 4.05 (s, 2 H, C(=O)CH₂N₃), 2.77 (dddd, J = 1.4, 6.0, 8.8, 12.5 Hz, 1 H, OCH₂CH₂), 2.26 (dq, J = 8.9, 11.8 Hz, 1 H, OCH₂CH₂)

¹³C NMR (101 MHz, CDCl₃) δ / ppm = 174.9 (OC=O), 167.5 (C=ONH), 66.0 (OCH₂), 52.2 (O=CCH₂N₃), 48.9 (CHNHC=O), 29.7 (OCH₂CH₂)

$[\alpha]_D^{20}$ / °10⁻¹cm²g⁻¹ = -32.6 (c / g(100 mL)⁻¹ = 0.043, DMSO)

The data are consistent with the literature.⁴

1.13 (*S*)-4-Bromo-*N*-(2-oxotetrahydrofuran-3-yl)butanamide 44



(*S*)-3-Aminodihydrofuran-2(3*H*)-one hydrobromide **38** (200 mg, 1.10 mmol, 1.00 eq.) and NaHCO₃ (170 mg, 2.02 mmol, 1.84 eq.) were dissolved in CH₂Cl₂ (2 mL) and H₂O (2 mL). Bromobutyl chloride (140 μ L, 224 mg, 1.21 mmol, 1.10 eq.) was then added dropwise. The reaction mixture was stirred for 1 h, after which the CH₂Cl₂ was removed under vacuum. The aqueous phase was extracted with EtOAc (7 \times 5 mL) and the combined organic layers were dried with MgSO₄. The solvent was removed under vacuum to give white crystals which were recrystallised from EtOAc to give white, needle-like crystals (219 mg, 0.878 mmol, 80 %).

mp $T / ^\circ\text{C} = 105$ (EtOAc)


IR (neat) $\nu_{\text{max}} / \text{cm}^{-1} = 3307.92$ (N-H), 3073.85 (C-H), 2948.93 (C-H), 1773.66 (lactone C=O), 1643.46 (amide C=O), 1541.39 (N-H bend)

¹H NMR (400 MHz, CDCl₃) $\delta / \text{ppm} = 6.31$ (br d, $J = 5.5$ Hz, 1 H, NH), 4.59 (ddd, $J = 6.2, 8.7, 11.5$ Hz, 1 H, CHNH₂C=O), 4.48 (dt, $J = 1.2, 8.9$ Hz, 1 H, OCH₂), 4.30 (ddd, $J = 5.8, 9.3, 11.3$ Hz, 1 H, OCH₂), 3.49 (t, $J = 6.3$ Hz, 2 H, CH₂Br), 2.82 (dddd, $J = 1.3, 5.9, 8.7, 12.5$ Hz, 1 H, OCH₂CH₂), 2.47 (t, $J = 7.3$ Hz, 2 H, C(=O)CH₂), 2.26 - 2.15 (m, 3 H, OCH₂CH₂ and C(=O)CH₂CH₂CH₂Br)

¹³C NMR (101 MHz, CDCl₃) $\delta / \text{ppm} = 175.4$ (OC=O), 172.3 (C(=O)NH), 66.1 (OCH₂), 49.3 (CHNH₂C=O), 33.9 (C(=O)CH₂), 33.1 (CH₂Br), 30.3 (OCH₂CH₂), 27.9 (C(=O)CH₂CH₂CH₂Br)

$[\alpha]_D^{26.6} / ^\circ 10^{-1} \text{cm}^2 \text{g}^{-1} = -78$ ($c / \text{g}(100 \text{ mL})^{-1} = 0.08333$, MeOH)

1.14 (*S*)-6-Bromo-*N*-(2-oxotetrahydrofuran-3-yl)hexanamide 45



(*S*)-3-Aminodihydrofuran-2(3*H*)-one hydrobromide **38** (100 mg, 0.549 mmol, 1.00 eq.) and NaHCO₃ (84.9 mg, 1.01 mmol, 1.84 eq.) were dissolved in CH₂Cl₂ (2 mL) and H₂O (2 mL). Bromohexanoyl chloride (93.0 μ L, 130 mg, 0.608 mmol, 1.11 eq.) was then added dropwise. The reaction mixture was stirred for 4 h, after which the CH₂Cl₂ was removed under vacuum. The mixture was then filtered, washed with H₂O (10 mL) and dried under high vacuum to give white, needle-like crystals (101 mg, 0.362 mmol, 66 %).

mp $T / ^\circ\text{C} = 106$ (CH₂Cl₂/H₂O)

IR (neat) $\nu_{\text{max}} / \text{cm}^{-1} = 3300.30$ (N-H), 3067.62 (C-H), 2937.37 (C-H), 2856.67 (C-H), 1784.83 (lactone C=O),

1639.33 (amide C=O), 1539.87 (N-H bend)


¹H NMR (400 MHz, CDCl₃) δ / ppm = 6.09 (br d, J = 5.7 Hz, 1 H, NH), 4.57 (ddd, J = 5.9, 8.6, 11.6 Hz, 1 H, CHNH₂C=O), 4.50 (dt, J = 1.3, 9.1 Hz, 1 H, OCH₂), 4.31 (ddd, J = 5.9, 9.3, 11.3 Hz, 1 H, OCH₂), 3.43 (t, J = 6.7 Hz, 2 H, C(=O)CH₂CH₂CH₂CH₂CH₂Br), 2.88 (dddd, J = 1.3, 5.9, 8.6, 12.6 Hz, 1 H, OCH₂CH₂), 2.30 (dt, J = 1.8, 7.5 Hz, 2 H, C(=O)CH₂CH₂CH₂CH₂CH₂Br), 2.16 (dtd, J = 8.9, 11.5, 12.5 Hz, 1 H, OCH₂CH₂), 1.90 (quin, J = 7.2 Hz, 2 H, C(=O)CH₂CH₂CH₂CH₂CH₂Br), 1.71 (quin, J = 7.6 Hz, 2 H, C(=O)CH₂CH₂CH₂CH₂CH₂Br), 1.59 - 1.46 (m, 2 H, C(=O)CH₂CH₂CH₂CH₂CH₂Br)

¹³C NMR (101 MHz, CDCl₃) δ / ppm = 175.5 (OC=O), 173.3 (C(=O)NH), 66.1 (OCH₂), 49.3 (CHNH₂C=O), 35.8 (C(=O)CH₂CH₂CH₂CH₂CH₂Br), 33.5 (C(=O)CH₂CH₂CH₂CH₂CH₂Br), 32.3 (C(=O)CH₂CH₂CH₂CH₂CH₂Br), 30.5 (OCH₂CH₂), 27.6 (C(=O)CH₂CH₂CH₂CH₂CH₂Br), 24.4 (C(=O)CH₂CH₂CH₂CH₂CH₂Br)

HRMS (ESI⁺) m/z / Da = 278.0381, [M+H]⁺, [C₁₀H₁₇BrNO₃]⁺ requires 278.0386

$[\alpha]_D^{26.6}$ / °10⁻¹cm²g⁻¹ = - 16 (c / g(100 mL)⁻¹ = 0.20833, MeOH)

1.15 (*S*)-6-Azido-*N*-(2-oxotetrahydrofuran-3-yl)hexanamide 47



(*S*)-6-Bromo-*N*-(2-oxotetrahydrofuran-3-yl)hexanamide (80 mg, 0.320 mmol, 1.00 eq.) and NaN₃ (26.3 mg, 0.405 mmol, 1.27 eq.) were heated in DMF (0.5 mL) for 5 h at 100 °C. The reaction mixture was then partitioned between CH₂Cl₂ (5 mL) and H₂O (5 mL). The aqueous phase was extracted twice more with CH₂Cl₂ (2 × 5 mL) and the organic layers were combined and dried over MgSO₄. The solvent was removed by rotary evaporation followed by high vacuum to give white, needle-like crystals (42.7 mg, 0.178 mmol, 56 %).

mp T / °C = 90.0 (CH₂Cl₂)

IR (neat) ν_{max} / cm⁻¹ = 3314.00 (N-H), 2931.56 (C-H), 2862.89 (C-H), 2095.06 (N₃), 1775.38 (lactone C=O), 1643.14 (amide C=O), 1547.90 (N-H bend)


¹H NMR (400 MHz, CDCl₃) δ / ppm = 5.97 (br d, J = 4.2 Hz, 1 H, NH), 4.56 (ddd, J = 5.7, 8.6, 11.7 Hz, 1 H, CHNH₂C=O), 4.50 (dt, J = 1.0, 9.1 Hz, 1 H, OCH₂), 4.31 (ddd, J = 5.8, 9.4, 11.3 Hz, 1 H, OCH₂), 3.31 (t, J = 6.9 Hz, 2 H, CH₂N₃), 2.90 (dddd, J = 1.1, 5.8, 8.6, 12.5 Hz, 1 H, OCH₂CH₂), 2.30 (dt, J = 1.8, 7.4 Hz, 2 H, O=CCH₂), 2.15 (dtd, J = 8.8, 11.5, 12.3 Hz, 1 H, OCH₂CH₂), 1.72 (quin, J = 7.6 Hz, 2 H, O=CCH₂CH₂CH₂CH₂CH₂N₃), 1.65 (quin, J = 7.2 Hz, 2 H, O=CCH₂CH₂CH₂CH₂CH₂N₃), 1.46 (m, 2 H, O=CCH₂CH₂CH₂CH₂CH₂N₃)

¹³C NMR (101 MHz, CDCl₃) δ / ppm = 175.4 (OC=O), 172.2 (C(=O)NH), 66.1 (OCH₂), 51.2 (C(=O)CH₂CH₂CH₂CH₂CH₂N₃), 49.4 (CHNH₂C=O), 35.9 (C(=O)CH₂CH₂CH₂CH₂CH₂N₃), 30.7 (OCH₂CH₂), 28.6 (C(=O)CH₂CH₂CH₂CH₂CH₂N₃), 26.3 (C(=O)CH₂CH₂CH₂CH₂CH₂N₃), 24.8 (C(=O)CH₂CH₂CH₂CH₂CH₂N₃)

HRMS (ESI⁺) m/z / Da = 241.1289, [M+H]⁺, [C₁₀H₁₇N₄O₃]⁺ requires 241.1295

$[\alpha]_D^{26.6}$ / °10⁻¹cm²g⁻¹ = - 16 (c / g(100 mL)⁻¹ = 0.20833, MeOH)

1.16 Hex-5-ynal **49**



Pyridinium chlorochromate (14.6 g, 68.1 mmol, 1.50 eq) and DCM (500 mL) were stirred at r.t. under argon. 5-hexyn-1-ol (5.00 mL, 45.4 mmol, 1 eq.) was added and the reaction mixture was stirred for 5 h followed by addition of Et₂O (125 mL) and silica gel (62.5 g). The suspension was stirred for 1 h then filtered through a pad of silica (100 g) and washed with Et₂O. The solvent was removed by rotary evaporation to give a pale yellow-green oil (4.72 g, 49.1 mmol, 72 %).


IR (neat) ν_{max} / cm⁻¹ = 3292.68 (alkyne C-H), 2943.26 (alkane C-H), 2830.88 (aldehyde C-H), 2728.56 (aldehyde C-H), 1720.29 (aldehyde C=O)

¹H NMR (400 MHz, CDCl₃) δ / ppm = 9.80 (s, 1 H, C(=O)H), 2.60 (t, J = 7.1 Hz, 2 H, CH₂C(=O)H), 2.26 (dt, J = 2.6, 6.8 Hz, 2 H, HC≡CH₂), 1.98 (t, J = 2.7 Hz, 1 H, HC≡C), 1.85 (quin, J = 7.0 Hz, 2 H, HC≡CCH₂CH₂)

¹³C NMR (101 MHz, CDCl₃) δ / ppm = 201.6 (C=O), 83.1 (HC≡C), 69.3 (HC≡C), 42.4 (CH₂C=O), 20.7 (HC≡CCH₂CH₂CH₂C=O), 17.6 (HC≡CCH₂CH₂CH₂C=O)

Spectroscopic data are consistent with the literature.⁶

1.17 *tert*-Butyl 4-(hex-5-yn-1-yl)piperazine-1-carboxylate **51**



Hex-5-ynal **49** (0.407 g, 4.24 mmol, 1.00 eq.) and *tert*-butyl piperazine-1-carboxylate (0.791 g, 4.24 mmol, 1.00 eq.) were stirred under a N₂ atmosphere in 1,2-dichloroethane (20 mL) for 2.5 h followed by addition of sodium triacetoxyborohydride (6.25 g, 29.5 mmol, 6.96 eq.) in four portions over 4 d. The mixture was stirred for a further day then NaHCO₃ (sat., aq., 120 mL) was added and the product extracted with EtOAc (2 × 100 mL). The solvent was dried over MgSO₄, and removed by rotary evaporation to give a colourless liquid (1.12 g, 4.21 mmol, 99 %).

TLC R_f (10 % MeOH/CH₂Cl₂) = 0.55


IR (neat) ν_{max} / cm⁻¹ = 3303.59 (alkyne C-H), 2939.96 (alkane C-H), 2865.23 (C-H), 2810.42 (C-H), 1691.29 (carbamate C=O)

^1H NMR (400 MHz, CDCl_3) δ / ppm = 3.44 (t, J = 5.2 Hz, 4 H, $\text{BocN}(\underline{\text{CH}_2})\underline{\text{CH}_2}$), 2.39 (t, J = 5.1 Hz, 4 H, $\text{HC}\equiv\text{CCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\underline{\text{CH}_2})\underline{\text{CH}_2}$), 2.37 (t, J = 7.3 Hz, 2 H, $\text{HC}\equiv\text{CCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}$), 2.23 (dt, J = 2.7, 6.8 Hz, 2 H, $\text{HC}\equiv\text{CCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}$), 1.96 (t, J = 2.7 Hz, 1 H, $\underline{\text{H}}\text{C}\equiv\text{CCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}$), 1.65 - 1.53 (m, 4 H, $\text{HC}\equiv\text{CCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}$), 1.47 (s, 9 H, $\underline{\text{CH}_3}$)

^{13}C NMR (101 MHz, CDCl_3) δ / ppm = 154.7 ($\text{NC}(=\text{O})\text{O}$), 84.2 ($\text{HC}\equiv\text{C}$), 79.6 ($\text{C}(\text{CH}_3)_3$), 68.5 ($\text{HC}\equiv\text{C}$), 60.4 ($\text{HC}\equiv\text{CCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}$), 58.0 ($\text{HC}\equiv\text{CCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\underline{\text{CH}_2})\underline{\text{CH}_2}$), 53.0 ($\text{BocN}(\underline{\text{CH}_2})\underline{\text{CH}_2}$), 28.4 ($\text{C}(\underline{\text{CH}_3})_3$), 26.3 ($\text{HC}\equiv\text{CCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}$), 25.7 ($\text{HC}\equiv\text{CCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}$), 18.3 ($\text{HC}\equiv\text{CCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}$)

HRMS (ESI^+) m/z / Da = 267.2073, $[\text{M}+\text{H}]^+$, $[\text{C}_{15}\text{H}_{27}\text{N}_2\text{O}_2]^+$ requires 267.2064

1.18 1-(Hex-5-yn-1-yl)piperazine 52



tert-Butyl 4-(hex-5-yn-1-yl)piperazine-1-carboxylate **51** (763 mg, 2.86 mmol) was stirred in TFA (10 mL) at r.t. for 2 h. The TFA was removed under vacuum followed by co-evaporation with CH_2Cl_2 (2×20 mL). The oil was diluted with H_2O (10 mL) and the pH adjusted to 14 with NaOH (10 % aq.). This mixture was extracted with CH_2Cl_2 (2×20 mL) and the combined organic layers were dried over MgSO_4 . The solvent was removed under vacuum and purified by column chromatography (SiO_2 MeOH/ CH_2Cl_2 3:7) to give a colourless liquid (476 mg, 2.86 mmol, 100 %).

TLC R_f (30 % MeOH/ CH_2Cl_2) = 0.20


IR (neat) ν_{max} / cm^{-1} = 3295.87 (alkyne C-H), 2941.07 (alkane C-H), 2810.64 (alkane C-H), 1637.22 (N-H bend)

^1H NMR (400 MHz, CDCl_3) δ / ppm = 2.88 (t, J = 4.9 Hz, 4 H, $\text{HN}(\underline{\text{CH}_2})\underline{\text{CH}_2}$), 2.39 (m, 4 H, $\text{HC}\equiv\text{CCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\underline{\text{CH}_2})\underline{\text{CH}_2}$), 2.31 (t, J = 7.1 Hz, 2 H, $\text{HC}\equiv\text{CCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}$), 2.20 (dt, J = 2.7, 6.8 Hz, 2 H, $\text{HC}\equiv\text{CCH}_2$), 2.05 (br s, 1 H, $\underline{\text{NH}}$), 1.93 (t, J = 2.7 Hz, 1 H, $\underline{\text{H}}\text{C}\equiv\text{C}$), 1.65 - 1.48 (m, 4 H, $\text{HC}\equiv\text{CCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}$)

^{13}C NMR (101 MHz, CDCl_3) δ / ppm = 84.3 ($\text{HC}\equiv\text{C}$), 68.4 ($\text{HC}\equiv\text{C}$), 58.6 ($\text{HC}\equiv\text{CCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}$), 54.5 ($\text{HC}\equiv\text{CCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\underline{\text{CH}_2})\underline{\text{CH}_2}$), 46.0 ($\text{HN}(\underline{\text{CH}_2})\underline{\text{CH}_2}$), 26.4 ($\text{HC}\equiv\text{CCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}$), 25.7 ($\text{HC}\equiv\text{CCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}$), 18.3 ($\text{HC}\equiv\text{CCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}$)

HRMS (ESI^+) m/z / Da = 167.1548, $[\text{M}+\text{H}]^+$, $[\text{C}_{10}\text{H}_{19}\text{N}_2]^+$ requires 167.1548

1.19 1-Cyclopropyl-6-fluoro-7-(4-(hex-5-yn-1-yl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid **54**



7-Chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid **53** (1.27 g, 4.51 mmol, 1 eq.), 1-(hex-5-yn-1-yl)piperazine **52** (1.5 g, 9.02 mmol, 2 eq.) and *N*-methyl-2-pyrrolidone (10 mL) were stirred in a microwave reactor at 115 °C for 24 h. The reaction mixture was cooled to r.t. and water (80 ml) was added. The mixture was stirred for 3 h and then filtered, and residue was washed with MeOH (50 ml). The resulting solid (0.571 g) was further purified by recrystallisation from EtOAc (50 ml). **54** was obtained as off-white crystals (0.219 g, 0.531 mmol, 11.8 %).

TLC R_f = 0.02 (10 % MeOH/CH₂Cl₂)

mp T / °C = 220 (MeOH, decomposes)

IR (neat) ν_{max} / cm⁻¹ = 3211.99 (alkyne C-H), 2459.32 (O-H), 1722.63 (carboxylic acid C=O), 1626.76 (quinolone C=O)


¹H NMR (500 MHz, DMSO-d₆) δ / ppm = 15.12 (br. s., 1 H, C(=O)OH), 8.69 (s, 1 H, *ortho* to C(=O)OH), 7.96 (d, J=13.0 Hz, 1 H, *ortho* to F), 7.61 (d, J=7.6 Hz, 1 H, *meta* to F), 3.82 - 3.92 (m, 3 H, NCH(CH₂)₂ and CH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂), 3.54 - 3.68 (br. m, 2 H, CH₂CH₂CH₂N(CH₂)CH₂), 3.45 (br. t, J=11.6 Hz, 2 H, CH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂), 3.21 - 3.29 (br. m, 2 H, CH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂), 3.11 - 3.20 (br. m, 2 H, CH₂CH₂CH₂N(CH₂)CH₂), 2.84 (t, J=2.7 Hz, 1 H, HC≡C), 2.24 (td, J=7.0, 2.7 Hz, 2 H, HC≡CCH₂), 1.83 (br. quin, J=7.5 Hz, 2 H, HC≡CCH₂CH₂CH₂), 1.52 (quin, J=7.4 Hz, 2 H, HC≡CCH₂CH₂), 1.29 - 1.36 (m, 2 H, NCH(CH₂)₂), 1.16 - 1.23 (m, 2 H, NCH(CH₂)₂)

¹³C NMR (126 MHz, DMSO-d₆) δ / ppm = 176.4 (C(=O)CC(=O)OH), 165.8 (C(=O)OH), 152.8 (d, J=248.5 Hz, *ipso* to F), 148.2 (CHCC(=O)OH), 143.7 (d, J=11.1 Hz, *para* to C(=O)), 139.1 (*para* to F), 119.4 (d, J=6.9 Hz, *ipso* to C(=O)), 111.2 (d, J=22.5 Hz, *ortho* to F and *ortho* to C(=O)), 106.9 (*meta* to F and *meta* to C(=O)), 106.9 (C(=O)CC(=O)OH), 83.9 (HC≡C), 71.8 (HC≡C), 55.0 (CH₂CH₂CH₂N), 50.5 (CH₂CH₂CH₂N(CH₂)CH₂), 46.3 (CH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂), 36.0 (NCH(CH₂)₂), 25.2 (HC≡CCH₂CH₂), 22.3 (HC≡CCH₂CH₂CH₂), 17.4 (HC≡CCH₂), 7.6 (NCH(CH₂)₂)

¹⁹F NMR (376.45 MHz, MeOD) δ / ppm = -121.82 (s, ciprofloxacin F)

HRMS (ESI⁺) m/z / Da = 412.2036, [M+H]⁺, [C₂₃H₂₇N₃O₃F]⁺ requires 412.2030

1.20 4-((2,4-Diaminopyrimidin-5-yl)methyl)-2,6-dimethoxyphenol **124**



Hydrobromic acid (48 % w/w, aq., 50 ml) was heated to 100 °C, then trimethoprim (5.00 g, 17.2 mmol) was added, and the suspension was stirred for 40 min under Ar. The mixture was removed from the heat, and NaOH (50 % w/w, aq., 15 ml) was added dropwise. The reaction mixture was then cooled slowly to 0 °C, and the resulting crystals were filtered out and washed with cold water. The crystals were then dissolved in hot water (80 ml), neutralized with NH₄OH (sat., aq.) and cooled slowly to 0 °C. The resulting crystals were filtered out, washed with cold water and dried under vacuum. **124** was obtained as pale pink prisms (2.06 g, 7.46 mmol, 43.4 %).

TLC R_f = 0.04 (5 % MeOH/CHCl₂)

mp T / °C = 238 (H₂O, decomposes)

IR (neat) ν_{max} / cm⁻¹ = 3314.0 (N-H), 3137.4 (N-H), 3045.3 (C-H), 3000.9 (C-H), 2938.1 (C-H), 2838.7 (C-H), 1662.9 (pyrimidine), 1645.2 (pyrimidine), 1626.6 (pyrimidine)


¹H NMR (400 MHz, MeOD) δ / ppm = 7.21 (s, 1 H, CHN), 6.54 (s, 2 H, *meta* to OCH₂), 4.87 (br. s., 5 H, OH, NH₂ × 2), 3.82 (s, 6 H, OCH3), 3.63 (s, 2 H, CCH2C)

¹³C NMR (101 MHz, MeOD) δ / ppm = 166.4 (CH₂CCNH₂), 162.0 (CHNCNH₂), 156.2 (CHNCNH₂), 149.8 (*ipso* to OCH₃), 135.9 (*ipso* to OH), 128.2 (*para* to OH), 111.7 (CH₂CCNH₂), 107.5 (*meta* to OH), 57.0 (OCH3), 33.9 (CCH₂C)

HRMS (ESI⁺) m/z / Da = 277.1295, [M+H]⁺ found, [C₁₃H₁₇N₄O₃]⁺ requires 277.1301

The data are consistent with the literature.⁷

1.21 5-(4-(Hex-5-yn-1-yloxy)-3,5-dimethoxybenzyl)pyrimidine-2,4-diamine **125**



4-((2,4-Diaminopyrimidin-5-yl)methyl)-2,6-dimethoxyphenol **124** (1.00 g, 3.62 mmol, 1 eq.), 6-chloro-1-hexyne **175** (0.524 ml, 0.420 g, 4.34 mmol, 1.2 eq.), Cs₂CO₃ (2.36 g, 7.24 mmol, 2 eq.) and anhydrous DMF (30 ml) were stirred at 70 °C for 7 h. The solvent was removed under reduced pressure, then CH₂Cl₂ (30 ml) was added and the mixture filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography using a Combiflash (SiO₂, 5 % MeOH/CH₂Cl₂). **125** was obtained as a pale cream amorphous solid (0.253 g, 0.709 mmol, 19.6 %).

TLC R_f = 0.14 (5 % MeOH/CH₂Cl₂)

IR (neat) ν_{max} / cm⁻¹ = 3451.4 (alkyne C-H), 3313.4 (N-H), 3136.7 (N-H), 3113.9 (N-H), 2944.2 (C-H), 2839.0 (C-H), 1635.1 (pyrimidine)


¹H NMR (400 MHz, MeOD) δ / ppm = 7.77 (s, 1 H, CHN), 6.37 (s, 2 H, *meta* to OCH₂), 4.83 (br. s., 2 H, CHNCNH₂), 4.63 (br. s., 2 H, CH₂CCNH₂), 3.95 (t, J = 6.3 Hz, 2 H, CH₂O), 3.79 (s, 6 H, OCH₃), 3.65 (s, 2 H, CCH₂C), 2.28 (td, J = 7.1, 2.6 Hz, 2 H, HC≡CCH₂), 1.94 (t, J = 2.7 Hz, 1 H, HC≡C), 1.81 - 1.90 (m, 2 H, CH₂CH₂O), 1.71 - 1.80 (m, 2 H, CH₂CH₂CH₂O)

¹³C NMR (101 MHz, MeOD) δ / ppm = 162.7 (CH₂CCNH₂), 162.0 (CHNCNH₂), 156.4 (CHNCNH₂), 153.8 (*ipso* to OCH₃), 136.0 (*ipso* to OCH₂), 133.6 (*para* to OCH₂), 106.5 (CH₂CCNH₂), 105.0 (*meta* to OCH₂), 84.5 (HC≡C), 72.6 (CH₂O), 68.3 (HC≡C), 56.1 (OCH₃), 34.7 (CCH₂C), 29.1 (CH₂CH₂O), 24.9 (CH₂CH₂CH₂O), 18.0 (HC≡CCH₂)

HRMS (ESI⁺) m/z / Da = 357.1920, [M+H]⁺ found, [C₁₉H₂₅N₄O₃]⁺ requires 357.1927

The compound has not been reported previously.

1.22 (*S*)-1-Cyclopropyl-6-fluoro-4-oxo-7-(4-(4-(1-(2-oxo-2-((2-oxotetrahydrofuran-3-yl)amino)ethyl)-1*H*-1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid **126**



50 % water/*t*-BuOH (2 ml) was degassed by bubbling N₂ through it. This was then added to a mixture of 1-cyclopropyl-6-fluoro-7-(4-(hex-5-yn-1-yl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid **176** (20.6 mg, 50.0 μ mol, 1 eq.) and (*S*)-2-azido-*N*-(2-oxotetrahydrofuran-3-yl)acetamide **41** (9.2 mg, 50.0 μ mol, 1 eq.). A similarly degassed solution of CuSO₄ · 5 H₂O (624 μ g, 2.5 μ mol, 0.05 eq. 50 mM), THPTA (1.09 mg, 2.5 μ mol, 0.05 eq. 50 mM) and sodium ascorbate (991 μ g, 5 μ mol, 0.1 eq., 100 mM) in 50 % water/*t*-BuOH (50 μ l) was then added. The mixture was stirred at r.t. under argon for 3h. On observation that the reaction had stalled, the reaction was degassed again, and a further portion of catalyst solution (50 μ l) was added. After a further 3h

the reaction mixture was evaporated under reduced pressure. The residue was purified by preparatory HPLC(?? % acetonitrile/water over 15 min). The combined pure fractions were evaporated under reduced pressure and then partitioned between NaHCO₃ (aq., sat., 10 ml) and 10 % *i*-PrOH/CHCl₃ (10 ml). The organic layer was dried with MgSO₄ and evaporated under reduced pressure. **126** was obtained as a white amorphous solid (8.8 mg, 14.8 μmol, 29.6 %).

IR (neat) ν_{max} / cm⁻¹ = 3266.3 (N-H), 2949.0 (C-H), 2934.8 (C-H), 2827.2 (C-H), 1778.0 (lactone C=O), 1724.9 (carboxylic acid C=O), 1665.0 (amide C=O), 1625.5 (quinolone C=O)


¹H NMR (400 MHz, DMSO d₆) δ / ppm = 15.23 (s, 1 H, C(=O)OH), 8.84 (d, J = 7.9 Hz, 1 H, NH), 8.66 (s, 1 H, *ortho* to C(=O)OH), 7.90 (d, J = 13.3 Hz, 1 H, *ortho* to F), 7.82 (s, 1 H, CH=CCH₂), 7.57 (d, J = 7.6 Hz, 1 H, *meta* to F), 5.13 (s, 1 H, C(=O)CHHN), 5.12 (s, 1 H, C(=O)CHHN), 4.64 (ddd, J = 10.9, 9.0, 7.8 Hz, 1 H, CHNH), 4.36 (td, J = 8.9, 1.7 Hz, 1 H, OCHH), 4.23 (ddd, J = 10.6, 8.8, 6.4 Hz, 1 H, OCHH), 3.83 (tt, J = 7.0, 4.0 Hz, 1 H, NCH(CH₂)₂), 3.32 (br s, 4 H, CH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂), 2.67 (t, J = 7.4 Hz, 2 H, CH=CCH₂), 2.58 (br t, J = 5.0 Hz, 4 H, CH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂), 2.42 - 2.49 (m, 1 H, OCH₂CHH), 2.40 (t, J = 7.1 Hz, 1 H, CH=CCH₂CH₂CH₂CH₂), 2.17 (dtd, J = 11.7, 10.8, 10.8, 9.0 Hz, 1 H, OCH₂CHH), 1.66 (quin, J = 7.2 Hz, 1 H, CH=CCH₂CH₂CH₂), 1.53 (quin, J = 7.2 Hz, 1 H, CH=CCH₂CH₂CH₂), 1.28 - 1.35 (m, 1 H, NCH(CHH)₂), 1.16 - 1.21 (m, 1 H, NCH(CHH)₂)

¹³C NMR (101 MHz, DMSO d₆) δ / ppm = 176.4 (C(=O)CC(=O)OH), 174.9 (OC(=O)), 166.0 (C(=O)OH), 165.9 (NH₂C(=O)), 153.1 (d, J = 250.8 Hz, *ipso* to F), 148.0 (CH=CC(=O)OH), 146.6 (CH=CCH₂), 145.3 (d, J = 9.6 Hz, *ipso* to piperazine), 139.2 (*para* to F), 123.4 (CH=CCH₂), 118.5 (d, J = 7.5 Hz, *para* to piperazine), 110.9 (d, J = 23.5 Hz, *ortho* to C=O and *ortho* to F), 106.7 (CC(=O)OH), 106.4 (d, J = 3.2 Hz, *meta* to C=O and *meta* to F), 65.4 (OCH₂), 57.3 (CH=CCH₂CH₂CH₂CH₂N), 52.4 (CH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂), 51.2 (C(=O)CH₂N), 49.5 (d, J = 4.3 Hz, CH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂), 48.2 (CHNH), 35.9 (NCH(CH₂)₂), 28.2 (CH₂CHNH), 26.8 (CH=CCH₂CH₂), 25.7 (CH=CCH₂CH₂CH₂), 24.9 (CH=CCH₂), 7.6 (NCH(CH₂)₂)

¹⁹F NMR (376.45 MHz, DMSO d₆) δ / ppm = ??

HRMS (ESI⁺) m/z / Da = 596.2627, [M+H]⁺ found, [C₂₉H₃₅FN₇O₆]⁺ requires 596.2633 [α]_D²⁰ / °10⁻¹cm²g⁻¹ = -3.5 (c / g(100 mL)⁻¹ = 0.0575, MeOH)

1.23 (*S*)-1-Cyclopropyl-6-fluoro-4-oxo-7-(4-(4-(1-(4-oxo-4-((2-oxotetrahydrofuran-3-yl)amino)butyl)-1*H*-1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid **127**



IDK
what
happened
after
this,
check,
weigh
etc.

column?
equipment?

50 % water/*t*-BuOH (2 ml) was degassed by bubbling N₂ through it. This was then added to a mixture of 1-cyclopropyl-6-fluoro-7-(4-(hex-5-yn-1-yl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid **176** (20.6 mg, 50.0 μmol, 1 eq.) and (*S*)-4-azido-*N*-(2-oxotetrahydrofuran-3-yl)butanamide **46** (10.6 mg, 50.0 μmol, 1 eq.). A similarly degassed solution of CuSO₄ · 5 H₂O (624 μg, 2.5 μmol, 0.05 eq. 50 mM), THPTA (1.09 mg, 2.5 μmol, 0.05 eq. 50 mM) and sodium ascorbate (991 μg, 5 μmol, 0.1 eq., 100 mM) in 50 % water/*t*-BuOH (50 μl) was then added. The mixture was stirred at r.t. under argon for 3h, then the reaction mixture was evaporated under reduced pressure. The residue was purified by preparatory HPLC(% acetonitrile/water over 15 min). The combined pure fractions were evaporated under reduced pressure and then partitioned between NaHCO₃ (aq., sat., 10 ml) and 10 % *i*-PrOH/CHCl₃ (10 ml). The organic layer was dried with MgSO₄ and evaporated under reduced pressure. **127** was obtained as a white amorphous solid (14.6 mg, 23.4 μmol, 46.8 %).

IR (neat) ν_{max} / cm⁻¹ = 3286.7 (N-H), 2949.7 (C-H), 2820.6 (C-H), 2778.0 (C-H), 1778.1 (lactone C=O), 1725.6 (carboxylic acid C=O), 1663.7 (amide C=O), 1625.8 (quinolone C=O)

¹H NMR (500 MHz, DMSO d₆) δ / ppm = 15.22 (br s, 1 H, C(=O)OH), 8.65 (s, 1 H, *ortho* to C(=O)OH), 8.40 (d, *J* = 8.0 Hz, 1 H, NH), 7.88 (d, *J* = 13.4 Hz, 1 H, *ortho* to F), 7.85 (s, 1 H, CH=CCH₂), 7.55 (d, *J* = 7.5 Hz, 1 H, *meta* to F), 4.53 (ddd, *J* = 10.9, 9.0, 8.1 Hz, 1 H, CHNH), 4.33 (td, *J* = 8.9, 1.8 Hz, 1 H, OCHH), 4.31 (t, *J* = 7.0 Hz, 2 H, CH₂NCH=C), 4.20 (ddd, *J* = 10.5, 8.8, 6.5 Hz, 1 H, OCHH), 3.82 (tt, *J* = 6.9, 4.0 Hz, 1 H, NCH(CH₂)₂), 3.32 (br. t, *J* = 4.2, 4.2 Hz, 4 H, CH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂), 2.64 (t, *J* = 7.4 Hz, 2 H, CH=CCH₂), 2.57 (br. t, *J* = 5.0, 5.0 Hz, 2 H, CH₂CH₂CH₂N(CH₂CH₂), 2.34 - 2.42 (m, 3 H, OCH₂CHH and CH=CCH₂CH₂CH₂CH₂), 2.09 - 2.19 (m, 3 H, OCH₂CHH and C(=O)CH₂), 2.02 (quin, *J* = 7.2 Hz, 2 H, C(=O)CH₂CH₂), 1.64 (quin, *J* = 7.6 Hz, 2 H, CH=CCH₂CH₂), 1.52 (quin, *J* = 7.2 Hz, 2 H, CH=CCH₂CH₂CH₂), 1.29 - 1.34 (m, 2 H, NCH(CHH)₂), 1.15 - 1.21 (m, 2 H, NCH(CHH)₂)


¹³C NMR (126 MHz, DMSO d₆) δ / ppm = 176.3 (C(=O)CC(=O)OH), 175.4 (OC(=O)), 171.2 (NHC(=O)), 166.0 (C(=O)OH), 153.0 (d, *J* = 248.6 Hz, *ortho* to F), 148.0 (CH=CC(=O)OH), 146.8 (CH=CCH₂), 145.2 (d, *J* = 9.6 Hz, *ipso* to piperazine), 139.2 (*para* to F), 121.7 (CH=CCH₂), 118.5 (d, *J* = 7.5 Hz, *para* to piperazine), 110.9 (d, *J* = 22.4 Hz, *ortho* to C=O and *ortho* to F), 106.7 (CC(=O)OH), 106.3 (d, *J* = 3.2 Hz, *meta* to C=O and *meta* to F), 65.3 (OCH₂), 57.3 (CH=CCH₂CH₂CH₂CH₂N), 52.4 (CH₂CH₂CH₂N(CH₂CH₂), 49.5 (CH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂), 49.4 (CH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂), 48.6 (CH₂NCH=C), 47.9 (NHC(=O)CH₂CH₂), 35.9 (NCH(CH₂)₂), 31.7 (NHC(=O)CH₂), 28.2 (CH₂CHNH), 26.9 (CH=CCH₂CH₂), 25.8 (NHC(=O)CH₂CH₂ and CH=CCH₂CH₂CH₂), 24.9 (CH=CCH₂), 7.6 (NCH(CH₂)₂)

¹⁹F NMR (376.45 MHz, MeOD) δ / ppm = ??

HRMS (ESI⁺) *m/z* / Da = 624.2928, [M+H]⁺ found, [C₃₁H₃₉FN₇O₆]⁺ requires 624.2946 [α]_D²⁰ / °10⁻¹cm²g⁻¹ = -10.6 (*c* / g(100 mL)⁻¹ = 0.094, MeOH)

IDK
what
happened
after
this,
was it
prep or
combi-
flash?,
check,
weigh
etc.
column?
equip-
ment?

1.24 (S)-1-Cyclopropyl-6-fluoro-4-oxo-7-(4-(4-(1-(6-oxo-6-((2-oxotetrahydrofuran-3-yl)amino)hexyl)-1H-1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid **128**



50 % water/*t*-BuOH (2 ml) was degassed by bubbling N₂ through it. This was then added to a mixture of 1-cyclopropyl-6-fluoro-7-(4-(hex-5-yn-1-yl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid **176** (20.6 mg, 50.0 μmol, 1 eq.) and (*S*)-6-azido-*N*-(2-oxotetrahydrofuran-3-yl)hexanamide **47** (12.0 mg, 50.0 μmol, 1 eq.). A similarly degassed solution of CuSO₄ · 5 H₂O (624 μg, 2.5 μmol, 0.05 eq. 50 mM), THPTA (1.09 mg, 2.5 μmol, 0.05 eq. 50 mM) and sodium ascorbate (991 μg, 5 μmol, 0.1 eq., 100 mM) in 50 % water/*t*-BuOH (50 μl) was then added. The mixture was stirred at r.t. under argon for 3h, then the reaction mixture was dry-loaded onto SiO₂ and purified by column chromatography using a Combiflash (SiO₂, 0-20 % MeOH/CH₂Cl₂). The combined pure fractions were dried with MgSO₄ and evaporated under reduced pressure. **126** was obtained as a white amorphous solid (12.4 mg, 19.0 μmol, 38.0 %).

TLC *R_f* = 0.30 (30 % MeOH/CH₂Cl₂)

IR (neat) ν_{max} / cm⁻¹ = 3301.8 (N-H), 2939.7 (C-H), 2857.5 (C-H), 1784.6 (lactone C=O), 1728.5 (carboxylic acid C=O), 1658.2 (amide C=O), 1625.5 (quinolone C=O)

¹H NMR (500 MHz, DMSO d₆) δ / ppm = 15.22 (br s, 1 H, C(=O)OH), 8.65 (s, 1 H, *ortho* to C(=O)OH), 8.32 (d, *J* = 8.0 Hz, 1 H, NH), 7.89 (d, *J* = 13.3 Hz, 1 H, *ortho* to F), 7.84 (s, 1 H, CH=CCH₂), 7.55 (d, *J* = 7.6 Hz, 1 H, *meta* to F), 4.51 (ddd, *J* = 10.9, 9.1, 7.9 Hz, 1 H, CHNH), 4.33 (td, *J* = 8.8, 1.8 Hz, 1 H, OCHH), 4.28 (t, *J* = 7.1 Hz, 2 H, CH₂NCH=C), 4.19 (ddd, *J* = 10.5, 8.7, 6.6 Hz, 1 H, OCHH), 3.82 (tt, *J* = 7.0, 4.0 Hz, 1 H, NCH(CH₂)₂), 3.32 (br t, *J* = 4.5, 4 H, CH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂), 2.63 (t, *J* = 7.5 Hz, 2 H, CH=CCH₂), 2.57 (br t, *J* = 4.2, 4.2 Hz, 4 H, CH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂), 2.33 - 2.41 (m, 3 H, OCH₂CHH and CH=CCH₂CH₂CH₂CH₂), 2.06 - 2.16 (m, 3 H, OCH₂CHH and C(=O)CH₂), 1.79 (quin, *J* = 7.4 Hz, 2 H, C(=O)CH₂CH₂CH₂CH₂), 1.63 (quin, *J* = 7.5 Hz, 2 H, CH=CCH₂CH₂), 1.45 - 1.56 (m, 4 H, C(=O)CH₂CH₂ and CH=CCH₂CH₂CH₂), 1.29 - 1.34 (m, 2 H, NCH(CH₂)₂), 1.19 - 1.25 (m, 2 H, C(=O)CH₂CH₂CH₂), 1.15 - 1.19 (m, 2 H, NCH(CH₂)₂)

¹³C NMR (126 MHz, DMSO d₆) δ / ppm = 176.4 (C(=O)CC(=O)OH), 175.4 (OC(=O)), 172.1 (NHC(=O)), 166.0 (C(=O)OH), 153.0 (d, *J* = 250.2 Hz, *ipso* to F), 148.0 (CH=CC(=O)OH), 146.8 (CH=CCH₂), 145.2 (d, *J* = 9.6 Hz, *ipso* to piperazine), 139.2 (*para* to F), 121.6 (CH=CCH₂), 118.5 (d, *J* = 8.0 Hz, *para* to piperazine), 110.9 (d, *J* = 23.5 Hz, *ortho* to C=O and *ortho* to F), 106.7 (CC(=O)OH), 106.3 (d, *J* = 2.1 Hz, *meta* to C=O and *meta* to F), 65.3 (OCH₂), 57.4 (CH=CCH₂CH₂CH₂CH₂N), 52.4 (CH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂), 49.5 (d, *J* = 3.2 Hz, CH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂), 49.0 (CH₂NCH=C), 47.8 (CHNH), 35.9 (NCH(CH₂)₂), 34.8 (NHC(=O)CH₂), 29.5 (CH₂CH₂NCH=C), 28.3 (CH₂CHNH), 26.9 (CH=CCH₂CH₂), 25.7 (CH=CCH₂CH₂CH₂),

how to
report?


IDK
what
happened
after
this,
check,
weigh
etc.

25.4 (NHC(=O)CH₂CH₂CH₂), 24.9 (CH=CCH₂), 24.5 (NHC(=O)CH₂CH₂), 7.6 (NCH(CH₂)₂)

¹⁹F NMR (376.45 MHz, MeOD) δ / ppm = ??

HRMS (ESI⁺) *m/z* / Da = 652.3254, [M+H]⁺ found, [C₃₃H₄₃FN₇O₆]⁺ requires 652.3248 [α]_D²⁰ / °10⁻¹cm²g⁻¹ = -8.5 (*c* / g(100 mL)⁻¹ = 0.106, MeOH)

1.25 1-Cyclopropyl-6-fluoro-7-(4-(4-(1-(2-heptyl-4-oxo-1,4-dihydroquinolin-6-yl)-1H-1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid **129**



50 % water/*t*-BuOH (1 ml) was degassed by bubbling N₂ through it. This was then added to a mixture of 1-cyclopropyl-6-fluoro-7-(4-(hex-5-yn-1-yl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid **176** (4.1 mg, 10.0 μmol, 1 eq.) and 6-azido-2-heptylquinolin-4(1*H*)-one **26** (2.8 mg, 10.0 μmol, 1 eq.). A similarly degassed solution of CuSO₄ · 5 H₂O (125 μg, 0.5 μmol, 0.05 eq. 50 mM), THPTA (218 μg, 0.5 μmol, 0.05 eq. 50 mM) and sodium ascorbate (198 μg, 1 μmol, 0.1 eq., 100 mM) in 50 % water/*t*-BuOH (10 μl) was then added. The mixture was stirred at r.t. under argon for 1.5 h, then the reaction mixture was evaporated under reduced pressure. The residue was purified by preparatory HPLC (50-100 % acetonitrile/water over ??min). The combined pure fractions were evaporated under reduced pressure and then partitioned between NaHCO₃ (aq., sat., 10 ml) and 10 % *i*-PrOH/CHCl₃ (10 ml). The organic layer was dried with MgSO₄ and evaporated under reduced pressure. **129** was obtained as a white amorphous solid (8.6 mg, 2.7 μmol, 27.0 %).

IR (neat) ν_{max} / cm⁻¹ = 2927.0 (C-H), 2865.5 (C-H), 1715.5 (carboxylic acid C=O), 1631.0 (ciprofloxacin quinolone C=O and HHQ C=O)

¹H NMR (400 MHz, MeOD) δ / ppm = ??

¹³C NMR (101 MHz, MeOD) δ / ppm = ??

¹⁹F NMR (376.45 MHz, MeOD) δ / ppm = ??


HRMS (ESI⁺) *m/z* / Da = 696.3667, [M+H]⁺ found, [C₃₉H₄₇FN₇O₄]⁺ requires 696.3668

check

column?
equipment?

needs
desalt-
ing

1.26 (*S*)-4-(4-(4-(4-((2,4-Diaminopyrimidin-5-yl)methyl)-2,6-dimethoxyphenoxy)butyl)-1H-1,2,3-triazol-1-yl)-*N*-(2-oxotetrahydrofuran-3-yl)butanamide **130**



Method?? pale brown gum 4.8 mg, 8.4 μ mol

TLC R_f = 0.30 (30 % MeOH/ CH_2Cl_2)

IR (neat) ν_{max} / cm^{-1} = 3340.5 (N-H), 3303.3 (N-H), 3182.5 (N-H), 2933.8 (C-H), 1774.2 (lactone C=O), 1659.7 (amide C=O and pyrimidine)


^1H NMR (400 MHz, MeOD) δ / ppm = ??

^{13}C NMR (101 MHz, MeOD) δ / ppm = ??

^{19}F NMR (376.45 MHz, MeOD) δ / ppm = ??

HRMS (ESI^+) m/z / Da = 569.2834, $[\text{M}+\text{H}]^+$ found, $[\text{C}_{27}\text{H}_{37}\text{N}_8\text{O}_6]^+$ requires 569.2836 $[\alpha]_D^{20}$ / $^{\circ}\text{10}^{-1}\text{cm}^2\text{g}^{-1}$ = -4.6 (c / $\text{g}(100\text{ mL})^{-1}$ = 0.0433, MeOH)

1.27 (*S*)-6-(4-(4-(4-((2,4-Diaminopyrimidin-5-yl)methyl)-2,6-dimethoxyphenoxy)butyl)-1H-1,2,3-triazol-1-yl)-*N*-(2-oxotetrahydrofuran-3-yl)hexanamide **131**



50 % water/*t*-BuOH (2 ml) was degassed by bubbling N_2 through it. This was then added to a mixture of 5-(4-(hex-5-yn-1-yloxy)-3,5-dimethoxybenzyl)pyrimidine-2,4-diamine **125** (20.6 mg, 50.0 μ mol, 1 eq.) and (*S*)-6-azido-*N*-(2-oxotetrahydrofuran-3-yl)hexanamide **47** (18.0 mg, 75.0 μ mol, 1.5 eq.). Similarly degassed solutions of $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (624 μg , 2.5 μ mol, 0.05 eq. 50 mM), THPTA (1.09 mg, 2.5 μ mol, 0.05 eq. 50 mM) and sodium ascorbate (991 μg , 5 μ mol, 0.1 eq., 100 mM) in water (50 μl) were then added. An extra portion of **47** (12.0 mg, 50.0 μ mol, 1 eq.) was added after 1 d. **131** was obtained as a clear gum (8.0 mg, 13.4 μ mol, 26.8 %).

TLC R_f = 0.35 (30 % MeOH/ CH_2Cl_2)


IR (neat) ν_{max} / cm^{-1} = 3336.0 (N-H), 3208.7 (N-H), 2941.1 (C-H), 2869.2 (C-H), 1775.2 (lactone C=O), 1657.3 (amide C=O and pyrimidine)

^1H NMR (500 MHz, DMSO d_6) δ / ppm = 8.34 (d, J = 8.0 Hz, 1 H, NH), 7.83 (s, 1 H, $\text{NCH}=\text{CCH}_2$), 7.50 (s, 1 H, $\text{CHN}=\text{CNH}_2$), 6.54 (s, 2 H, *meta* to CH_2), 6.17 (br s, 2 H, CH_2CCNH_2), 5.77 (br s, 2 H, $\text{CHN}=\text{CNH}_2$), 4.51 (ddd, J = 11.0, 9.0, 8.1 Hz, 1 H, CHNH), 4.33 (td, J = 8.8, 1.9 Hz, 1 H, $\text{CHHOC}(=\text{O})$), 4.27 (t, J = 7.1 Hz, 2 H, CH_2N), 4.19 (ddd, J = 10.5, 8.7, 6.5 Hz, 1 H, $\text{CHHOC}(=\text{O})$), 3.80 (t, J = 6.3 Hz, 2 H, CH_2O), 3.70 (s, 6 H, CH_3), 3.52 (s, 2 H, CCH_2C), 2.64 (t, J = 7.5 Hz, 2 H, $\text{CH}=\text{CCH}_2$), 2.36 (dddd, J = 12.1, 8.9, 6.7, 1.8 Hz, 1 H, CHHCHNH), 2.06 - 2.16 (m, 3 H, CHHCHNH and $\text{C}(=\text{O})\text{CH}_2$), 1.78 (quin, J = 7.4 Hz, 2 H, $\text{CH}_2\text{CH}_2\text{N}$), 1.73 (quin, J = 7.7 Hz, 2 H, $\text{CH}=\text{CCH}_2\text{CH}_2$), 1.63 (quin, J = 6.8 Hz, 2 H, $\text{CH}_2\text{CH}_2\text{O}$), 1.52 (quin, J = 7.5 Hz, 2 H, $\text{C}(=\text{O})\text{CH}_2\text{CH}_2$), 1.17 - 1.27 (m, 2 H, $\text{C}(=\text{O})\text{CH}_2\text{CH}_2\text{CH}_2$)

^{13}C NMR (125 MHz, DMSO d_6) δ / ppm = 175.4 ($\text{OC}(=\text{O})$), 172.0 ($\text{NHC}(=\text{O})$), 162.2 ($\text{CC}(\text{NH}_2)\text{N}$), 161.8 ($\text{NC}(\text{NH}_2)\text{N}$), 154.8 ($\text{CHNC}(\text{NH}_2)\text{N}$), 152.8 (*ipso* to OCH_3), 146.7 ($\text{CH}=\text{CCH}_2\text{CH}_2$), 135.5 (*para* to CH_2O), 134.8 (*ipso* to CH_2O), 121.6 ($\text{CH}=\text{CCH}_2\text{CH}_2$), 105.9 ($\text{CH}_2\text{CC}(\text{NH}_2)=\text{N}$), 105.8 (*meta* to CH_2O), 71.9 ($\text{CH}_2\text{CH}_2\text{CH}_2\text{O}$), 65.2 ($\text{OCH}_2\text{CH}_2\text{CHNH}$), 55.8 (OCH_3), 49.0 (CH_2N), 47.8 (CHNH), 34.8 ($\text{C}(=\text{O})\text{CH}_2$), 32.9 (CCH_2C), 29.4 ($\text{CH}_2\text{CH}_2\text{N}$), 29.1 ($\text{CH}_2\text{CH}_2\text{CH}_2\text{O}$), 28.2 ($\text{OCH}_2\text{CH}_2\text{CHNH}$), 25.5 ($\text{CH}=\text{CCH}_2\text{CH}_2$), 25.3 ($\text{C}(=\text{O})\text{CH}_2\text{CH}_2\text{CH}_2$), 24.7 ($\text{CH}=\text{CCH}_2\text{CH}_2$), 24.4 ($\text{C}(=\text{O})\text{CH}_2\text{CH}_2$)

HRMS (ESI^+) m/z / Da = 597.3149, $[\text{M}+\text{H}]^+$ found, $[\text{C}_{29}\text{H}_{41}\text{N}_8\text{O}_6]^+$ requires 597.3144 $[\alpha]_D^{20}$ / $^\circ 10^{-1}\text{cm}^2\text{g}^{-1}$ = -3.6 (c / $\text{g}(100\text{ mL})^{-1}$ = 0.11, MeOH)

1.28 6-(4-(4-(4-((2,4-Diaminopyrimidin-5-yl)methyl)-2,6-dimethoxyphenoxy)butyl)-1*H*-1,2,3-triazol-1-yl)-2-heptylquinolin-4(1*H*)-one **132**



50 % water/*t*-BuOH (1 ml) was degassed by bubbling N_2 through it. This was then added to a mixture of 5-(4-(hex-5-yn-1-yloxy)-3,5-dimethoxybenzyl)pyrimidine-2,4-diamine **125** (3.6 mg, 10.0 μmol , 1 eq.) and 6-azido-2-heptylquinolin-4(1*H*)-one **26** (2.8 mg, 10.0 μmol , 1 eq.). A similarly degassed solution of $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (125 μg , 0.5 μmol , 0.05 eq. 50 mM), THPTA (218 μg , 0.5 μmol , 0.05 eq. 50 mM) and sodium ascorbate (198 μg , 1 μmol , 0.1 eq., 100 mM) in water (10 μl) was then added. The mixture was stirred at r.t. under argon for 1.5 h, then the reaction mixture was evaporated under reduced pressure. The residue was purified by preparatory HPLC (5-100 % acetonitrile/water over 20 min). The combined pure fractions were evaporated under reduced pressure. **132** was obtained as a clear gum (2.6 mg, 4.1 μmol , 41.0 %).

TLC R_f = 0.17 (20 % MeOH/ CH_2Cl_2)

IR (neat) ν_{max} / cm^{-1} = 2927.7 (C-H), 2855.5 (C-H), 1664.1 (pyrimidine), 1645.4 (pyrimidine and HHQ C=O),


column?
equip-
ment?

¹H NMR (500 MHz, DMSO d₆) δ / ppm = 11.80 (s, 1 H, NH), 8.69 (s, 1 H, NCH=CCH₂), 8.41 (d, J = 2.7 Hz, 1 H, *ortho* to C=O), 8.17 (dd, J = 9.0, 2.6 Hz, 1 H, *para* to C=O), 7.73 (d, J = 9.0 Hz, 1 H, *ortho* to NH), 7.51 (br s, 4 H, NH₂), 7.41 (s, 1 H, CHN=CNH₂), 6.61 (s, 2 H, *meta* to CH₂), 6.02 (d, J = 1.8 Hz, 1 H, C(=O)CH), 3.86 (t, J = 6.3 Hz, 2 H, CH₂O), 3.73 (s, 6 H, OCH₃), 3.57 - 3.62 (m, 2 H, CCH₂C), 2.78 (t, J = 7.5 Hz, 2 H, CH=CCH₂), 2.63 (t, J = 7.3 Hz, 2 H, HNCCH₂), 1.85 (quin, J = 7.5 Hz, 2 H, CH=CCH₂CH₂), 1.61 - 1.78 (m, 4 H, HNCCH₂CH₂ and CH=CCH₂CH₂CH₂), 1.31 - 1.40 (m, 4 H, HNCCH₂CH₂CH₂CH₂), 1.25 - 1.31 (m, 4 H, CH₃CH₂CH₂), 0.86 (t, J = 7.2 Hz, 3 H, CH₃CH₂)

¹³C NMR (125 MHz, DMSO d₆) δ / ppm = 176.4 (C=O), 164.1 (CC(NH₂)N), 154.3 (HNC), 154.2 (NC(NH₂)N), 153.1 (*ipso* to OCH₃), 148.3 (CH=CCH₂CH₂), 140.2 (CHNC(NH₂)N), 139.6 (*ipso* to NH), 135.4 (*ipso* to CH₂O), 132.8 (*para* to CH₂O), 132.1 (*para* to NH), 124.9 (*ipso* to C=O), 123.7 (*para* to C=O), 120.3 (CH=CCH₂CH₂), 120.0 (*meta* to C=O and *ortho* to NH), 115.1 (*ortho* to C=O and *meta* to NH), 109.0 (CH₂CC(NH₂)=N), 108.0 (C(=O)CH), 106.3 (*meta* to CH₂O), 72.0 (CH₂CH₂CH₂O), 56.0 (OCH₃), 33.3 (HNCCH₂), 32.1 (CCH₂C), 31.2 (CH₃CH₂CH₂), 29.1 (CH₂CH₂O), 28.3 - 28.6 (CH₃CH₂CH₂CH₂CH₂CH₂), 25.3 (CH₂CH₂CH₂O), 24.7 (CH=CCH₂), 22.1 (CH₃CH₂), 14.0 (CH₃CH₂)

HRMS (ESI⁺) m/z / Da = 641.3557, [M+H]⁺ found, [C₃₅H₄₅N₈O₄]⁺ 641.3558

1.29 2-(6-(4-(4-(4-((2,4-Diaminopyrimidin-5-yl)methyl)-2,6-dimethoxyphenoxy)butyl)-1H-1,2,3-triazol-1-yl)hexyl)-3-hydroxyquinolin-4(1H)-one **133**



50 % water/*t*-BuOH (1 ml) was degassed by bubbling N₂ through it. This was then added to a mixture of 5-(4-(hex-5-yn-1-yloxy)-3,5-dimethoxybenzyl)pyrimidine-2,4-diamine **125** (14.2 mg, 39.8 μ mol, 1 eq.) and 2-(6-azidoheptyl)-3-hydroxyquinolin-4(1H)-one **70** (11.4 mg, 39.8 μ mol, 1 eq.). A similarly degassed solution of CuSO₄ · 5 H₂O (1.25 mg, 5 μ mol, 0.125 eq. 50 mM), THPTA (2.18 mg, 5 μ mol, 0.125 eq. 50 mM) and sodium ascorbate (1.98 mg, 10 μ mol, 0.25 eq., 100 mM) in water (100 μ l) was then added. The mixture was stirred at r.t. under argon for 3 h, then MeOH (1 ml) was added and the reaction mixture was dry-loaded onto SiO₂ and purified by column chromatography (SiO₂, 0-20 % MeOH/CH₂Cl₂). The combined pure fractions were dried with MgSO₄ and evaporated under reduced pressure. **133** was obtained as a pale brown amorphous solid (4.7 mg, 7.3 μ mol, 18.3 %).

TLC R_f = 0.21 (20 % MeOH/CH₂Cl₂)

IR (neat) ν_{max} / cm⁻¹ = 2924.8 (C-H), 2853.4 (C-H), 1660.0 (pyrimidine), 1638.8 (pyrimidine and PQS C=O),


¹H NMR (500 MHz, DMSO d₆) δ / ppm = 11.53 (br s, 1 H, NH), 8.09 (d, J = 8.0 Hz, 1 H, *ortho* to C=O), 7.83 (s, 1 H, NCH=CCH₂), 7.48 - 7.57 (m, 3 H, *para* to C=O, *ortho* to NH and CHN=CNH₂), 7.21 (ddd, J =

8.0, 6.3, 1.5 Hz, 1 H, *para* to NH), 6.55 (s, 2 H, *meta* to CH₂), 4.28 (t, *J* = 7.1 Hz, 2 H, CH₂N), 3.80 (t, *J* = 6.2 Hz, 2 H, CH₂O), 3.70 (s, 6 H, CH₃), 3.53 (d, *J* = 0.3 Hz, 2 H, CCH₂C), 2.73 (t, *J* = 7.5 Hz, 2 H, HNCCH₂), 2.64 (t, *J* = 7.4 Hz, 2 H, CH=CCH₂), 1.80 (quin, *J* = 7.4 Hz, 2 H, CH₂CH₂N), 1.73 (quin, *J* = 7.5 Hz, 2 H, CH=CCH₂CH₂), 1.66 (quin, *J* = 7.2 Hz, 2 H, HNCCH₂CH₂), 1.62 (quin, *J* = 6.8 Hz, 2 H, CH₂CH₂O), 1.33 - 1.40 (m, 2 H, HNCCH₂CH₂CH₂), 1.27 - 1.32 (m, 2 H, HNCCH₂CH₂CH₂CH₂)

¹³C NMR (125 MHz, DMSO d₆) δ / ppm = 168.9 (C=O), 162.5 (CC(NH₂)N), 162.5 (NC(NH₂)N), 152.9 (CHNC(NH₂)N), 152.8 (*ipso* to OCH₃), 146.8 (CH=CCCH₂CH₂), 137.7 (COH), 137.3 (*para* to OH), 135.4 (HNC), 135.1 (*para* to CH₂O), 134.8 (*ipso* to CH₂O), 129.9 (*para* to C=O), 124.4 (*ortho* to C=O and *meta* to NH), 122.1 (*ipso* to C=O), 121.5 (*para* to NH), 121.4 (CH=CCH₂CH₂), 117.7 (*meta* to C=O and *ortho* to NH), 106.2 (CH₂CC(NH₂)=N), 105.8 (*meta* to CH₂O), 71.9 (CH₂CH₂CH₂O), 55.8 (OCH₃), 49.0 (CH₂N), 32.8 (CCH₂C), 29.5 (CH₂CH₂N), 29.0 (CH₂CH₂O), 28.1 (HNCCH₂CH₂CH₂), 27.9 (HNCCH₂), 27.6 (HNCCH₂CH₂), 25.6 (CH₂CH₂CH₂N), 25.4 (CH₂CH₂CH₂O), 24.6 (CH=CCH₂CH₂)

HRMS (ESI⁺) *m/z* / Da = 643.3365, [M+H]⁺ found, [C₃₄H₄₃N₈O₅]⁺ requires 643.3351

1.30 Methyl 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate **134**



Ciprofloxacin **97** (10.0 g, 30 mmol, 1 eq.) and *p*-toluenesulfonic acid (8.60 mg, 44.5 mmol, 1.5 eq.) were refluxed in methanol (500 ml) for 72 h. The mixture was cooled to room temperature and NaHCO₃ (sat., aq., 100 ml) and water (300 ml) were added. The product was extracted with CH₂Cl₂ (2 × 400 ml), which was dried over MgSO₄ and evaporated under reduced pressure. **134** was obtained as a white amorphous solid (9.16 g, 26.5 mmol, 83.3 %).

TLC R_f = 0.13 (5 % MeOH/CH₂Cl₂)

IR (neat) ν_{max} / cm⁻¹ = 2947.9 (C-H), 2834.9 (C-H), 1720.9 (ester C=O), 1616.8 (quinolone C=O)

¹H NMR (400 MHz, MeOD) δ / ppm = 8.55 (s, 1 H, *ortho* to C(=O)OCH₃), 7.71 (d, J = 13.5 Hz, 1 H, *ortho* to F), 7.41 (d, J = 7.2 Hz, 1 H, *meta* to F), 3.83 (s, 3 H, CH₃), 3.62 (tt, J = 7.4, 3.5 Hz, 1 H, NCH(CH₂)₂), 3.24 - 3.29 (m, 4 H, HN(CH₂CH₂)CH₂CH₂), 3.02 - 3.10 (m, 4 H, HN(CH₂)CH₂), 1.31 - 1.38 (m, 2 H, NCH(CH₂)₂), 1.12 - 1.20 (m, 2 H, NCH(CH₂)₂)

¹³C NMR (101 MHz, MeOD) δ / ppm = 175.2 (C(=O)CC(=O)OCH₃), 166.8 (C(=O)OCH₃), 154.9 (d, J = 248.0 Hz, *ipso* to F), 150.1 (C=CC(=O)OCH₃), 146.6 (d, J = 10.4 Hz, *ipso* to piperazine), 139.9 (*para* to F), 123.3 (d, J = 6.9 Hz, *para* to piperazine), 113.0 (d, J = 23.4 Hz, *ortho* to C=O and *ortho* to F), 110.1 (CC(=O)OCH₃), 107.1 (d, J = 3.5 Hz, *meta* to C=O and *meta* to F), 52.3 (CH₃), 51.7 (HN(CH₂CH₂)CH₂CH₂), 51.6 (HN(CH₂CH₂)CH₂CH₂), 46.5 (HN(CH₂)CH₂), 36.4 (NCH(CH₂)₂), 8.7 (NCH(CH₂)₂)


¹⁹F NMR (376.45 MHz, MeOD) δ / ppm = -124.8 (s, ciprofloxacin **F**)

1dp

HRMS (ESI⁺) m/z / Da = 346.1569, [M+H]⁺ found, [C₁₈H₂₁FN₃O₃]⁺ requires 346.1567

The data are consistent with the literature.⁸

1.31 4-Bromo-*N*-(2-oxotetrahydrothiophen-3-yl)butanamide **135**



3-Aminodihydrothiophen-2(3H)-one hydrochloride **177** (15.0 g, 97.6 mmol, 1 eq.) and NaHCO₃ (16.4 g, 195 mmol, 2 eq.) were added to CH₂Cl₂ (150 ml) and water (150 ml). 4-Bromobutyryl chloride **42** (11.3 ml, 107 mmol, 1.1 eq.) was added dropwise over 45 min at 0 °C and the mixture was stirred for a further 1 h. The organic layer was separated and the aqueous layer was extracted with a second portion of CH₂Cl₂ (150 ml). The combined organic layers were dried over MgSO₄ and evaporated under reduced pressure. **135** was obtained as a white, amorphous solid (22.7 g, 85.8 mmol, 87.9 %)

TLC R_f = 0.19 (50 % EtOAc/PE)

IR (neat) ν_{max} / cm⁻¹ = 3265.9 (amide N-H), 3063.2 (amide N-H), 1694.3 (thiolactone C=O), 1650.5 (amide C=O)


¹H NMR (400 MHz, CDCl₃) δ / ppm = 6.08 (d, J = 6.1 Hz, 1 H, NH), 4.54 (dt, J = 12.9, 6.5 Hz, 1 H, CHNH), 3.49 (t, J = 6.4 Hz, 2 H, CH₂Br), 3.37 (ddd, J = 12.2, 11.5, 5.3 Hz, 1 H, SCHH), 3.26 (ddd, J = 11.5, 6.9, 1.3 Hz, 1 H, SCHH), 2.91 (dddd, J = 12.5, 6.7, 5.3, 1.3 Hz, 1 H, SCH₂CHH), 2.45 (t, J = 7.4 Hz, 1 H, C(=O)CHH), 2.45 (t, J = 6.8 Hz, 1 H, C(=O)CHH), 2.20 (quin, J = 6.7 Hz, 1 H, C(=O)CH₂CH₂), 1.96 (dddd, J = 12.7, 12.5, 12.2, 7.0 Hz, 1 H, SCH₂CHH)

¹³C NMR (101 MHz, CDCl₃) δ / ppm = 205.4 (SC(=O)), 172.1 (NHC(=O)), 59.4 (CHNH), 34.1 (C(=O)CH₂), 33.1 (CH₂Br), 31.8 (SCH₂CH₂), 28.0 (C(=O)CH₂CH₂), 27.5 (SCH₂)

HRMS (ESI⁺) m/z / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

The compound has been synthesised previously^{9,10} but characterisation was not published.

1.32 4-Azido-*N*-(2-oxotetrahydrothiophen-3-yl)butanamide **136**



4-Bromo-*N*-(2-oxotetrahydrothiophen-3-yl)butanamide **135** (6.00 g, 27.0 mmol, 1 eq.) and NaN₃ (3.51 g, 54.1 mmol, 2 eq.) were refluxed in acetonitrile (120 ml) for 1.5 h. The solvent was evaporated under reduced pressure and the residue was partitioned between water (150 ml) and CH₂Cl₂ (150 ml). The aqueous layer was extracted twice more with CH₂Cl₂ (2 × 150 ml) and the combined organic fractions were dried with MgSO₄ and evaporated under reduced pressure. **136** was obtained as a yellow, sticky solid (4.60 g, 20.1 mmol, 89.3 %).

TLC R_f = 0.19 (50 % EtOAc/PE)

IR (neat) ν_{max} / cm⁻¹ = 3285.6 (N-H), 2963.9 (C-H), 2100.2 (azide), 1697.4 (thiolactone C=O), 1647.4 (amide C=O)

¹H NMR (400 MHz, CDCl₃) δ / ppm = 6.71 (d, J = 7.3 Hz, 1 H, NH), 4.54 (dt, J = 13.0, 7.0 Hz, 1 H, CHNH), 3.30 (t, J = 6.7 Hz, 2 H, CH₂N₃), 3.31 (td, J = 11.7, 5.3 Hz, 1 H, 1 H, SCHH), 3.19 (ddd, J = 11.3, 7.0, 1.2 Hz, 1 H, SCHH), 2.70 (dddd, J = 12.4, 6.8, 5.3, 1.2 Hz, 1 H, SCH₂CHH), 2.29 (t, J = 7.5 Hz, 1 H,

Orientation
are not
unam-
biguous
without
noesy.


C(=O)CHH), 2.28 (t, $J = 7.1$ Hz, 1 H, C(=O)CHH), 1.97 (qd, $J = 12.4, 7.0$ Hz, 1 H, SCH₂CHH), 1.85 (quin, $J = 6.9$ Hz, 2 H, C(=O)CH₂CH₂)

¹³C NMR (101 MHz, CDCl₃) δ / ppm = 205.4 (SC(=O)), 172.3 (NHC(=O)), 59.4 (CHNH), 50.6 (CH₂N₃), 32.8 (C(=O)CH₂), 31.8 (SCH₂CH₂), 27.5 (SCH₂), 24.6 (C(=O)CH₂CH₂)

HRMS (ESI⁺) m/z / Da = 251.0565, [M+Na]⁺ found, [C₈H₁₂N₄NaO₂S]⁺ requires 251.0573

The compound has not been reported previously.

1.33 Methyl 1-cyclopropyl-6-fluoro-4-oxo-7-(4-(4-oxo-4-((2-oxotetrahydrothiophen-3-yl)amino)butyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate **137**



Methyl 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate **134** (50 mg, 0.145 mmol, 1 eq.), 4-bromo-*N*-(2-oxotetrahydrothiophen-3-yl)butanamide **135** (34.5 mg, 0.145 mmol, 1 eq.) and K₂CO₃ (20 mg, 0.145 mmol, 1 eq.) were stirred in acetonitrile (2 ml) at 50 °C under argon. After 24 h a further portion of **135** (34.5 mg, 0.145 mmol, 1 eq.) was added. After another 24 h a further portion was added (69.0 mg, 0.290 mmol, 2 eq.). After another 24 h the temperature was raised so the mixture was at reflux. After a final 24 h the precipitate was filtered off and the filtrate was purified by column chromatography (SiO₂, 5-10 % MeOH/CH₂Cl₂). **137** was obtained as a cream-coloured amorphous solid (9.4 mg, 0.018 mmol, 12.2 %).

TLC R_f = 0.47 (10 % MeOH/CH₂Cl₂)

IR (neat) ν_{max} / cm⁻¹ = 2944.2 (C-H), 2832.4 (C-H), 1722.4 (ester C=O), 1700.4 (thiolactone C=O), 1669.6 (amide C=O), 1617.3 (quinolone C=O)

¹H NMR (500 MHz, MeOD) δ / ppm = 8.53 (s, 1 H, *ortho* to C(=O)OCH₃), 7.68 (d, $J=13.4$ Hz, 1 H, *ortho* to F), 7.41 (d, $J=7.3$ Hz, 1 H, *meta* to F), 4.67 (dd, $J=12.9, 6.9$ Hz, 1 H, CHNH), 3.83 (s, 3 H, OCH₃), 3.61 (tt, $J=6.9, 4.1$ Hz, 1 H, NCH(CH₂)₂), 3.39 - 3.49 (m, 5 H, SCHH), 3.26 - 3.33 (m, 1 H, SCHH and CH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂), 2.93 - 3.03 (m, 4 H, CH₂CH₂CH₂N(CH₂)CH₂), 2.79 (br. t, $J=7.2, 7.2$ Hz, 2 H, C(=O)CH₂CH₂CH₂), 2.59 (dddd, $J=12.4, 6.9, 5.4, 1.4$ Hz, 1 H, SCH₂CHH), 2.39 (t, $J=7.20$ Hz, 1 H, C(=O)CHH), 2.38 (t, $J=6.94$ Hz, 1 H, C(=O)CHH), 2.18 (qd, $J=12.4, 7.0$ Hz, 1 H, SCH₂CHH), 1.97 (quin, $J=7.2$ Hz, 2 H, C(=O)CH₂CH₂), 1.32 - 1.37 (m, 2 H, NCH(CHH)₂), 1.13 - 1.19 (m, 2 H, NCH(CHH)₂)

¹³C NMR (126 MHz, MeOD) δ / ppm = 207.0 (SC(=O)), 175.7 (NHC(=O)), 175.1 (C(=O)CC(=O)OCH₃), 166.6 (C(=O)OCH₃), 154.7 (d, $J=249.0$ Hz, *ipso* to F), 150.2 (s, CH=CC(=O)OCH₃), 145.6 (d, $J=10.6$ Hz, *ipso* to piperazine), 139.8 (*para* to F), 123.5 (d, $J=6.9$ Hz, *para* to piperazine), 113.1 (d, $J=23.6$ Hz, *ortho*

to C=O and *ortho* to F), 110.0 ($\underline{\text{C}}\text{C}(=\text{O})\text{OCH}_3$), 107.4 (*meta* to C=O and *meta* to F), 60.2 ($\underline{\text{C}}\text{HNH}$), 58.5 ($\text{C}(=\text{O})\text{CH}_2\text{CH}_2\underline{\text{C}}\text{H}_2$), 53.8 ($\text{C}(=\text{O})\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\underline{\text{C}}\text{H}_2)\underline{\text{C}}\text{H}_2$), 52.3 ($\text{O}\underline{\text{C}}\text{H}_3$), 50.1 ($\text{C}(=\text{O})\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{CH}_2\underline{\text{C}}\text{H}_2)\text{CH}_2\text{CH}_2$), 50.0 ($\text{C}(=\text{O})\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{CH}_2\text{CH}_2)\text{CH}_2\underline{\text{C}}\text{H}_2$), 36.5 ($\text{N}\underline{\text{C}}\text{H}(\text{CH}_2)_2$), 34.5 ($\text{C}(=\text{O})\underline{\text{C}}\text{H}_2$), 31.7 ($\text{SCH}_2\underline{\text{C}}\text{H}_2$), 28.1 (SCH_2), 22.9 ($\text{C}(=\text{O})\text{CH}_2\underline{\text{C}}\text{H}_2\text{CH}_2$), 8.7 ($\text{NCH}(\underline{\text{C}}\text{H}_2)_2$)


^{19}F NMR (376.45 MHz, MeOD) δ / ppm = -125.35 (s, ciprofloxacin F)

HRMS (ESI⁺) m/z / Da = 531.2083, $[\text{M}+\text{H}]^+$ found, $[\text{C}_{26}\text{H}_{32}\text{FN}_4\text{O}_5\text{S}]^+$ requires 531.2077

The compound has been synthesised previously.^{9,10} Only HRMS characterisation was published, and this agrees with the result above.

check??

1.34 1-Cyclopropyl-6-fluoro-4-oxo-7-(4-(4-(1-(4-oxo-4-((2-oxotetrahydrothiophen-3-yl)amino)butyl)-1H-1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid **138**



1-Cyclopropyl-6-fluoro-7-(4-(hex-5-yn-1-yl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid **176** (12.9 mg, 31.4 μmol , 1 eq.), 4-azido-*N*-(2-oxotetrahydrothiophen-3-yl)butanamide **136** (7.2 mg, 31.4 μmol , 1 eq.), CuI (3.6 mg, 18.9 μmol , 0.6 eq.) and DIPEA (8.00 μl , 5.9 mg, 45.9 μmol , 1.5 eq.) were stirred in CH_2Cl_2 (1.4 ml) at r.t. under Ar for 3 h. Water (10 ml) was added, and the organic layer was separated off. The aqueous layer was further extracted with 10 % *i*-PrOH/ CHCl_3 (3×10 ml), and the combined organic layers were dried with MgSO_4 and concentrated under reduced pressure. **138** was obtained as a white amorphous solid (16.5 mg, 25.9 μmol , 82.5 %).

IR (neat) ν_{max} / cm^{-1} = 2918.8 (C-H), 1712.7 (carboxylic acid C=O and thiolactone C=O), 1657.6 (amide C=O), 1626.8 (quinolone C=O), 1616.2 (triazole)


^1H NMR (400 MHz, MeOD) δ / ppm = ??

^{13}C NMR (101 MHz, MeOD) δ / ppm = ??

^{19}F NMR (376.45 MHz, MeOD) δ / ppm = -124.86 (s, ciprofloxacin F)

HRMS (ESI⁺) m/z / Da = 640.2739, $[\text{M}+\text{H}]^+$ found, $[\text{C}_{31}\text{H}_{39}\text{FN}_7\text{O}_5\text{S}]^+$ requires 640.2712

1.35 1-Cyclopropyl-6-fluoro-4-oxo-7-(4-((((4-(1-(4-oxo-4-(2-oxotetrahydrothiophen-3-yl)amino)butyl)-1H-1,2,3-triazol-4-yl)butanoyl)oxy)methoxy)carbonyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid **139**



1-Cyclopropyl-6-fluoro-7-(4-((((hex-5-ynoyloxy)methoxy)carbonyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid **178** (203 mg, 0.407 mmol, 1 eq.), 4-azido-*N*-(2-oxotetrahydrothiophen-3-yl)butanamide **136** (92.8 mg, 0.407 mmol, 1 eq.), CuI (40 mg, 0.190 mmol, 0.5 eq.) and DIPEA (0.356 ml, 0.264 mg, 2.04 mmol, 5 eq.) were stirred in CH₂Cl₂ (18.6 ml) at r.t. under Ar for 3 h. The mixture was filtered and the filtrate was dry-loaded onto SiO₂ and purified by column chromatography (SiO₂, 5-10 % MeOH/CH₂Cl₂). **139** was obtained as pale brown/yellow amorphous solid (14.7 mg, 20.2 μmol, 5.0 %).

TLC R_f = 0.40 (5 % CH₂Cl₂/MeOH)

IR (neat) ν_{max} / cm⁻¹ = 3054.9 (C-H), 1715.8 (carboxylic acid C=O and ester C=O), 1696.2 (carbamate C=O and thiolactone C=O), 1651.2 (amide C=O), 1629.2 (quinolone C=O)

¹H NMR (400 MHz, DMSO d₆) δ / ppm = 15.16 (br. s., 1 H, C(=O)OH), 8.65 (s, 1 H, *ortho* to C(=O)OH), 8.21 (d, J = 8.5 Hz, 1 H, NH), 7.89 (d, J = 13.1 Hz, 1 H, *ortho* to F), 7.85 (s, 1 H, CH=CCH₂), 7.57 (d, J = 7.4 Hz, 1 H, *meta* to F), 5.74 (s, 1 H, OCH₂O), 4.58 (ddd, J = 12.6, 8.1, 7.2 Hz, 1 H, CHNH), 4.30 (t, J = 6.9 Hz, 2 H, C(=O)CH₂CH₂CH₂N), 3.80 (tt, J = 6.9, 3.6 Hz, 1 H, NCH(CH₂)₂), 3.62 (br t, J = 5.2, 5.2 Hz, 4 H, C(=O)N(CH₂)CH₂), 3.38 (td, J = 11.4, 5.5 Hz, 1 H, SCHH), 3.34 (br. s, 4 H, C(=O)N(CH₂CH₂)CH₂CH₂), 3.27 (ddd, J = 11.0, 6.9, 1.6 Hz, 1 H, SCHH), 2.64 (t, J = 7.6 Hz, 2 H, CH=CCH₂), 2.44 (t, J = 7.5 Hz, 2 H, CH₂C(=O)O), 2.40 (dddd, J = 12.3, 6.8, 5.4, 1.4 Hz, 1 H, SCH₂CHH), 2.12 (t, J = 7.8 Hz, 1 H, NHC(=O)CHH), 2.12 (t, J = 6.8 Hz, 1 H, NHC(=O)CHH), 1.98 - 2.07 (m, 3 H, SCH₂CHH and NHC(=O)CH₂CH₂), 1.86 (quin, J = 7.5 Hz, 2 H, CH=CCH₂CH₂), 1.29 - 1.36 (m, 2 H, NCH(CHH)₂), 1.14 - 1.21 (m, 2 H, NCH(CHH)₂)

¹³C NMR (101 MHz, DMSO d₆) δ / ppm = 205.5 (SC(=O)), 176.4 (C(=O)CC(=O)OH), 171.8 (C(=O)OCH₂O), 171.3 (NHC(=O)), 165.9 (C(=O)OH), 152.8 (d, J = 249.7 Hz, *ipso* to F), 152.9 (OC(=O)N), 148.1 (CH=CC(=O)OH), 146.0 (CH=CCH₂), 144.9 (d, J = 9.6 Hz, *ipso* to piperazine), 139.1 (*para* to F), 122.0 (CH=CCH₂), 118.9 (d, J = 7.5 Hz, *para* to piperazine), 111.0 (d, J = 23.5 Hz, *ortho* to C=O and *ortho* to F), 106.8 (CC(=O)OH, and *meta* to C=O and *meta* to F), 80.3 (OCH₂O), 58.2 (CHNH), 49.1 (C(=O)N(CH₂CH₂)CH₂CH₂), 49.1 (C(=O)N(CH₂CH₂)CH₂CH₂), 48.6 (C(=O)CH₂CH₂CH₂N), 43.4 (N(CH₂)CH₂), 43.0 (N(CH₂)CH₂), 35.9 (NCH(CH₂)₂), 32.7 (CH=CCH₂CH₂CH₂C(=O)), 31.8 (NHC(=O)CH₂), 30.1 (SCH₂CH₂), 26.8 (SCH₂), 25.8 (C(=O)CH₂CH₂CH₂N), 24.2 (CH=CCH₂CH₂CH₂C(=O)), 24.0 (CH=CCH₂CH₂CH₂C(=O)), 7.6 (NCH(CH₂)₂)


¹⁹F NMR (376.45 MHz, DMSO d₆) δ / ppm = ??

no F

HRMS (ESI⁺) m/z / Da = 728.2502, [M+H]⁺ found, [C₃₃H₃₉FN₇O₉S]⁺ requires 728.2503

The compound has not been reported previously.

1.36 1-Cyclopropyl-6-fluoro-4-oxo-7-(4-((1-((4-(1-(4-oxo-4-((2-oxotetrahydrothiophen-3-yl)amino)butyl)-1H-1,2,3-triazol-4-yl)butanoyl)oxy)ethoxy)carbonyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid 140



Method?? white amorphous solid 1.2 mg, 1.6 μ mol

TLC R_f = 0.33 (10 % MeOH/CH₂Cl₂)

IR (neat) ν_{max} / cm⁻¹ = ??


¹H NMR (400 MHz, MeOD) δ / ppm = ??

¹³C NMR (101 MHz, MeOD) δ / ppm = ??

¹⁹F NMR (376.45 MHz, MeOD) δ / ppm = ??

HRMS (ESI⁺) m/z / Da = 742.2670, [M+H]⁺ found, [C₃₄H₄₁FN₇O₉S]⁺ requires 742.2671

1.37 4-Bromo-N-(2-methoxyphenyl)butanamide 141



2-Methoxyaniline **179** (9.12 ml, 10.0 g, 81.2 mmol, 1 eq.) and NaHCO₃ (8.19 g, 97.4 mmol, 1.2 eq.) were dissolved in water (100 ml) and CH₂Cl₂ (100 ml). The mixture was cooled to 0 °C and 4-bromobutyryl chloride **42** (9.40 ml, 15.1 g, 81.2 mmol, 1 eq.) was added dropwise over 15 min. The mixture was stirred at 0 °C for 1.5 h, then the aqueous layer was removed. The organic layer was dried with MgSO₄ and evaporated under reduced pressure. **141** was obtained as an initially colourless liquid which slowly turned blue then black if left out on the bench (11.0 g, 40.6 mmol, 50.0 %).

TLC $R_f = 0.16$ (10 % EtOAc/P.E.)

IR (neat) $\nu_{max} / \text{cm}^{-1} = 3410.2$ (N-H), 3313.4 (N-H), 2961.6 (C-H), 2939.5 (C-H), 2902.5 (C-H), 1676.4 (amide C=O)


^1H NMR (400 MHz, CDCl_3 d_1) $\delta / \text{ppm} = 8.32$ (dd, $J = 8.0, 1.7$ Hz, 1 H, *ortho* to NH), 7.85 (br s, 1 H, NH), 7.02 (td, $J = 7.9, 1.7$ Hz, 1 H, *para* to NH), 6.93 (td, $J = 7.7, 1.4$ Hz, 1 H, *para* to OCH_3), 6.85 (dd, $J = 8.1, 1.5$ Hz, 1 H, *ortho* to OCH_3), 3.85 (s, 3 H, CH_3), 3.50 (t, $J = 6.4$ Hz, 2 H, CH_2Br), 2.56 (t, $J = 7.1$ Hz, 2 H, C(=O)CH_2), 2.25 (quin, $J = 6.7$ Hz, 2 H, $\text{C(=O)CH}_2\text{CH}_2$)

^{13}C NMR (101 MHz, CDCl_3 d_1) $\delta / \text{ppm} = 169.4$ (C(=O)), 147.6 (*ipso* to OCH_3), 127.2 (*ipso* to NH), 123.5 (*para* to NH), 120.7 (*para* to OCH_3), 119.6 (*ortho* to NH and *meta* to OCH_3), 109.8 (*ortho* to OCH_3 and *meta* to NH), 55.5 (CH_3), 35.4 (C(=O)CH_2), 33.1 (CH_2Br), 27.9 ($\text{C(=O)CH}_2\text{CH}_2$)

HRMS (ESI^+) $m/z / \text{Da} = 272.0287$, $[\text{M}+\text{H}]^+$ found, $[\text{C}_{11}\text{H}_{15}\text{BrNO}_2]^+$ requires 272.0286

The compound has not been reported previously.

1.38 4-Bromo-*N*-(3-methoxyphenyl)butanamide 142



3-Methoxyaniline **180** (3.04 ml, 3.33 g, 27.1 mmol, 1 eq.) and NaHCO_3 (2.73 g, 32.5 mmol, 1.2 eq.) were dissolved in water (30 ml) and CH_2Cl_2 (30 ml). The mixture was cooled to 0 °C and 4-bromobutyryl chloride **42** (3.13 ml, 5.03 g, 27.1 mmol, 1 eq.) was added dropwise over 5 min. The mixture was stirred at 0 °C for 1 h, then the aqueous layer was removed. The organic layer was dry-loaded onto SiO_2 and purified by column chromatography using a Combiflash (SiO_2 , 0-100 % EtOAc/P.E.). **142** was obtained as a pale pink amorphous solid (3.66 g, 13.5 mmol, 49.6 %).

how to report?

TLC $R_f = 0.18$ (25 % EtOAc/P.E.)

IR (neat) $\nu_{max} / \text{cm}^{-1} = 1670.9$ (amide C=O)


^1H NMR (400 MHz, CDCl_3 d_1) $\delta / \text{ppm} = 8.45$ (s, 1 H, NH), 7.27 (t, $J = 2.2$ Hz, 1 H, *ortho* to OCH_3 and *ortho* to NH), 7.14 (t, $J = 8.1$ Hz, 1 H, *meta* to OCH_3 and *meta* to NH), 7.02 (d, $J = 8.3$ Hz, 1 H, *para* to OCH_3), 6.62 (dd, $J = 8.2, 2.1$ Hz, 1 H, *para* to NH), 3.71 (s, 3 H, CH_3), 3.42 (t, $J = 6.5$ Hz, 2 H, CH_2Br), 2.51 (t, $J = 6.9$ Hz, 2 H, C(=O)CH_2), 2.19 (quin, $J = 6.8$ Hz, 2 H, $\text{C(=O)CH}_2\text{CH}_2$)

^{13}C NMR (101 MHz, CDCl_3 d_1) $\delta / \text{ppm} = 170.3$ (C(=O)), 159.9 (*ipso* to OCH_3), 139.0 (*ipso* to NH), 129.5 (*meta* to OCH_3 and *meta* to NH), 112.1 (*para* to OCH_3), 109.9 (*para* to NH), 105.7 (*ortho* to OCH_3 and *ortho* to NH), 55.2 (CH_3), 35.3 (C(=O)CH_2), 33.2 (CH_2Br), 28.0 ($\text{C(=O)CH}_2\text{CH}_2$)

HRMS (ESI^+) $m/z / \text{Da} = ??$, $[\text{M}+\text{H}]^+$ found, $[?]^+$ requires ??

The compound has not been reported previously.

1.39 4-Azido-*N*-(2-methoxyphenyl)butanamide **143**



4-Bromo-*N*-(2-methoxyphenyl)butanamide **141** (2.05 g, 7.51 mmol, 1 eq.) and NaN₃ (1.17 g, 18.0 mmol, 2.4 eq.) were refluxed in acetonitrile (100 ml) for 2 h. The mixture was cooled and filtered, and the filtrate was dry-loaded onto SiO₂ and purified by column chromatography using a Combiflash (SiO₂, 8-14 % then hold at 14 % EtOAc/P.E.). **143** was obtained as an initially colourless liquid which slowly turned blue then black if left out on the bench (0.469 g, 2.00 mmol, 26.7 %).

how to
report?

TLC R_f = 0.20 (25 % EtOAc/P.E.)

IR (neat) ν_{max} / cm⁻¹ = 3419.7 (N-H), 3329.6 (N-H), 2094.8 (azide), 1672.3 (amide C=O)


¹H NMR (400 MHz, CDCl₃ d₁) δ / ppm = 8.32 (dd, J = 7.9, 1.0 Hz, 1 H, *ortho* to NH), 7.86 (br s, 1 H, NH), 7.00 (td, J = 7.5, 1.5 Hz, 1 H, *para* to NH), 6.90 (td, J = 7.7, 1.1 Hz, 1 H, *para* to OCH₃), 6.83 (dd, J = 8.1, 1.4 Hz, 1 H, *ortho* to OCH₃), 3.81 (s, 3 H, CH₃), 3.33 (t, J = 6.7 Hz, 2 H, CH₂Br), 2.42 (t, J = 7.2 Hz, 2 H, C(=O)CH₂), 1.94 (quin, J = 6.9 Hz, 2 H, C(=O)CH₂CH₂)

¹³C NMR (101 MHz, CDCl₃ d₁) δ / ppm = 169.5 (C(=O)), 147.6 (*ipso* to OCH₃), 127.1 (*ipso* to NH), 123.4 (*para* to NH), 120.5 (*para* to OCH₃), 119.5 (*ortho* to NH and *meta* to OCH₃), 109.6 (*ortho* to OCH₃ and *meta* to NH), 55.2 (CH₃), 50.3 (CH₂N₃), 33.9 (C(=O)CH₂), 24.3 (C(=O)CH₂CH₂)

HRMS (ESI⁺) m/z / Da = 257.1010, [M+H]⁺ found, [C₁₁H₁₄N₄NaO₂]⁺ requires 257.1014

The data are consistent with the literature.¹¹

1.40 4-Azido-*N*-(3-methoxyphenyl)butanamide **144**



4-Bromo-*N*-(3-methoxyphenyl)butanamide **142** (2.05 g, 7.51 mmol, 1 eq.) and NaN₃ (1.17 g, 18.0 mmol, 2.4 eq.) were refluxed in acetonitrile (100 ml) for 7 h. The mixture was cooled and filtered, and the filtrate was dry-loaded onto SiO₂ and purified by column chromatography using a Combiflash (SiO₂, 0-100 % EtOAc/P.E.). **144** was obtained as a straw-coloured liquid (0.294 g, 1.25 mmol, 16.7 %).

how to
report?

TLC R_f = 0.37 (50 % EtOAc/P.E.)

IR (neat) ν_{max} / cm^{-1} = 3298.3 (N-H), 2094.7 (azide), 1661.7 (amide C=O)


^1H NMR (400 MHz, MeOD) δ / ppm = 8.63 (br s, 1 H, NH), 7.26 (t, J = 2.3 Hz, 1 H, *ortho* to OCH₃ and *ortho* to NH), 7.15 (t, J = 8.1 Hz, 1 H, *meta* to OCH₃ and *meta* to NH), 7.01 (dd, J = 7.8, 1.6 Hz, 1 H, *para* to OCH₃), 6.63 (dd, J = 8.2, 1.9 Hz, 1 H, *para* to NH), 3.69 (s, 3 H, CH₃), 3.28 (t, J = 6.7 Hz, 2 H, CH₂N₃), 2.39 (t, J = 7.4 Hz, 2 H, C(=O)CH₂), 1.91 (quin, J = 7.0 Hz, 2 H, C(=O)CH₂CH₂)

^{13}C NMR (101 MHz, MeOD) δ / ppm = 170.8 (C(=O)), 159.6 (*ipso* to OCH₃), 138.9 (*ipso* to NH), 129.2 (*meta* to OCH₃ and *meta* to NH), 112.3 (*para* to OCH₃), 109.5 (*para* to NH), 106.0 (*ortho* to OCH₃ and *ortho* to NH), 54.8 (CH₃), 50.4 (CH₂N₃), 33.6 (C(=O)CH₂), 24.4 (C(=O)CH₂CH₂)

HRMS (ESI⁺) m/z / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

The compound has not been reported previously.

1.41 Methyl 1-cyclopropyl-6-fluoro-7-(4-(4-((2-methoxyphenyl)amino)-4-oxobutyl)-piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate **145**



Methyl 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate **134** (500 mg, 1.45 mmol, 1 eq.), 4-bromo-*N*-(2-methoxyphenyl)butanamide **141** (788 mg, 2.90 mmol, 2 eq.), DIPEA (1.28 ml, 950 mg, 7.35 mmol, 5 eq.), NaI (275 mg, 1.83 mmol, 1.3 eq.) and acetonitrile (10 ml) were stirred in a microwave reactor at 100 °C for 4 h. The mixture was dry-loaded onto SiO₂ and purified by column chromatography (SiO₂, 4 % MeOH/CH₂Cl₂). **145** was obtained as a bright pink glass (79.7 mg, 0.149 mmol, 10.2 %).

how to report?

TLC R_f = 0.40 (10 % MeOH/CH₂Cl₂)

IR (neat) ν_{max} / cm^{-1} = 2947.1 (C-H), 2833.7 (C-H), 1718.9 (ester C=O), 1685.3 (amide C=O), 1617.3 (quinolone C=O)

^1H NMR (400 MHz, CDCl₃ d₁) δ / ppm = 8.48 (s, 1 H, *ortho* to C(=O)OCH₃), 8.36 (d, J = 7.9 Hz, 1 H, *ortho* to NH), 7.87 - 7.99 (m, 2 H, *ortho* to F and NH), 7.19 (d, J = 6.5 Hz, 1 H, *meta* to F), 7.01 (t, J = 7.5 Hz, 1 H, *para* to NH), 6.93 (t, J = 7.7 Hz, 1 H, *para* to OCH₃), 6.85 (d, J = 7.9 Hz, 1 H, *ortho* to OCH₃), 3.88 (s, 3 H, C(=O)OCH₃), 3.85 (s, 3 H, aromatic OCH₃), 3.41 (tt, J = 6.9, 4.0 Hz, 1 H, NCH(CH₂)₂), 3.25 (br t, J = 5.0, 5.0 Hz, 4 H, C(=O)CH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂), 2.67 (br t, J = 5.0, 5.0 Hz, 4 H, C(=O)CH₂CH₂CH₂N(CH₂)CH₂), 2.53 (t, J = 7.0 Hz, 2 H, C(=O)CH₂CH₂CH₂N), 2.47 (t, J = 7.1 Hz, 2 H, C(=O)CH₂CH₂CH₂N), 1.97 (quin, J = 6.8 Hz, 2 H, C(=O)CH₂CH₂CH₂N), 1.25 - 1.33 (m, 2 H, NCH(CH₂)₂), 1.07 - 1.14 (m, 2 H, NCH(CH₂)₂)

^{13}C NMR (101 MHz, CDCl_3 d_1) δ / ppm = 172.9 ($\text{C}(=\text{O})\text{CC}(=\text{O})\text{OCH}_3$), 170.8 ($\text{NHC}(=\text{O})$), 166.2 ($\text{C}(=\text{O})\text{OCH}_3$), 153.3 (d, $J = 248.0$ Hz, *ipso* to F), 148.2 ($\text{C}=\text{CC}(=\text{O})\text{OCH}_3$), 147.6 (*ipso* to OCH_3), 144.4 (d, $J = 10.4$ Hz, *ipso* to piperazine), 137.9 (*para* to F), 127.6 (*ipso* to NH), 123.4 (*para* to NH), 122.7 (d, $J = 7.8$ Hz, *para* to piperazine), 121.0 (*para* to OCH_3), 119.7 (*ortho* to NH and *meta* to OCH_3), 113.0 (d, $J = 22.5$ Hz, *ortho* to C=O and *ortho* to F), 109.8 (*ortho* to OCH_3 and *meta* to NH, and $\text{CC}(=\text{O})\text{OCH}_3$), 104.7 (*meta* to C=O and *meta* to F), 57.2 ($\text{CH}_2\text{CH}_2\text{CH}_2\text{N}$), 55.6 (aromatic OCH_3), 52.7 ($\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{CH}_2)\text{CH}_2$), 51.9 ($\text{C}(=\text{O})\text{OCH}_3$), 49.8 ($\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{CH}_2\text{CH}_2)\text{CH}_2\text{CH}_2$), 49.8 ($\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{CH}_2\text{CH}_2)\text{CH}_2\text{CH}_2$), 35.5 ($\text{CH}_2\text{CH}_2\text{CH}_2\text{N}$), 34.5 ($\text{NCH}(\text{CH}_2)_2$), 22.3 ($\text{CH}_2\text{CH}_2\text{CH}_2\text{N}$), 8.0 ($\text{NCH}(\text{CH}_2)_2$)


^{19}F NMR (376.45 MHz, CDCl_3 d_1) δ / ppm = ??

Check
for F

HRMS (ESI^+) m/z / Da = 537.2523, $[\text{M}+\text{H}]^+$ found, $[\text{C}_{29}\text{H}_{34}\text{FN}_4\text{O}_5]^+$ requires 537.2513

The compound has not been reported previously.

1.42 Methyl 1-cyclopropyl-6-fluoro-7-(4-(4-((3-methoxyphenyl)amino)-4-oxobutyl)-piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate **146**



Methyl 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate **134** (500 mg, 1.45 mmol, 1 eq.), 4-bromo-*N*-(3-methoxyphenyl)butanamide **142** (788 mg, 2.90 mmol, 2 eq.), DIPEA (1.28 ml, 950 mg, 7.35 mmol, 5 eq.), NaI (275 mg, 1.83 mmol, 1.3 eq.) and acetonitrile (10 ml) were stirred in a microwave reactor at 100 °C for 4 h. The mixture was evaporated under reduced pressure and partitioned between CH_2Cl_2 (50 ml) and water (50 ml). The organic layer was separated off and the aqueous layer was extracted again with CH_2Cl_2 (50 ml). The combined organic layers were dried with MgSO_4 and purified by column chromatography (SiO_2 , 0-4 % $\text{MeOH}/\text{CH}_2\text{Cl}_2$). **146** was obtained as an off-white amorphous solid (81.7 mg, 0.152 mmol, 10.5 %).

how to
report?

TLC $R_f = 0.38$ (10 % $\text{MeOH}/\text{CH}_2\text{Cl}_2$)

IR (neat) ν_{max} / cm^{-1} = 3270.8 (amide N-H) 2943.8 (C-H), 2817.0 (C-H), 1729.5 (ester C=O), 1682.0 (amide C=O), 1613.5 (quinolone C=O)

^1H NMR (400 MHz, CDCl_3) δ / ppm = 8.56 (s, 1 H, *ortho* to $\text{C}(=\text{O})\text{OCH}_3$), 8.06 (d, $J = 13.3$ Hz, 1 H, *ortho* to F), 8.02 (br s, 1 H, NH), 7.34 (t, $J = 1.7$ Hz, 1 H, *ortho* to OCH_3 and *ortho* to NH), 7.25 (d, $J = 7.0$ Hz, 1 H, *meta* to F), 7.20 (t, $J = 8.2$ Hz, 1 H, *meta* to OCH_3 and *meta* to NH), 6.98 (dd, $J = 7.8$, 1.7 Hz, 1 H, *para* to OCH_3), 6.65 (dd, $J = 8.2$, 2.1 Hz, 1 H, *para* to NH), 3.93 (s, 3 H, $\text{C}(=\text{O})\text{OCH}_3$), 3.80 (s, 3 H, aromatic OCH_3), 3.42 (tt, $J = 6.8$, 3.7 Hz, 1 H, $\text{NCH}(\text{CH}_2)_2$), 3.31 (br t, $J = 4.3$, 4.3 Hz, 4 H, $\text{C}(=\text{O})\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{CH}_2\text{CH}_2)\text{CH}_2\text{CH}_2$), 2.73 (br t, $J = 4.5$, 4.5 Hz, 4 H, $\text{C}(=\text{O})\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{CH}_2)\text{CH}_2$),

2.58 (t, $J = 6.5$ Hz, 2 H, C(=O)CH₂CH₂CH₂N), 2.48 (t, $J = 6.8$ Hz, 2 H, C(=O)CH₂CH₂CH₂N), 2.00 (quin, $J = 6.8$ Hz, 2 H, C(=O)CH₂CH₂CH₂N), 1.29 - 1.36 (m, 2 H, NCH(CH₂)₂), 1.11 - 1.17 (m, 2 H, NCH(CH₂)₂)


¹³C NMR (101 MHz, CDCl₃) δ / ppm = 173.1 (C(=O)CC(=O)OCH₃), 170.9 (NHC(=O)), 166.3 (C(=O)OCH₃), 160.1 (*ipso* to OCH₃), 153.3 (d, $J=250.1$ Hz, *ipso* to F), 148.4 (C=CC(=O)OCH₃), 144.1 (d, $J=10.1$ Hz, *ipso* to piperazine), 139.4 (*ipso* to NH), 138.0 (*para* to F), 129.6 (*meta* to NH and *meta* to OCH₃), 123.3 (d, $J=6.4$ Hz, *para* to piperazine), 113.4 (d, $J=23.3$ Hz, *ortho* to C=O and *ortho* to F), 111.8 (*para* to OCH₃), 110.0 (CC(=O)OCH₃), 109.8 (*para* to NH), 105.5 (*ortho* to OCH₃ and *ortho* to NH), 105.0 (*meta* to C=O and *meta* to F), 57.0 (CH₂CH₂CH₂N), 55.3 (aromatic OCH₃), 52.6 (CH₂CH₂CH₂N(CH₂)CH₂), 52.1 (C(=O)OCH₃), 49.2 (CH₂CH₂CH₂N(CH₂)CH₂CH₂), 35.2 (CH₂CH₂CH₂N), 34.6 (NCH(CH₂)₂), 21.7 (CH₂CH₂CH₂N), 8.2 (NCH(CH₂)₂)

¹⁹F NMR (376.45 MHz, MeOD) δ / ppm = -123.5 (s, ciprofloxacin F)

HRMS (ESI⁺) m/z / Da = 537.2500, [M+H]⁺ found, [C₂₉H₃₄FN₄O₅]⁺ requires 537.2513

The compound has not been reported previously.

1.43 1-Cyclopropyl-6-fluoro-7-(4-(4-(1-(4-((2-methoxyphenyl)amino)-4-oxobutyl)-1H-1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid **147**



1-Cyclopropyl-6-fluoro-7-(4-(hex-5-yn-1-yl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid **176** (24.1 mg, 58.6 μ mol, 1 eq.) and 4-azido-*N*-(2-methoxyphenyl)butanamide **143** (13.7 mg, 58.5 μ mol, 1 eq.) were dissolved in water (3 ml), *t*-BuOH (9 ml) and CH₂Cl₂ (9 ml), and the mixture was degassed by bubbling through N₂. A solution of CuSO₄ and THPTA (117 μ l, 5.85 μ mol, 0.1 eq., 50 mM, aq.) was added, followed by a solution of sodium ascorbate (234 μ l, 11.7 μ mol, 0.2 eq., 50 mM, aq.). The mixture was stirred at room temperature under argon for 16 h. Water (25 ml), CH₂Cl₂ (25 ml) and MeOH (5 ml) were added and the organic layer was separated off, dry-loaded onto SiO₂ and purified by column chromatography using a Combiflash (SiO₂, 3-23 % MeOH/CH₂Cl₂). **147** was obtained as a clear glass (14.7 mg, 22.8 μ mol, 39.0 %).

TLC R_f = 0.28 (10 % MeOH/CH₂Cl₂)

IR (neat) ν_{max} / cm⁻¹ = 2926.5 (C-H), 2846.6 (C-H), 1723.4 (carboxylic acid C=O), 1682.0 (amide C=O), 1625.8 (quinolone C=O), 1612.8 (triazole)

¹H NMR (400 MHz, CDCl₃) δ / ppm = 15.05 (br s, 1 H, C(=O)OH), 8.76 (s, 1 H, *ortho* to C(=O)OH), 8.31

how to phrase this?

how to report??

(dd, $J = 8.0, 1.7$ Hz, 1 H, *ortho* to NH), 8.00 (d, $J = 13.0$ Hz, 1 H, *ortho* to F), 7.83 (br s, 1 H, NH), 7.37 (s, 1 H, $\text{CH}=\text{CCH}_2$), 7.35 (d, $J = 7.2$ Hz, 1 H, *meta* to F), 7.04 (td, $J = 7.7, 1.7$ Hz, 1 H, *para* to NH), 6.95 (td, $J = 7.8, 1.5$ Hz, 1 H, *para* to OCH_3), 6.88 (dd, $J = 8.1, 1.4$ Hz, 1 H, *ortho* to OCH_3), 4.47 (t, $J = 6.7$ Hz, 2 H, $\text{C}(=\text{O})\text{CH}_2\text{CH}_2\text{CH}_2\text{N}$), 3.88 (s, 3 H, CH_3), 3.54 (tt, $J = 6.9, 4.0$ Hz, 1 H, $\text{NCH}(\text{CH}_2)_2$), 3.35 (br t, $J = 4.7$ Hz, 4 H, $\text{CH}=\text{CCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{CH}_2\text{CH}_2)\text{CH}_2\text{CH}_2$), 2.76 (t, $J = 7.5$ Hz, 2 H, $\text{CH}=\text{CCH}_2$), 2.66 (t, $J = 4.7$ Hz, 4 H, $\text{CH}=\text{CCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{CH}_2)\text{CH}_2$), 2.47 (t, $J = 7.3$ Hz, 2 H, $\text{CH}=\text{CCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}$), 2.44 (t, $J = 6.8$ Hz, 2 H, $\text{C}(=\text{O})\text{CH}_2\text{CH}_2\text{CH}_2\text{N}$), 2.32 (quin, $J = 6.7$ Hz, 2 H, $\text{C}(=\text{O})\text{CH}_2\text{CH}_2\text{CH}_2\text{N}$), 1.75 (quin, $J = 7.6$ Hz, 2 H, $\text{CH}=\text{CCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}$), 1.61 (quin, $J = 7.5$ Hz, 2 H, $\text{CH}=\text{CCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}$), 1.35 - 1.42 (m, 2 H, $\text{NCH}(\text{CHH})_2$), 1.17 - 1.22 (m, 2 H, $\text{NCH}(\text{CHH})_2$)


^{13}C NMR (101 MHz, CDCl_3) δ / ppm = 177.1 ($\text{C}(=\text{O})\text{CC}(=\text{O})\text{OH}$), 169.5 ($\text{NHC}(=\text{O})$), 167.0 ($\text{C}(=\text{O})\text{OH}$), 153.7 (d, $J = 251.4$ Hz, *ipso* to F), 148.1 ($\text{CH}=\text{CCH}_2$), 147.8 (*ipso* to OCH_3), 147.3 ($\text{C}=\text{CC}(=\text{O})\text{OH}$), 145.9 (d, $J = 10.4$ Hz, *ipso* to piperazine), 139.1 (*para* to F), 127.3 (*ipso* to NH), 123.9 (*para* to NH), 121.0 (*para* to OCH_3), 120.9 ($\text{CH}=\text{CCH}_2$), 119.7 (*para* to piperazine, and *ortho* to NH and *meta* to OCH_3), 112.4 (d, $J = 23.4$ Hz, *ortho* to C=O and *ortho* to F), 109.9 (*ortho* to OCH_3 and *meta* to NH), 108.1 ($\text{CC}(=\text{O})\text{OH}$), 104.7 (*meta* to C=O and *meta* to F), 58.1 ($\text{CH}=\text{CCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}$), 55.6 (CH_3), 52.8 ($\text{CH}=\text{CCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{CH}_2)\text{CH}_2$), 49.8 ($\text{CH}=\text{CCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{CH}_2\text{CH}_2)\text{CH}_2\text{CH}_2$), 49.8 ($\text{CH}=\text{CCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{CH}_2\text{CH}_2)\text{CH}_2\text{CH}_2$), 49.1 ($\text{C}(=\text{O})\text{CH}_2\text{CH}_2\text{CH}_2\text{N}$), 35.2 ($\text{NCH}(\text{CH}_2)_2$), 33.8 ($\text{C}(=\text{O})\text{CH}_2\text{CH}_2\text{CH}_2\text{N}$), 27.3 ($\text{CH}=\text{CCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}$), 26.4 ($\text{CH}=\text{CCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}$), 26.0 ($\text{C}(=\text{O})\text{CH}_2\text{CH}_2\text{CH}_2\text{N}$), 25.5 ($\text{CH}=\text{CCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}$), 8.2 ($\text{NCH}(\text{CH}_2)_2$)

^{19}F NMR (376.45 MHz, CDCl_3) δ / ppm = -120.7 (s, ciprofloxacin F)

HRMS (ESI⁺) m/z / Da = 646.3132, $[\text{M}+\text{H}]^+$ found, $[\text{C}_{34}\text{H}_{41}\text{FN}_7\text{O}_5]^+$ requires 646.3153

The compound has not been reported previously.

1.44 1-Cyclopropyl-6-fluoro-7-(4-(4-(1-(4-((3-methoxyphenyl)amino)-4-oxobutyl)-1H-1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 148



1-Cyclopropyl-6-fluoro-7-(4-(hex-5-yn-1-yl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid **176** (24.1 mg, 58.6 μmol , 1 eq.) and 4-azido-*N*-(3-methoxyphenyl)butanamide **144** (13.7 mg, 58.5 μmol , 1 eq.) were dissolved in water (1 ml), *t*-BuOH (9 ml) and CH_2Cl_2 (10 ml), and the mixture was degassed by bubbling through N_2 . A solution of CuSO_4 and THPTA (58.5 μl , 5.85 μmol , 0.1 eq. 100 mM, aq.) was added, followed by a solution of sodium ascorbate (117 μl , 11.7 μmol , 0.2 eq., 100 mM, aq.). The mixture was stirred at room temperature under argon for 2 h, then the solvent was removed under reduced pressure. The residue was partitioned between

water (15 ml) and CH₂Cl₂ (15 ml), and the aqueous layer was extracted a further four times with CH₂Cl₂ (4 × 15 ml). The combined organic layers were dried with MgSO₄, dry-loaded onto SiO₂ and purified by column chromatography (SiO₂, 0-10 % MeOH/CH₂Cl₂). **148** was obtained as a clear glass (1.9 mg, 2.9 μmol, 5.0 %).

TLC R_f = 0.22 (10 % MeOH/CH₂Cl₂)

IR (neat) ν_{max} / cm⁻¹ = 2922.8 (C-H), 2849.5 (C-H), 1725.8 (carboxylic acid C=O), 1684.7 (amide C=O), 1624.5 (quinolone C=O), 1612.2 (triazole)

¹H NMR (400 MHz, DMSO d₆) δ / ppm = 15.23 (br s, 1 H, C(=O)OH), 9.89 (s, 1 H, NH), 8.66 (s, 1 H, *ortho* to C(=O)OH), 7.90 (d, J = 13.4 Hz, 1 H, *ortho* to F), 7.88 (s, 1 H, CH=CCH₂), 7.55 (d, J = 7.6 Hz, 1 H, *meta* to F), 7.27 (t, J = 2.1 Hz, 1 H, *ortho* to C=O and *ortho* to F), 7.16 (t, J = 8.1 Hz, 1 H, *meta* to OCH₃ and *meta* to NH), 7.08 (d, J = 7.8 Hz, 1 H, *para* to OCH₃), 6.59 (ddd, J = 8.1, 2.4, 0.7 Hz, 1 H, *para* to NH), 4.36 (t, J = 6.9 Hz, 2 H, C(=O)CH₂CH₂CH₂N), 3.81 (tt, J = 6.7, 4.0 Hz, 1 H, NCH(CH₂)₂), 3.70 (s, 3 H, CH₃), 3.28 - 3.32 (m, 4 H, CH=CCH₂CH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂), 2.64 (t, J = 7.5 Hz, 2 H, CH=CCH₂), 2.56 (m, J = 4.2, 4.2 Hz, 4 H, CH=CCH₂CH₂CH₂CH₂N(CH₂)CH₂), 2.38 (t, J = 7.3 Hz, 2 H, CH=CCH₂CH₂CH₂CH₂N), 2.30 (t, J = 7.4 Hz, 2 H, C(=O)CH₂CH₂CH₂N), 2.10 (quin, J = 7.1 Hz, 2 H, C(=O)CH₂CH₂CH₂N), 1.64 (quin, J = 7.5 Hz, 2 H, CH=CCH₂CH₂CH₂CH₂N), 1.51 (quin, J = 7.2 Hz, 2 H, CH=CCH₂CH₂CH₂CH₂N), 1.27 - 1.33 (m, 2 H, NCH(CH₂)₂), 1.15 - 1.20 (m, 2 H, NCH(CH₂)₂)


¹³C NMR (101 MHz, DMSO d₆) δ / ppm = 176.3 (C(=O)CC(=O)OH), 170.1 (NHC(=O)), 165.9 (C(=O)OH), 159.4 (*ipso* to OCH₃), 153.0 (d, J = 248.6 Hz, *ipso* to F), 148.0 (CH=CCH₂), 146.9 (C=CC(=O)OH), 145.2 (d, J = 10.7 Hz, *ipso* to piperazine), 140.3 (*para* to F), 139.2 (*ipso* to NH), 129.4 (*meta* to OCH₃ and *meta* to NH), 121.7 (CH=CCH₂), 118.5 (d, J = 7.5 Hz, *para* to piperazine), 111.3 (*para* to OCH₃), 110.9 (d, J = 22.4 Hz, *ortho* to C=O and *ortho* to F), 108.4 (*para* to NH), 106.7 (CC(=O)OH), 106.3 (*meta* to C=O and *meta* to F), 104.8 (*ortho* to OCH₃ and *ortho* to NH), 57.3 (CH=CCH₂CH₂CH₂CH₂N), 54.9 (CH₃), 52.4 (CH=CCH₂CH₂CH₂CH₂N(CH₂)CH₂), 49.5 (CH=CCH₂CH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂), 49.4 (CH=CCH₂CH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂), 48.7 (C(=O)CH₂CH₂CH₂N), 35.8 (NCH(CH₂)₂), 32.9 (C(=O)CH₂CH₂CH₂N), 26.8 (CH=CCH₂CH₂CH₂CH₂N), 25.7 (CH=CCH₂CH₂CH₂CH₂N), 25.5 (C(=O)CH₂CH₂CH₂N), 24.9 (CH=CCH₂CH₂CH₂CH₂N), 7.6 (NCH(CH₂)₂)

¹⁹F NMR (376.45 MHz, DMSO d₆) δ / ppm = -121.5 (s, ciprofloxacin F)

HRMS (ESI⁺) m/z / Da = 646.3159, [M+H]⁺ found, [C₃₄H₄₁FN₇O₅]⁺ requires 646.3153

The compound has not been reported previously.

1.45 Methyl 7-(4-(4-(*tert*-butoxy)-4-oxobutyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate **149**



Methyl 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate **134** (200 mg, 0.579 mmol, 1 eq.), *tert*-butyl 4-bromobutanoate **181** (103 μ l, 130 mg, 0.581 mmol, 1 eq.), NaI (86.9 mg, 0.580 mmol, 1 eq.), TEA (316 μ l, 229 mg, 2.27 mmol, 4 eq.) and acetonitrile (10 ml) were stirred in a microwave reactor at 100 °C for 8 h. A second portion of *tert*-butyl 4-bromobutanoate **181** (103 μ l, 130 mg, 0.581 mmol, 1 eq.) was added, and the mixture was stirred in a microwave reactor at 100 °C for a further 8 h. The mixture was then dry-loaded onto SiO₂ and purified by column chromatography (SiO₂, 0-4 % MeOH/CH₂Cl₂). **149** was obtained as a white amorphous solid (141 mg, 0.289 mmol, 49.9 %).

how to report?

how to report?

TLC R_f = 0.12 (4 % MeOH/CH₂Cl₂)

IR (neat) ν_{max} / cm⁻¹ = 2961.6 (C-H), 2830.5 (C-H), 1732.2 (*t*-Bu ester C=O) 1717.2 (ciprofloxacin ester C=O), 1620.6 (quinolone C=O)

¹H NMR (400 MHz, CDCl₃) δ / ppm = 8.39 (s, 1 H, *ortho* to C(=O)OCH₃), 7.82 (d, J = 13.3 Hz, 1 H, *ortho* to F), 7.17 (d, J = 7.2 Hz, 1 H, *meta* to F), 3.83 (s, 3 H, CH₃), 3.40 (tt, J = 7.2, 3.6 Hz, 1 H, NCH(CH₂)₂), 3.22 (t, J = 4.3 Hz, 4 H, CH₂N(CH₂CH₂)CH₂CH₂), 2.63 (t, J = 4.4 Hz, 4 H, CH₂N(CH₂)CH₂), 2.41 (t, J = 7.3 Hz, 2 H, CH₂N(CH₂)CH₂), 2.25 (t, J = 7.4 Hz, 2 H, CH₂CH₂CH₂N(CH₂)CH₂), 1.78 (quin, J = 7.3 Hz, 2 H, CH₂CH₂N(CH₂)CH₂), 1.41 (s, 9 H, C((CH₃)₃)), 1.24 (m, 2 H, NCH(CH₂)₂), 1.09 (m, 2 H, NCH(CH₂)₂)

should be ranges ideally, go back if time


¹³C NMR (101 MHz, CDCl₃) δ / ppm = 172.7 (C(=O)CC(=O)OCH₃), 172.6 (C(=O)OC(CH₃)₃), 165.9 (C(=O)OCH₃), 153.1 (d, J = 249.7 Hz, *ipso* to F), 148.1 (C=CC(=O)OCH₃), 144.3 (d, J = 10.4 Hz, *ipso* to piperazine), 137.7 (*para* to F), 122.5 (d, J = 6.9 Hz, *para* to piperazine) 112.6 (d, J = 22.5 Hz, *ortho* to C=O and *ortho* to F), 109.5 (CC(=O)OCH₃) 104.7 (*meta* to C=O and *meta* to F), 80.0 (C(CH₃)₃), 57.4 (C(=O)CH₂CH₂CH₂N), 52.7 (C(=O)CH₂CH₂CH₂N(CH₂)CH₂), 51.7 (CH₃), 49.7 (C(=O)CH₂CH₂CH₂N(CH₂)CH₂CH₂), 49.7 (C(=O)CH₂CH₂CH₂N(CH₂)CH₂CH₂), 34.4 (NCH(CH₂)₂), 33.2 (C(=O)CH₂), 28.0 (C(CH₃)₃), 22.0 (C(=O)CH₂CH₂), 7.9 (NCH(CH₂)₂)

¹⁹F NMR (376.45 MHz, CDCl₃) δ / ppm = -123.50 (s, ciprofloxacin F)

HRMS (ESI⁺) m/z / Da = 488.2562, [M+H]⁺ found, [C₂₆H₃₅FN₃O₅]⁺ requires 488.2561

The compound has not been reported previously.

1.46 4-(4-(1-Cyclopropyl-6-fluoro-3-(methoxycarbonyl)-4-oxo-1,4-dihydroquinolin-7-yl)piperazin-1-yl)butanoic acid, trifluoroacetic acid salt **150**



Methyl 7-(4-(4-(*tert*-butoxy)-4-oxobutyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate **149** (20 mg, 41.0 μ mol) and TFA (0.2 ml) were stirred in CH_2Cl_2 (1.8 ml) at r.t. for 16 h then evaporated under reduced pressure. **150** was obtained as a white solid (21.4 mg, 39.2 μ mol, 95.6 %).

mp $T / ^\circ\text{C} = 225\text{-}231$ (CH_2Cl_2 , decomposes)

IR (neat) $\nu_{\text{max}} / \text{cm}^{-1} = 1722.7$ (ciprofloxacin ester $\text{C}=\text{O}$), 1699.0 (alkyl carboxylic acid $\text{C}=\text{O}$), 1673.3 (TFA $\text{C}=\text{O}$), 1614.6 (quinolone $\text{C}=\text{O}$)

^1H NMR (400 MHz, $\text{DMSO-}d_6$) $\delta / \text{ppm} = 8.47$ (s, 1 H, *ortho* to $\text{C}(=\text{O})\text{OH}$), 7.80 (d, $J = 13.2$ Hz, 1 H, *ortho* to F), 7.47 (d, $J = 7.4$ Hz, 1 H, *meta* to F), 3.73 (s, 3 H, CH_3), 3.66 (tt, $J = 7.2, 3.7$ Hz, 1 H, $\text{NCH}(\text{CH}_2)_2$), 3.30 - 3.54 (br s, 8 H, $\text{CH}_2\text{N}(\text{CH}_2)\text{CH}_2$ and $\text{CH}_2\text{N}(\text{CH}_2\text{CH}_2)\text{CH}_2\text{CH}_2$), 3.13 - 3.22 (m, 2 H, $\text{CH}_2\text{N}(\text{CH}_2)\text{CH}_2$), 2.36 (t, $J = 7.1$ Hz, 2 H, $\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{CH}_2)\text{CH}_2$), 1.87 - 1.98 (m, 2 H, $\text{CH}_2\text{CH}_2\text{N}(\text{CH}_2)\text{CH}_2$), 1.22 - 1.30 (m, 2 H, $\text{NCH}(\text{CH}_2)_2$), 1.06 - 1.15 (m, 2 H, $\text{NCH}(\text{CH}_2)_2$)

^{13}C NMR (101 MHz, $\text{DMSO-}d_6$) $\delta / \text{ppm} = 173.5$ ($\text{CH}_2\text{C}(=\text{O})\text{OH}$), 171.6 ($\text{C}(=\text{O})\text{CC}(=\text{O})\text{OCH}_3$), 164.9 ($\text{C}(=\text{O})\text{OCH}_3$), 158.2 (q, $J = 31.5$ Hz, $\text{CF}_3\text{C}(=\text{O})\text{OH}$), 152.5 (d, $J = 247.6$ Hz, *ipso* to F), 148.5 ($\text{C}=\text{CC}(=\text{O})\text{OH}$), 142.3 (d, $J = 10.7$ Hz, *ipso* to piperazine), 138.0 (*para* to F), 122.6 (d, $J = 6.4$ Hz, *para* to piperazine), 117.2 (q, $J = 299.8$ Hz, CF_3), 111.9 (d, $J = 22.4$ Hz, *ortho* to $\text{C}=\text{O}$ and *ortho* to F), 109.1 ($\text{CC}(=\text{O})\text{OCH}_3$), 106.9 (*meta* to $\text{C}=\text{O}$ and *meta* to F), 55.1 ($\text{C}(=\text{O})\text{CH}_2\text{CH}_2\text{CH}_2\text{N}$), 51.4 (CH_3), 50.8 ($\text{C}(=\text{O})\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{CH}_2)\text{CH}_2$), 46.7 ($\text{C}(=\text{O})\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{CH}_2\text{CH}_2)\text{CH}_2\text{CH}_2$), 46.7 ($\text{C}(=\text{O})\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{CH}_2\text{CH}_2)\text{CH}_2\text{CH}_2$), 34.9 ($\text{NCH}(\text{CH}_2)_2$), 30.6 ($\text{C}(=\text{O})\text{CH}_2$), 19.1 ($\text{C}(=\text{O})\text{CH}_2\text{CH}_2$), 7.6 ($\text{NCH}(\text{CH}_2)_2$)


^{19}F NMR (376.45 MHz, $\text{DMSO-}d_6$) $\delta / \text{ppm} = -73.62$ (s, CF_3), -124.61 (s, ciprofloxacin F)

HRMS (ESI^+) $m/z / \text{Da} = 432.1921$, $[\text{M}+\text{H}]^+$ found, $[\text{C}_{22}\text{H}_{27}\text{FN}_3\text{O}_5]^+$ requires 432.1935


The compound has not been reported previously.

not
sure
how to
draw/name
this?

1.47 (1*S*,2*S*)-2-(((*S*)-1-Phenylethyl)amino)cyclopentan-1-ol 151 and (1*R*,2*R*)-2-(((*S*)-1-phenylethyl)amino)cyclopentan-1-ol 152



160



161

(*S*)-1-phenylethan-1-amine **182** (7.85 ml, 7.38 g, 60.9 mmol, 1 eq.) was dissolved in CH₂Cl₂ (50 ml) and stirred rapidly at 0 °C. A solution of AlMe₃ (31 ml, 2.0 M in heptane, 60.9 mmol) was added dropwise and the solution was stirred at 0 °C for 1 h. A solution of cyclohexene oxide **183** (5.71 ml, 5.50 g, 65.4 mmol, 1.1 eq.) in CH₂Cl₂ (50 ml) was then added dropwise, and the mixture was stirred at 0 °C for a further 3 h, followed by 48 h at r.t.. The mixture was cooled to 0 °C and NaF (11 g, 262 mmol, 4.3 eq.) was added portionwise, followed by water (7.00 ml, 7.00 g, 389 mmol, 6.4 eq.) and CH₂Cl₂ (50 ml). The suspension was allowed to warm to r.t. and stirred for 1 h, then filtered through Celite and washed with CH₂Cl₂ (500 ml). The filtrate was dried with K₂CO₃, concentrated under reduced pressure and purified by column chromatography (SiO₂, 20:5:1 hexane:EtOAc:TEA). **151** was obtained as a pale yellow oil (4.08 g, 19.9 mmol, 32.6 %). **152** was obtained as pale yellow crystals (4.48 g, 21.8 mmol, 35.8 %).

fix image sizes

(1*S*,2*S*)-2-(((*S*)-1-Phenylethyl)amino)cyclopentan-1-ol 151

TLC R_f = 0.25 (15:5:1 hexane:EtOAc:TEA)

IR (neat) ν_{max} / cm⁻¹ = 3300.0 (br, O-H), 2959.7 (C-H), 2870.1 (C-H)

¹H NMR (400 MHz, CDCl₃) δ / ppm = 7.28 - 7.38 (m, 4 H, *ortho* and *meta* to CHCH₃), 7.21 - 7.28 (m, 1 H, *para* to CHCH₃), 3.83 (q, J = 6.6 Hz, 1 H, CHCH₃), 3.78 (q, J = 7.0 Hz, 1 H, CHOH), 2.62 (dt, J = 8.2, 7.2 Hz, 1 H, CHNH), 1.97 (quin, J = 6.7 Hz, 1 H, CH₂CHNH), 1.90 (quin, J = 6.9 Hz, 1 H, CH₂CHOH), 1.56 - 1.68 (m, CH₂CH₂CHOH), 1.43 (dq, J = 12.5, 8.0 Hz, 1 H, CH₂CHOH), 1.37 (d, J = 6.6 Hz, 3 H, CH₃), 1.25 - 1.36 (m, 1 H, CH₂CHNH)

¹³C NMR (101 MHz, CDCl₃) δ / ppm = 144.75 (*ipso* to CHCH₃), 128.26 (*meta* to CHCH₃), 126.72 (*para* to CHCH₃), 126.30 (*ortho* to CHCH₃), 77.65 (CHOH), 63.38 (CHNH), 56.20 (CHCH₃), 31.74 (CH₂CHOH), 29.22 (CH₂CHNH), 24.58 (CH₃), 19.57 (CH₂CH₂CHOH)

HRMS (ESI⁺) m/z / Da = 206.1554, [M+H]⁺ found, [C₁₃H₂₀NO]⁺ requires 206.1545 [α]_D²⁰ / °10⁻¹cm²g⁻¹ = -92.8 (c / g(100 mL)⁻¹ = 1.19, MeOH)

(1*R*,2*R*)-2-(((*S*)-1-Phenylethyl)amino)cyclopentan-1-ol 152

TLC R_f = 0.36 (15:5:1 hexane:EtOAc:TEA)

mp T / °C = 66-71.5 (hexane, EtOAc, TEA)

IR (neat) ν_{max} / cm⁻¹ = 3150.0 (br, O-H), 2950.9 (C-H), 2868.2 (C-H)

fix spacings for subtitles

¹H NMR (400 MHz, CDCl₃) δ / ppm = 7.28 - 7.34 (m, 4 H, *ortho* and *meta* to CHCH₃), 7.20 - 7.26 (m, 1 H, *para* to CHCH₃), 3.86 (q, J = 6.6 Hz, 1 H, CHCH₃), 3.85 (q, J = 6.6 Hz, 1 H, CHOH), 2.83 (td, J = 7.6, 5.7 Hz, 1 H, CHNH), 1.85 - 1.97 (m, 1 H, CHHCHOH), 1.77 (dtd, J = 12.9, 7.9, 7.9, 4.9 Hz, 1 H, CHHCHNH), 1.55 - 1.68 (m, 2 H, CH₂CH₂CHOH), 1.47 - 1.55 (m, 1 H, CHHCHOH), 1.36 (d, J = 6.6 Hz, 3 H, CH₃), 1.12 (dq, J = 12.7, 8.1 Hz, 1 H, CHHCHNH)


¹³C NMR (101 MHz, CDCl₃) δ / ppm = 145.61 (*ipso* to CHCH₃), 128.08 (*meta* to CHCH₃), 126.61 (*para* to CHCH₃), 126.33 (*ortho* to CHCH₃), 77.43 (CHOH), 64.45 (CHNH), 56.62 (CHCH₃), 32.01 (CH₂CHOH), 30.56 (CH₂CHNH), 23.30 (CH₃), 20.06 (CH₂CH₂CHOH)

HRMS (ESI⁺) m/z / Da = 206.1553, [M+H]⁺ found, [C₁₃H₂₀NO]⁺ requires 206.1545

$[\alpha]_D^{20}$ / °10⁻¹cm²g⁻¹ = -23.9 (c / g(100 mL)⁻¹ = 0.96, MeOH)

The compounds have been synthesised previously,¹²⁻¹⁴ but NMR data were not published.

1.48 (1*S*,2*S*)-2-Aminocyclopentan-1-ol **153**



(1*S*,2*S*)-2-(((*S*)-1-Phenylethyl)amino)cyclopentan-1-ol **151** (3.90 g, 19.0 mmol, 1 eq.), Pd(OH)₂ (20 wt. % on C, moistened with 50 wt. % water, 1 g, 0.712 mmol, 0.04 eq.) and MeOH (50 ml) were stirred in a Paar hydrogenator at r.t. and 3 atm for 2 days. The mixture was then filtered through Celite and evaporated under reduced pressure. **153** was obtained as a yellow oil (1.92 g, 19.0 mmol, 100 %).

TLC R_f = 0.10 (10 % MeOH/CH₂Cl₂)

IR (neat) ν_{max} / cm⁻¹ = 3300.0 (br, O-H), 2958.3 (C-H), 2871.5 (C-H)

¹H NMR (400 MHz, MeOD) δ / ppm = 3.77 (ddd, J =6.6, 6.2, 5.6, 1 H, CHOH), 3.00 (td, J =7.3, 5.6 Hz, 1 H, CHNH₂), 2.00 (dtd, J =13.0, 7.7, 7.7, 5.6 Hz, 1 H, CHHCHNH₂), 1.97 (ddt, J =13.0, 8.7, 6.6, 6.6 Hz, 1 H, CHHCHOH), 1.63 - 1.77 (m, 2 H, CH₂CH₂CHOH), 1.53 (ddt, J =13.0, 9.5, 6.2, 6.2 Hz, 1 H, CHHCHOH), 1.37 (ddt, J =13.0, 8.3, 7.8, 7.8 Hz, 1 H, CHHCHNH₂)

¹³C NMR (101 MHz, MeOD) δ / ppm = 80.7 (CHOH), 60.8 (CHNH₂), 33.2 (CH₂CHOH), 32.1 (CH₂CHNH₂), 21.2 (CH₂CH₂CHOH)

HRMS (ESI⁺) m/z / Da = 102.0917, [M+H]⁺ found, [C₅H₁₂NO]⁺ requires 102.0913


$[\alpha]_D^{20}$ / °10⁻¹cm²g⁻¹ = -30.9 (c / g(100 mL)⁻¹ = 1.5, EtOH)

The data are consistent with the literature.^{13,15}

consistent
with
other
data?

check

1.49 (1*R*,2*R*)-2-Aminocyclopentan-1-ol **154**



(1*R*,2*R*)-2-(((*S*)-1-Phenylethyl)amino)cyclopentan-1-ol **152** (3.00 g, 14.6 mmol, 1 eq.), Pd(OH)₂ (20 wt. % on C, moistened with 50 wt. % water, 0.5 g, 0.356 mmol, 0.025 eq.) and MeOH (50 ml) were stirred in a Paar hydrogenator at r.t. and 2.5 atm for 2 days. The mixture was then filtered through Celite and evaporated under reduced pressure. **154** was obtained as a yellow oil (1.48 g, 14.6 mmol, 100 %).

TLC R_f = 0.10 (10 % MeOH/CH₂Cl₂)

IR (neat) ν_{max} / cm⁻¹ = 3300.0 (O-H), 2969.2 (C-H), 2872.7 (C-H)

¹H NMR (400 MHz, MeOD) δ / ppm = 3.77 (ddd, J =6.6, 6.2, 5.6, 1 H, CHOH), 3.00 (td, J = 7.4, 5.6 Hz, 1 H, CHNH₂), 2.00 (dtd, J = 13.0, 7.7, 7.7, 5.6 Hz, 1 H, CHHCHNH₂), 1.97 (ddt, J = 13.0, 8.7, 6.4, 6.4 Hz, 1 H, CHHCHOH), 1.64 - 1.77 (m, 2 H, CH₂CH₂CHOH), 1.53 (ddt, J = 13.0, 9.5, 6.2, 6.2 Hz, 1 H, CHHCHOH), 1.37 (ddt, J = 12.8, 8.5, 7.7, 7.7 Hz, 1 H, CHHCHNH₂)


¹³C NMR (101 MHz, MeOD) δ / ppm = 80.6 (CHOH), 60.7 (CHNH₂), 33.2 (CH₂CHOH), 32.2 (CH₂CHNH₂), 21.2 (CH₂CH₂CHOH)

HRMS (ESI⁺) m/z / Da = 102.0915, [M+H]⁺ found, [C₅H₁₂NO]⁺ requires 102.0913

$[\alpha]_D^{20}$ / °10⁻¹cm²g⁻¹ = 33.4 (c / g(100 mL)⁻¹ = 0.5, EtOH)

The data are consistent with the literature.^{13,15}

1.50 (1*R*,2*R*)-2-((*tert*-butyldimethylsilyl)oxy)cyclopentan-1-amine **155**



(1*R*,2*R*)-2-aminocyclopentan-1-ol **154** (0.480 g, 4.75 mmol) was stirred in dry CH₂Cl₂ (20 ml) under N₂ at 0 °C. TEA (3.14 ml, 2.28 g, 22.5 mmol, 5 eq.) was added dropwise, followed by TBSOTf (3 ml, 3.45 g, 13.1 mmol, 3 eq.) dropwise. The reaction was allowed to reach r.t. and stirred for 1 h. The reaction was quenched with NH₄Cl, diluted with CH₂Cl₂ (20 ml) and washed with water (20 ml). The organic phase was dried with Na₂SO₄, concentrated under reduced pressure and purified by column chromatography (SiO₂, 4 % MeOH/CH₂Cl₂). **155**(RR) was obtained as a yellow oil (1.00 g, 4.64 mmol, 97.7 %).

TLC $R_f = 0.23$ (10 % MeOH/CH₂Cl₂, ninhydrin stain)

check
stains
for oth-
ers


¹H NMR (400 MHz, CDCl₃) δ / ppm = 4.13 (q, $J = 5.8$ Hz, 1 H, CH₂OSi), 3.31 (td, $J = 7.1, 5.2$ Hz, 1 H, CHNH₂), 2.09 - 2.19 (m, 1 H, CHHCHNH₂), 1.97 (ddq, $J = 8.8, 7.0, 6.0, 6.0, 6.0$ Hz, 1 H, CHHCHOSi), 1.74 - 1.86 (m, 2 H, CH₂CH₂CHOSi), 1.64 - 1.74 (m, 1 H, CHHCHOSi), 1.58 (ddt, $J = 13.2, 9.1, 6.0, 6.0$ Hz, 1 H, CHHCHNH₂), 0.88 (s, 9 H, C(CH₃)₃), 0.09 (s, 3 H, SiCH₃), 0.07 (s, 3 H, SiCH₃)

¹³C NMR (101 MHz, CDCl₃) δ / ppm = 76.29 (CHOSi), 59.69 (CHNH), 32.18 (CH₂CHOSi), 26.78 (CH₂CHNH₂), 25.62 (C(CH₃)₃), 19.73 (CH₂CH₂CHOSi), 17.74 (C(CH₃)₃), -4.82 (SiCH₃), -5.23 (SiCH₃)

HRMS (ESI⁺) m/z / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

$[\alpha]_D^{20}$ / °10⁻¹cm²g⁻¹ = ?? (c / g(100 mL)⁻¹ = ??, MeOH)

1.51 4-Chloro-*N*-((1*S*,2*S*)-2-hydroxycyclopentyl)butanamide **156**



(1*S*,2*S*)-2-aminocyclopentan-1-ol **153** (500 mg, 4.94 mmol, 1 eq.), TEA (827 μ l, 600 mg, 5.93 mmol, 1.2 eq.) and CH₂Cl₂ (20 ml) were stirred at 0°C. 4-Chlorobutyryl chloride **185** (608 μ l, 766 mg, 5.43 mmol, 1.1 eq.) was added dropwise over 5 min. The mixture was stirred at 0°C for 30 min, then water (50 ml) was added. The organic layer was separated off, and the aqueous layer was extracted with CH₂Cl₂ (7×50 ml). The combined organic layers were dried with MgSO₄, concentrated under reduced pressure and purified by column chromatography (SiO₂, Et₂O). **186**(SS) was obtained as a white amorphous solid (651 mg, 3.16 mmol, 64.1 %).

TLC $R_f = 0.35$ (EtOAc, ninhydrin stain)

check
stains
for oth-
ers

mp T / °C = ?? (??)

IR (neat) ν_{max} / cm⁻¹ = 3277.6 (N-H and O-H), 2962.2 (C-H), 2876.0 (C-H), 1636.3 (amide C=O)


¹H NMR (400 MHz, CDCl₃) δ / ppm = 6.12 (br s, 1 H, NH), 4.42 (br s, 1 H, OH), 3.94 (q, $J = 6.6$ Hz, 1 H, CHOH), 3.82 (tt, $J = 8.4, 5.3$ Hz, 1 H, CHNH), 3.60 (t, $J = 6.2$ Hz, 2 H, CH₂Cl), 2.38 (t, $J = 7.2$ Hz, 2 H, CH₂C=O), 2.05 - 2.16 (m, 3 H, CHHCHNH and CH₂CH₂Cl), 1.96 - 2.04 (m, 1 H, CHHCHOH), 1.74 - 1.85 (m, 1 H, CHHCH₂CHOH), 1.58 - 1.73 (m, 2 H, CHHCH₂CHOH and CHHCHOH), 1.43 (dq, $J = 12.7, 8.3$ Hz, 1 H, CHHCHNH)

¹³C NMR (101 MHz, CDCl₃) δ / ppm = 173.8 (C=O), 79.4 (CHOH), 60.6 (CHNH), 44.4 (CH₂Cl), 32.8 (CH₂C=O), 32.4 (CH₂CHOH), 30.1 (CH₂CHNH), 28.0 (CH₂CH₂Cl), 21.1 (CH₂CH₂CHOH)

HRMS (ESI⁺) m/z / Da = 228.0787, [M+Na]⁺ found, [C₉H₁₆ClNNaO₂]⁺ requires 228.0762

$[\alpha]_D^{20}$ / °10⁻¹cm²g⁻¹ = -13.0 (c / g(100 mL)⁻¹ = 0.5, MeOH)

1.52 4-Chloro-*N*-((1*R*,2*R*)-2-hydroxycyclopentyl)butanamide **157**



(1*R*,2*R*)-2-aminocyclopentan-1-ol **154** (72.3 mg, 716 μ mol, 1 eq.), TEA (500 μ l, 363 mg, 3.58 mmol, 5 eq.) and CH₂Cl₂ (5 ml) were stirred at 0°C. 4-Chlorobutyryl chloride **185** (179 μ l, 226 mg, 1.60 mmol, 1.1 eq.) was added dropwise over 5 min. The mixture was stirred at 0°C for 30 min, then water (10 ml) was added. The organic layer was separated off, and the aqueous layer was extracted with 10 % *i*-PrOH/CHCl₃ (2 \times 10 ml). The combined organic layers were dried with MgSO₄, concentrated under reduced pressure and purified by column chromatography (SiO₂, Et₂O). **157** was obtained as a white amorphous solid (35.6 mg, 173 μ mol, 24.2 %).

times
with
spaces?

TLC R_f = 0.35 (EtOAc)

mp T / °C = ?? (??)


¹H NMR (400 MHz, CDCl₃) δ / ppm = 6.05 (br s, 1 H, NH), 4.55 (br s, 1 H, OH), 3.95 (q, J=6.6 Hz, 1 H, CHOH), 3.82 (tt, J=8.4, 5.3 Hz, 1 H, CHNH), 3.60 (t, J=6.2 Hz, 2 H, CH₂Cl), 2.38 (t, J=7.0 Hz, 2 H, CH₂C=O), 2.05 - 2.17 (m, 3 H, CHHCHNH and CH₂CH₂Cl), 1.94 - 2.05 (m, 1 H, CHHCHOH), 1.74 - 1.86 (m, 1 H, CHHCH₂CHOH), 1.58 - 1.74 (m, 2 H, CHHCH₂CHOH and CHHCHOH), 1.42 (dq, J=12.5, 8.4 Hz, 1 H, CHHCHNH)

¹³C NMR (101 MHz, CDCl₃) δ / ppm = 173.8 (C=O), 79.4 (CHOH), 60.6 (CHNH), 44.4 (CH₂Cl), 32.8 (CH₂C=O), 32.4 (CH₂CHOH), 30.2 (CH₂CHNH), 28.0 (CH₂CH₂Cl), 21.2 (CH₂CH₂CHOH)

HRMS (ESI⁺) m/z / Da = 206.0939, [M+H]⁺ found, [C₉H₁₇ClNO₂]⁺ requires 206.0948

$[\alpha]_D^{20}$ / °10⁻¹cm²g⁻¹ = 10.0 (c / g(100 mL)⁻¹ = 0.05, MeOH)

1.53 4-Azido-*N*-((1*R*,2*R*)-2-((*tert*-butyldimethylsilyl)oxy)cyclopentyl)butanamide **158**



(1*R*,2*R*)-2-((*tert*-butyldimethylsilyl)oxy)cyclopentan-1-amine **155** (50 mg, 0.232 mmol, 1 eq.) and NaHCO₃ (22.0 mg, 0.262 mmol, 1.1 eq.) were added to CH₂Cl₂ (3 ml) and water (3 ml). 4-Bromobutyryl chloride (25.3 ml, 40.5 mg, 0.219 mmol, 0.95 eq.) was added dropwise at 0 °C and the mixture was stirred for 3 h. The aqueous layer was removed and NaN₃ (100 mg, 1.54 mmol, 6.6 eq.) and DMF (3 ml) were added. The mixture was stirred at 40 °C for 6 h. The solvents were then evaporated using a N₂ stream and the residue was purified by column chromatography (SiO₂, 0.5 % MeOH/CH₂Cl₂). **187**(RR) was obtained as a clear liquid (71 mg, 0.217 mmol, 99.2 %).

check
brackets
inside for
all

TLC R_f = 0.84 (1 % MeOH/CH₂Cl₂)

IR (neat) ν_{max} / cm⁻¹ = 3287.9 (N-H), 2953.4 (C-H), 2933.2 (C-H), 2882.7 (C-H), 2857.1 (C-H), 2094.9 (azide), 1639.4 (amide C=O)


¹H NMR (400 MHz, CDCl₃) δ / ppm = 5.35 (d, J = 5.1 Hz, 1 H, NH), 3.97 - 4.01 (m, 1 H, CHOSi), 3.93 - 3.98 (m, 1 H, CHNH), 3.35 (t, J = 6.6 Hz, 2 H, CH₂N₃), 2.24 (t, J = 7.0 Hz, 2 H, CH₂C=O), 2.09 - 2.19 (m, 1 H, CHHCHNH), 1.89 - 1.97 (quin, J = 6.8 Hz, 2 H, CH₂CH₂N₃), 1.74 - 1.84 (m, 2 H, CHHCHOSi and CHHCH₂CHOSi), 1.60 - 1.70 (m, 1 H, CHHCH₂CHOSi), 1.51 - 1.61 (m, 1 H, CHHCHOSi), 1.31 - 1.39 (m, 1 H, CHHCHNH), 0.87 (s, 9 H, C(CH₃)₃), 0.08 (s, 3 H, SiCH₃), 0.06 (s, 3 H, SiCH₃)

¹³C NMR (101 MHz, CDCl₃) δ / ppm = 171.17 (C=O), 77.80 (CHOSi), 58.36 (CHNH), 50.77 (CH₂N₃), 33.29 (CH₂C=O), 32.57 (CH₂CHOSi), 29.36 (CH₂CHNH), 25.72 (C(CH₃)₃), 24.77 (CH₂CH₂N₃), 20.40 (CH₂CH₂CHOSi), 17.95 (C(CH₃)₃), -4.75 (SiCH₃)

HRMS (ESI⁺) m/z / Da = 327.2221, [M+H]⁺ found, [C₁₅H₃₁N₄O₂Si]⁺ requires 327.2216

$[\alpha]_D^{20}$ / °10⁻¹cm²g⁻¹ = 12.4 (c / g(100 mL)⁻¹ = 0.5, MeOH)

1.54 4-Azido-*N*-((1*S*,2*S*)-2-hydroxycyclopentyl)butanamide **159**



4-Chloro-*N*-((1*S*,2*S*)-2-hydroxycyclopentyl)butanamide **156** (200 mg, 0.972 mmol, 1 eq.) and NaN₃ (126 mg, 1.94 mmol, 2 eq.) were stirred in acetonitrile (4 ml) at 50 °C for 16 h. The solvent was then evaporated under reduced pressure and the residue was partitioned between water (20 ml) and 10 % *i*-PrOH/CHCl₃ (20 ml). The aqueous layer was extracted again with 10 % *i*-PrOH/CHCl₃ (3 × 20 ml) and the combined organic fractions were dried with MgSO₄ and evaporated under reduced pressure. **159** was obtained as white needles (181 mg, 0.852 mmol, 87.6 %).

TLC R_f = 0.35 (EtOAc, ninhydrin stain)

mp T / °C = 56-59.5 (*i*-PrOH, CHCl₃)

check
stains
for others

IR (neat) ν_{max} / cm^{-1} = 3279.9 (N-H and O-H), 2965.6 (C-H), 2875.4 (C-H), 2094.6 (azide), 1636.8 (amide C=O)


^1H NMR (400 MHz, CDCl_3) δ / ppm = 6.72 (d, J = 4.4 Hz, 1 H, NH), 4.82 (br. s., 1 H, OH), 3.88 (q, J = 6.6 Hz, 1 H, CHOH), 3.75 (tdd, J = 8.4, 8.4, 6.6, 4.4 Hz, 1 H, CHNH), 3.28 (t, J = 6.6 Hz, 2 H, CH_2N_3), 2.23 (t, J = 7.3 Hz, 2 H, $\text{CH}_2\text{C=O}$), 2.04 (dtd, J = 13.0, 8.0, 8.0, 4.9 Hz, 1 H, CHHCHNH), 1.92 (dtd, J = 13.0, 7.6, 7.6, 5.8 Hz, 1 H, CHHCHOH), 1.84 (quin, J = 7.0 Hz, 2 H, $\text{CH}_2\text{CH}_2\text{N}_3$), 1.59 - 1.77 (m, 2 H, $\text{CH}_2\text{CH}_2\text{CHOH}$), 1.54 (ddt, J = 12.7, 9.0, 6.7, 6.7 Hz, 1 H, CHHCHOH), 1.39 (dq, J = 12.9, 8.4 Hz, 1 H, CHHCHNH)

^{13}C NMR (101 MHz, CDCl_3) δ / ppm = 173.8 (C=O), 78.8 (CHOH), 59.9 (CHNH), 50.5 (CH_2N_3), 32.5 ($\text{CH}_2\text{C=O}$), 32.0 (CH_2CHOH), 29.5 (CH_2CHNH), 24.6 ($\text{CH}_2\text{CH}_2\text{N}_3$), 20.7 ($\text{CH}_2\text{CH}_2\text{CHOH}$)

HRMS (ESI^+) m/z / Da = 235.1174, $[\text{M}+\text{Na}]^+$ found, $[\text{C}_9\text{H}_{16}\text{N}_4\text{NaO}_2]^+$ requires 235.1171

$[\alpha]_D^{20}$ / $^{\circ}\text{10}^{-1}\text{cm}^2\text{g}^{-1}$ = -10.2 (c / g(100 mL)^{-1} = 0.5, MeOH)

1.55 4-Azido-*N*-((1*R*,2*R*)-2-hydroxycyclopentyl)butanamide **160**



4-Chloro-*N*-((1*S*,2*S*)-2-hydroxycyclopentyl)butanamide **156** (35.0 mg, 0.170 mmol, 1 eq.) and NaN_3 (22.1 mg, 0.340 mmol, 2 eq.) were stirred in acetonitrile (2 ml) at 50 $^{\circ}\text{C}$ for 24 h. The reaction mixtures was then partitioned between water (20 ml) and 10 % *i*-PrOH/ CHCl_3 (5 ml). The aqueous layer was extracted again with 10 % *i*-PrOH/ CHCl_3 (2×5 ml) and the combined organic fractions were dried with MgSO_4 and evaporated under reduced pressure. **159** was obtained as a white solid (16.2 mg, 0.0764 mmol, 45.0 %).

TLC R_f = 0.35 (EtOAc)

IR (neat) ν_{max} / cm^{-1} = 3286.7 (N-H and O-H), 2957.6 (C-H), 2930.6 (C-H), 2860.7 (C-H), 2094.7 (azide), 1642.2 (amide C=O)


^1H NMR (400 MHz, CDCl_3) δ / ppm = 5.82 (br s, 1 H, NH), 4.45 (br. s., 1 H, OH), 3.96 (q, J =6.6 Hz, 1 H, CHOH), 3.83 (tdd, J =8.5, 8.5, 6.0, 4.6 Hz, 1 H, CHNH), 3.37 (t, J =6.4 Hz, 2 H, CH_2N_3), 2.31 (t, J =7.2 Hz, 2 H, $\text{CH}_2\text{C=O}$), 2.09 - 2.19 (m, 1 H, CHHCHNH), 1.99 - 2.06 (m, 1 H, CHHCHOH), 1.90 - 1.97 (m, 2 H, $\text{CH}_2\text{CH}_2\text{N}_3$), 1.60 - 1.85 (m, 3 H, $\text{CH}_2\text{CHHCHOH}$), 1.42 (dq, J =12.8, 8.3 Hz, 1 H, CHHCHNH)

^{13}C NMR (101 MHz, CDCl_3) δ / ppm = 173.8 (C=O), 79.7 (CHOH), 61.0 (CHNH), 50.7 (CH_2N_3), 32.8 ($\text{CH}_2\text{C=O}$), 32.6 (CH_2CHOH), 30.5 (CH_2CHNH), 24.7 ($\text{CH}_2\text{CH}_2\text{N}_3$), 21.3 ($\text{CH}_2\text{CH}_2\text{CHOH}$)

HRMS (ESI^+) m/z / Da = 235.1178, $[\text{M}+\text{Na}]^+$ found, $[\text{C}_9\text{H}_{16}\text{N}_4\text{NaO}_2]^+$ requires 235.1171

$$[\alpha]_D^{20} / ^\circ 10^{-1} \text{cm}^2 \text{g}^{-1} = 10.0 \text{ (} c / \text{g(100 mL)}^{-1} = 0.01, \text{ MeOH)}$$

1.56 Methyl 1-cyclopropyl-6-fluoro-7-(4-(4-(((1*S*,2*S*)-2-hydroxycyclopentyl)amino)-4-oxobutyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate **161**



150 (200 mg, 0.367 mmol, 1 eq.), **153** (80 mg, 0.791 mmol, 2.1 eq.), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (112 mg, 0.584 mmol, 1.6 eq.), 1-hydroxybenzotriazole (96 mg, 0.710 mmol, 1.9 eq.) and DIPEA (192 μ l, 142 mg, 1.10 mmol, 3 eq.) were dissolved in DMF (5 ml) and stirred at r.t. for 16 h. The solvent was removed using a stream of N₂ and the residue was purified by preparatory HPLC (5-60 % acetonitrile/water over 12 min). The combined pure fractions were evaporated under reduced pressure and then partitioned between NaHCO₃ (aq., sat., 10 ml) and CH₂Cl₂ (10 ml). The organic layer was removed and the aqueous layer was extracted twice more with CH₂Cl₂ (2 \times 10 ml). The combined organic fractions were dried with MgSO₄ and evaporated under reduced pressure. **161** was obtained as a white amorphous solid (73.0 mg, 0.142 mmol, 38.7 %).

TLC R_f = 0.43 (30 % MeOH/EtOAc)

IR (neat) ν_{max} / cm⁻¹ = 2972.9 (C-H), 2901.5 (C-H), 1728.4 (ester C=O), 1656.3 (amide C=O), 1612.9 (quinolone C=O)

¹H NMR (400 MHz, DMSO d₆) δ / ppm = 8.44 (s, 1 H, *ortho* to C(=O)OCH₃), 7.75 (d, J = 13.5 Hz, 1 H, *ortho* to F), 7.70 (d, J = 7.2 Hz, 1 H, CHNH), 7.43 (d, J = 7.5 Hz, 1 H, *meta* to F), 4.74 (d, J = 4.0 Hz, 1 H, CHOH), 3.78 - 3.82 (m, 1 H, CHOH), 3.74 - 3.78 (m, 1 H, CHNH), 3.74 (s, 3 H, CH₃), 3.65 (tt, J = 7.2, 3.9 Hz, 1 H, NCH(CH₂)₂), 3.25 (t, J = 4.8 Hz, 4 H, CH₂N(CH₂CH₂)CH₂CH₂), 2.57 (br s, 4 H, CH₂N(CH₂CH₂), 2.34 (t, J = 7.4 Hz, 2 H, CH₂N(CH₂)CH₂), 2.11 (t, J = 7.4 Hz, 2 H, CH₂CH₂CH₂N(CH₂)CH₂), 1.92 (dddd, J = 13.0, 8.7, 7.3, 6.0 Hz, 1 H, CHHCHNH), 1.78 (dddd, J = 12.6, 8.9, 6.3, 6.3 Hz, 1 H, CHHCHOH), 1.69 (quin, J = 7.3 Hz, 2 H, CH₂CH₂N(CH₂)CH₂), 1.54 - 1.65 (m, 2 H, CH₂CH₂CHOH), 1.42 (ddt, J = 13.1, 8.2, 5.3, 5.3 Hz, 1 H, CHHCHOH), 1.32 (dddd, J = 13.4, 8.5, 6.8, 5.8 Hz, 1 H, CHHCHNH), 1.21 - 1.29 (m, 2 H, NCH(CH₂)₂), 1.07 - 1.13 (m, 2 H, NCH(CH₂)₂)

¹³C NMR (101 MHz, DMSO d₆) δ / ppm = 171.9 (CH₂C(=O)NH), 171.6 (C(=O)CC(=O)OCH₃), 165.0 (C(=O)OCH₃), 152.6 (d, J = 246.5 Hz, *ipso* to F), 148.3 (C=CC(=O)OCH₃), 143.9 (d, J = 10.7 Hz, *ipso* to piperazine), 138.1 (*para* to F), 121.8 (d, J = 6.4 Hz, *para* to piperazine), 111.5 (d, J = 22.4 Hz, *ortho* to C=O and *ortho* to F), 109.0 (CC(=O)OCH₃), 106.2 (*meta* to C=O and *meta* to F), 76.3 (CHOH), 57.6 (CHNH), 57.2 (C(=O)CH₂CH₂CH₂N), 52.4 (C(=O)CH₂CH₂CH₂N(CH₂CH₂), 51.3 (CH₃), 49.6 (C(=O)CH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂)


34.8 ($\text{NCH}(\text{CH}_2)_2$), 33.3 ($\text{C}(=\text{O})\text{CH}_2$), 32.2 (CH_2CHOH), 29.5 (CH_2CHNH), 22.5 ($\text{C}(=\text{O})\text{CH}_2\text{CH}_2$), 20.6 ($\text{CH}_2\text{CH}_2\text{CHOH}$), 7.6 ($\text{NCH}(\text{CH}_2)_2$)

^{19}F NMR (376.45 MHz, DMSO d_6) δ / ppm = -124.3 (ciprofloxacin F)

HRMS (ESI^+) m/z / Da = 515.2661, $[\text{M}+\text{H}]^+$ found, $[\text{C}_{27}\text{H}_{36}\text{FN}_4\text{O}_5]^+$ requires 515.2670

$[\alpha]_D^{20}$ / $^\circ 10^{-1} \text{cm}^2 \text{g}^{-1}$ = -6.0 (c / $\text{g}(100 \text{ mL})^{-1}$ = 0.05, MeOH)

1.57 Methyl 1-cyclopropyl-6-fluoro-7-(4-(4-(((1*R*,2*R*)-2-hydroxycyclopentyl)amino)-4-oxobutyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate **162**



150 (52.1 mg, 95.5 μmol , 1 eq.), **154** (19.5 mg, 193 μmol , 2 eq.), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (29.7 mg, 155 μmol , 1.6 eq.), 1-hydroxybenzotriazole (25.8 mg, 191 μmol , 2 eq.) and DIPEA (33.3 μl , 24.7 mg, 191 μmol , 2 eq.) were dissolved in DMF (2 ml) and stirred at r.t. for 16 h. The solvent was removed using a stream of N_2 and the residue was purified by preparatory HPLC (5-50 % acetonitrile/water over 15 min). The combined pure fractions were evaporated under reduced pressure and then partitioned between NaHCO_3 (aq., sat., 5 ml) and CH_2Cl_2 (5 ml). The organic layer was removed and the aqueous layer was extracted twice more with CH_2Cl_2 ($2 \times 5 \text{ ml}$). The combined organic fractions were dried with MgSO_4 and evaporated under reduced pressure. **161** was obtained as a white amorphous solid (4.9 mg, 9.5 μmol , 9.9 %).

not
done
yet?

TLC R_f = 0.38 (30 % MeOH/ CH_2Cl_2)

IR (neat) ν_{max} / cm^{-1} = 2937.7 (C-H), 1721.4 (ester C=O), 1620.5 (amide C=O and quinolone C=O)

^1H NMR (500 MHz, DMSO d_6) δ / ppm = 8.44 (s, 1 H, *ortho* to $\text{C}(=\text{O})\text{OCH}_3$), 7.75 (d, $J=13.5 \text{ Hz}$, 1 H, *ortho* to F), 7.69 (d, $J=6.9 \text{ Hz}$, 1 H, CHNH), 7.43 (d, $J=7.6 \text{ Hz}$, 1 H, *meta* to F), 4.73 (br s, 1 H, CHOH), 3.77 - 3.81 (m, 1 H, CHOH), 3.74 - 3.77 (m, 1 H, CHNH), 3.73 (s, 3 H, CH_3), 3.65 (tt, $J=6.9, 4.0 \text{ Hz}$, 1 H, $\text{NCH}(\text{CH}_2)_2$), 3.24 (br. t, $J=4.2, 4.2 \text{ Hz}$, 4 H, $\text{CH}_2\text{N}(\text{CH}_2\text{CH}_2)\text{CH}_2\text{CH}_2$), 2.55 (br t, $J=5.0, 5.0 \text{ Hz}$, 4 H, $\text{CH}_2\text{N}(\text{CH}_2)\text{CH}_2$), 2.32 (t, $J=7.2 \text{ Hz}$, 2 H, $\text{CH}_2\text{N}(\text{CH}_2)\text{CH}_2$), 2.10 (t, $J=7.4 \text{ Hz}$, 2 H, $\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{CH}_2)\text{CH}_2$), 1.92 (dddd, $J=13.0, 8.7, 7.3, 6.0 \text{ Hz}$, 1 H, CHHCHNH), 1.77 (ddt, $J=12.6, 8.9, 6.3, 6.3 \text{ Hz}$, 1 H, CHHCHOH), 1.68 (quin, $J=7.4 \text{ Hz}$, 2 H, $\text{CH}_2\text{CH}_2\text{N}(\text{CH}_2)\text{CH}_2$), 1.53 - 1.64 (m, 2 H, $\text{CH}_2\text{CH}_2\text{CHOH}$), 1.42 (ddt, $J=12.9, 8.4, 5.2, 5.2 \text{ Hz}$, 1 H, CHHCHOH), 1.31 (ddt, $J=13.0, 8.6, 6.4, 6.4 \text{ Hz}$, 1 H, CHHCHNH), 1.22 - 1.28 (m, 2 H, $\text{NCH}(\text{CHH})_2$), 1.06 - 1.12 (m, 2 H, $\text{NCH}(\text{CHH})_2$)

^{13}C NMR (126 MHz, DMSO d_6) δ / ppm = 171.9 ($\text{CH}_2\text{C}(=\text{O})\text{NH}$), 171.5 ($\text{C}(=\text{O})\text{CC}(=\text{O})\text{OCH}_3$), 165.0 ($\text{C}(=\text{O})\text{OCH}_3$), 152.6 (d, $J=247.4$ Hz, *ipso* to F), 148.2 ($\text{C}=\text{CC}(=\text{O})\text{OCH}_3$), 143.9 (d, $J=10.3$ Hz, *ipso* to piperazine), 138.1 (*para* to F), 121.7 (d, $J=6.4$ Hz, *para* to piperazine), 111.5 (d, $J=23.0$ Hz, *ortho* to C=O and *ortho* to F), 109.0 ($\text{CC}(=\text{O})\text{OCH}_3$), 106.2 (*meta* to C=O and *meta* to F), 76.2 (CHOH), 57.6 (CHNH), 57.2 ($\text{C}(=\text{O})\text{CH}_2\text{CH}_2\text{CH}_2\text{N}$), 52.4 ($\text{C}(=\text{O})\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{CH}_2\text{CH}_2)$), 51.3 (CH_3), 49.6 ($\text{C}(=\text{O})\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{CH}_2\text{CH}_2)\text{CH}_2\text{CH}_2$), 49.6 ($\text{C}(=\text{O})\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{CH}_2\text{CH}_2)\text{CH}_2\text{CH}_2$), 34.7 ($\text{NCH}(\text{CH}_2)_2$), 33.2 ($\text{C}(=\text{O})\text{CH}_2$), 32.2 (CH_2CHOH), 29.5 (CH_2CHNH), 22.5 ($\text{C}(=\text{O})\text{CH}_2\text{CH}_2$), 20.6 ($\text{CH}_2\text{CH}_2\text{CHOH}$), 7.5 ($\text{NCH}(\text{CH}_2)_2$)


^{19}F NMR (376.45 MHz, MeOD) δ / ppm = -125.47

HRMS (ESI $^+$) m/z / Da = 515.2667, $[\text{M}+\text{H}]^+$ found, $[\text{C}_{27}\text{H}_{36}\text{FN}_4\text{O}_5]^+$ requires 515.2670

$[\alpha]_D^{20}$ / $^\circ 10^{-1}\text{cm}^2\text{g}^{-1}$ = 8.0 (c / $\text{g}(100\text{ mL})^{-1}$ = 0.05, MeOH)

still
TFA
present
after
de-
salt at-
tempt

1.58 Methyl (*R*)-1-cyclopropyl-6-fluoro-4-oxo-7-(4-(4-oxo-4-((2-oxocyclopentyl)amino)butyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate **163**



Methyl 1-cyclopropyl-6-fluoro-7-(4-(4-(((1*R*,2*R*)-2-hydroxycyclopentyl)amino)-4-oxobutyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate **162** (20.0 mg, 38.9 μmol , 1 eq.) and Dess-Martin Periodane (32.8 mg, 77.4 μmol , 2 eq.) were stirred in CH_2Cl_2 (3 ml) for 6 h. The solvent was removed under reduced pressure and the residue was purified by preparatory HPLC (5-50 % acetonitrile/water over 10 min). The combined pure fractions were evaporated under reduced pressure, then NaHCO_3 (aq., sat., 30 ml) and 10 % *i*-PrOH/ CHCl_3 (30 ml) were added. The organic layer was removed and dried with MgSO_4 , then evaporated under reduced pressure. **163** was obtained as a white amorphous solid (11.3 mg, 22.0 μmol , 56.7 %).

^1H NMR (400 MHz, MeOD) δ / ppm = ??


^{13}C NMR (101 MHz, MeOD) δ / ppm = ??

^{19}F NMR (376.45 MHz, MeOD) δ / ppm = ??

HRMS (ESI $^+$) m/z / Da = 513.2495, $[\text{M}+\text{H}]^+$ found, $[\text{C}_{27}\text{H}_{34}\text{FN}_4\text{O}_5]^+$ requires 513.2513

$[\alpha]_D^{20}$ / $^\circ 10^{-1}\text{cm}^2\text{g}^{-1}$ = 6.7 (c / $\text{g}(100\text{ mL})^{-1}$ = 0.075, MeOH)

1.59 7-(4-(4-(1-(4-(((1*R*,2*R*)-2-((*tert*-butyldimethylsilyl)oxy)cyclopentyl)amino)-4-oxobutyl)-1*H*-1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid **164**



1-Cyclopropyl-6-fluoro-7-(4-(hex-5-yn-1-yl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid **176** (42.9 mg, 104 μmol , 1 eq.) and 4-azido-*N*-(((1*R*,2*R*)-2-((*tert*-butyldimethylsilyl)oxy)cyclopentyl)butanamide **187** (RR) (33.9 mg, 104 μmol , 1 eq.) were dissolved in 10 % water/*t*-BuOH (3 ml), and the mixture was degassed by bubbling N_2 through it. A solution of CuSO_4 and THPTA (104 μl , 10.4 μmol , 0.1 eq. 100 mM, aq.) was added, followed by a solution of sodium ascorbate (208 μl , 20.8 μmol , 0.2 eq., 100 mM, aq.). The mixture was stirred at room temperature under argon for 16 h, then solvent was removed under reduced pressure. The residue was partitioned between water (10 ml) and CH_2Cl_2 (10 ml), the organic layer was separated and the aqueous layer was extracted again with CH_2Cl_2 (10 ml). The combined organic layers were dried with MgSO_4 and evaporated under reduced pressure. **164** was obtained as a clear glass (67.1 mg, 90.9 μmol , 87.4 %).

IR (neat) ν_{max} / cm^{-1} = 2951.3 (C-H), 2929.2 (C-H), 2855.5 (C-H), 1741.0 (carboxylic acid C=O), 1640.3 (amide C=O), 1626.6 (quinolone C=O), 1612.3 (triazole)

^1H NMR (400 MHz, CDCl_3) δ / ppm = 8.67 (s, 1 H, *ortho* to C(=O)OH), 7.87 (d, J = 13.1 Hz, 1 H, *ortho* to F), 7.34 (s, 1 H, $\text{CH}=\text{CCH}_2$), 7.33 (d, J = 8.2 Hz, 1 H, *meta* to F), 5.92 (t, J = 6.6 Hz, 1 H, CHNH), 4.35 (t, J = 6.7 Hz, 2 H, $\text{CH}_2\text{NCH}=\text{C}$), 3.96 - 4.02 (m, 1 H, CHOSi), 3.90 - 3.96 (m, 1 H, CHNH), 3.55 (tt, J = 6.7, 4.0 Hz, 1 H, $\text{NCH}(\text{CH}_2)_2$), 3.34 (br t, J = 5.0 Hz, 4 H, $\text{CH}_2\text{N}(\text{CH}_2\text{CH}_2)\text{CH}_2\text{CH}_2$), 2.71 (t, J = 7.5 Hz, 2 H, $\text{CH}=\text{CCH}_2$), 2.66 (br s, 4 H, $\text{CH}_2\text{N}(\text{CH}_2)\text{CH}_2$), 2.46 (t, J = 7.3 Hz, 2 H, $\text{CH}_2\text{N}(\text{CH}_2)\text{CH}_2$), 2.03 - 2.22 (m, 5 H, CHHCHNH , $\text{C}(=\text{O})\text{CH}_2$ and $\text{C}(=\text{O})\text{CH}_2\text{CH}_2$), 1.65 - 1.83 (m, 4 H, CHHCHOSi , $\text{CHHCH}_2\text{CHOSi}$ and $\text{NCH}=\text{CCH}_2\text{CH}_2$), 1.47 - 1.65 (m, 4 H, CHHCHOSi , $\text{CHHCH}_2\text{CHOSi}$ and $\text{NCH}=\text{CCH}_2\text{CH}_2$), 1.33 - 1.41 (m, 3 H, CHHCHNH and $\text{NCH}(\text{CHH})_2$), 1.14 - 1.20 (m, 2 H, $\text{NCH}(\text{CHH})_2$), 0.82 (s, 9 H, $\text{C}(\text{CH}_3)_3$), 0.03 (s, 3 H, SiCH_3), 0.01 (s, 3 H, SiCH_3)

^{13}C NMR (101 MHz, CDCl_3) δ / ppm = 176.9 ($\text{C}(=\text{O})\text{CC}(=\text{O})\text{OH}$), 170.9 ($\text{CH}_2\text{C}(=\text{O})\text{NH}$), 166.9 ($\text{C}(=\text{O})\text{OH}$), 153.5 (d, J = 251.4 Hz, *ipso* to F), 147.9 ($\text{CH}=\text{CCH}_2$), 147.2 ($\text{C}=\text{CC}(=\text{O})\text{OH}$), 145.8 (d, J = 10.4 Hz, *ipso* to piperazine), 139.0 (*para* to F), 120.9 ($\text{NCH}=\text{CCH}_2$), 119.4 (d, J = 7.8 Hz, *para* to piperazine), 112.0 (d, J = 23.4 Hz, *ortho* to C=O and *ortho* to F), 107.7 ($\text{CC}(=\text{O})\text{OH}$), 104.7 (d, J = 3.5 Hz, *meta* to C=O and *meta* to F), 77.7 (CHOSi), 58.2 (CHNH), 57.9 ($\text{CH}=\text{CCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}$), 52.6 ($\text{CH}=\text{CCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{CH}_2)\text{CH}_2$), 49.5 (d, J = 6.1 Hz, $\text{CH}=\text{CCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{CH}_2\text{CH}_2)\text{CH}_2\text{CH}_2$), 48.9 (d, J = 3.5 Hz, $\text{CH}_2\text{NCH}=\text{CCH}_2$), 35.3 ($\text{NCH}(\text{CH}_2)_2$), 32.6 ($\text{C}(=\text{O})\text{CH}_2$), 32.6 (CH_2CHOSi), 29.3 (CH_2CHNH), 27.2 ($\text{CH}=\text{CCH}_2\text{CH}_2$), 26.0 - 26.3 ($\text{C}(=\text{O})\text{CH}_2\text{CH}_2$ and $\text{CH}=\text{CCH}_2\text{CH}_2\text{CH}_2$), 25.6 ($\text{C}(\text{CH}_3)_3$), 25.4 ($\text{CH}=\text{CCH}_2$), 20.4 ($\text{CH}_2\text{CH}_2\text{CHOSi}$),

17.8 ($\underline{\text{C}}(\text{CH}_3)_3$), 8.1 ($\text{NCH}(\underline{\text{C}}\text{H}_2)_2$), -4.8 ($\text{Si}\underline{\text{C}}\text{H}_3$)


^{19}F NMR (376.45 MHz, CDCl_3) δ / ppm = ??

F??

HRMS (ESI^+) m/z / Da = 738.4164, $[\text{M}+\text{H}]^+$ found, $[\text{C}_{38}\text{H}_{57}\text{FN}_7\text{O}_5\text{Si}]^+$ requires 738.4169

$[\alpha]_D^{20}$ / $^\circ 10^{-1} \text{cm}^2 \text{g}^{-1}$ = 4.5 (c / $\text{g}(100 \text{ mL})^{-1}$ = 0.2, MeOH)

1.60 1-Cyclopropyl-6-fluoro-7-(4-(4-(1-(4-(((1*S*,2*S*)-2-hydroxycyclopentyl)amino)-4-oxobutyl)-1*H*-1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 165



1-Cyclopropyl-6-fluoro-7-(4-(hex-5-yn-1-yl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid **176** (42.9 mg, 104 μmol , 1 eq.) and 4-azido-*N*-((1*S*,2*S*)-2-hydroxycyclopentyl)butanamide **159** (22.0 mg, 104 μmol , 1 eq.) were dissolved in 10 % water/*t*-BuOH (3 ml), and the mixture was degassed by bubbling N_2 through it. A solution of CuSO_4 and THPTA (104 μl , 10.4 μmol , 0.1 eq. 100 mM, aq.) was added, followed by a solution of sodium ascorbate (208 μl , 20.8 μmol , 0.2 eq., 100 mM, aq.). The mixture was stirred at room temperature under argon for 16 h. Water (30 ml) and CH_2Cl_2 (30 ml) were added, the organic layer was separated and the aqueous layer was extracted again with CH_2Cl_2 (4 \times 30 ml). The combined organic layers were dried with MgSO_4 and evaporated under reduced pressure. The residue was purified by preparatory HPLC (5-95 % acetonitrile/water over 20 min). The combined pure fractions were evaporated under reduced pressure and then partitioned between NaHCO_3 (aq., sat., 10 ml) and 10 % *i*-PrOH/ CHCl_3 (10 ml). The organic layer was dried with MgSO_4 and evaporated under reduced pressure. **164** was obtained as a white amorphous solid (17.6 mg, 28.2 μmol , 27.1 %).

IR (neat) ν_{max} / cm^{-1} = 2967.0 (C-H), 2902.2 (C-H), 1721.4 (carboxylic acid C=O), 1646.7 (amide C=O), 1627.0 (quinolone C=O), 1613.0 (triazole)

^1H NMR (700 MHz, $\text{DMSO}-d_6$) δ / ppm = 8.64 (s, 1 H, *ortho* to C(=O)OH), 7.87 (d, J = 13.3 Hz, 1 H, *ortho* to F), 7.84 (s, 1 H, $\underline{\text{C}}\text{H}=\text{CCH}_2$), 7.75 (d, J = 7.1 Hz, 1 H, $\text{CHN}\underline{\text{H}}$), 7.54 (d, J = 7.5 Hz, 1 H, *meta* to F), 4.73 (d, J = 3.8 Hz, 1 H, $\text{CHO}\underline{\text{H}}$), 4.29 (t, J = 6.9 Hz, 2 H, $\underline{\text{C}}\text{H}_2\text{NCH}=\text{C}$), 3.78 - 3.83 (m, 1 H, $\text{NCH}(\underline{\text{C}}\text{H}_2)_2$), 3.75 - 3.78 (m, 1 H, $\underline{\text{C}}\text{HOH}$), 3.71 - 3.75 (m, 1 H, $\text{CH}\underline{\text{N}}\text{H}$), 3.31 (br t, J = 4.3 Hz, 4 H, $\text{CH}_2\text{N}(\underline{\text{C}}\text{H}_2\text{CH}_2)\text{CH}_2\underline{\text{C}}\text{H}_2$), 2.63 (t, J = 7.5 Hz, 2 H, $\text{CH}=\text{CCH}_2$), 2.56 (br t, J = 4.2 Hz, 4 H, $\text{CH}_2\text{N}(\underline{\text{C}}\text{H}_2)\underline{\text{C}}\text{H}_2$), 2.37 (t, J = 7.3 Hz, 2 H, $\underline{\text{C}}\text{H}_2\text{N}(\text{CH}_2)\text{CH}_2$), 2.03 - 2.06 (m, 2 H, $\text{C}(=\text{O})\underline{\text{C}}\text{H}_2$), 1.97 - 2.02 (m, 2 H, $\text{C}(=\text{O})\text{CH}_2\underline{\text{C}}\text{H}_2$), 1.89 (dddd, J = 13.1, 8.9, 7.4, 5.7 Hz, 1 H, $\text{CH}\underline{\text{H}}\text{CHN}\underline{\text{H}}$), 1.75 (ddt, J = 13.0, 8.9, 6.4, 6.4 Hz, 1 H, $\text{CH}\underline{\text{H}}\text{CHOH}$), 1.61 - 1.66

(m, 2 H, CH=CCH₂CH₂), 1.57 - 1.61 (m, 1 H, CHHCH₂CHOH), 1.54 - 1.57 (m, 1 H, CHHCH₂CHOH), 1.49 - 1.53 (m, 2 H, CH=CCH₂CH₂CH₂), 1.40 (ddt, *J* = 13.0, 8.4, 5.3, 5.3 Hz, 1 H, CHHCHOH), 1.29 - 1.32 (m, 2 H, NCH(CHH)₂), 1.25 - 1.29 (m, 1 H, CHHCHNH), 1.13 - 1.20 (m, 2 H, NCH(CHH)₂)


¹³C NMR (175 MHz, DMSO d₆) δ / ppm = 176.3 (C(=O)CC(=O)OH), 170.9 (CH₂C(=O)NH), 166.1 (C(=O)OH), 153.0 (d, *J* = 251.4 Hz, *ipso* to F), 147.9 (C=CC(=O)OH), 146.9 (CH=CCH₂), 145.2 (d, *J* = 8.7 Hz, *ipso* to piperazine), 139.2 (*para* to F), 121.7 (NCH=CCH₂), 118.7 (d, *J* = 5.8 Hz, *para* to piperazine), 111.0 (d, *J* = 23.3 Hz, *ortho* to C=O and *ortho* to F), 106.3 (*meta* to C=O and *meta* to F and CC(=O)OH), 76.2 (CHOH), 57.6 (CHNH), 57.4 (CH=CCH₂CH₂CH₂CH₂N), 52.5 (CH=CCH₂CH₂CH₂CH₂N(CH₂CH₂)), 49.5 (d, *J* = 4.4 Hz, CH=CCH₂CH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂), 48.8 (CH₂NCH=CCH₂), 35.8 (NCH(CH₂)₂), 32.2 (CH₂CHOH), 32.0 (C(=O)CH₂), 29.5 (CH₂CHNH), 26.9 (CH=CCH₂CH₂), 26.0 (C(=O)CH₂CH₂), 25.8 (CH=CCH₂CH₂CH₂), 25.0 (CH=CCH₂), 20.5 (CH₂CH₂CHOH), 7.6 (NCH(CH₂)₂)

¹⁹F NMR (376.45 MHz, MeOD) δ / ppm = -122.12 (s, ciprofloxacin F)

HRMS (ESI⁺) *m/z* / Da = 624.3314, [M+H]⁺ found, [C₃₂H₄₃FN₇O₅]⁺ requires 624.3310

$[\alpha]_D^{20}$ / °10⁻¹cm²g⁻¹ = -3.6 (*c* / g(100 mL)⁻¹ = 0.0833, MeOH)

1.61 1-Cyclopropyl-6-fluoro-7-(4-(4-(1-(4-(((1*R*,2*R*)-2-hydroxycyclopentyl)amino)-4-oxobutyl)-1*H*-1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 166



Method?? white amorphous solid 7.2 mg, 11.5 μ mol

IR (neat) ν_{max} / cm⁻¹ = 2954.9 (C-H), 2917.9 (C-H), 2850.2 (C-H), 1722.1 (carboxylic acid C=O), 1647.3 (amide C=O), 1626.7 (quinolone C=O) 1611.9 (triazole)

¹H NMR (400 MHz, MeOD) δ / ppm = ??

¹³C NMR (101 MHz, MeOD) δ / ppm = ??


¹⁹F NMR (376.45 MHz, MeOD) δ / ppm = ??

HRMS (ESI⁺) *m/z* / Da = 624.3298, [M+H]⁺ found, [C₃₂H₄₃FN₇O₅]⁺ requires 624.3310

$$[\alpha]_D^{20} / ^\circ 10^{-1} \text{cm}^2 \text{g}^{-1} = -25.0 \text{ (} c / \text{g(100 mL)}^{-1} = 0.08, \text{ MeOH)}$$

explain
discrep-
ancy

1.62 (*trans*)-2-Aminocyclohexan-1-ol **167**



Cyclohexene oxide **188** (10 ml, 9.70 g, 98.8 mmol, 1 eq.), NH_3 (90 ml, 35 % w/w aq., 27.7 g, 791 mmol, 8 eq.) and MeOH (100 ml) were stirred at r.t. for 72 h. The solvent was removed by blowing a stream of N_2 over it, followed by evaporation under high vacuum

TLC $R_f = 0.04$ (30 % MeOH/ CH_2Cl_2)


IR (neat) $\nu_{\text{max}} / \text{cm}^{-1} = 3350.4$ (N-H), 3306.2 (br, O-H), 2926.9 (C-H), 2852.6 (C-H)

^1H NMR (400 MHz, CDCl_3) $\delta / \text{ppm} = 3.01$ (td, $J = 9.4, 4.8$ Hz, 1 H, CHOH), 2.80 - 2.92 (m, 2 H, OH and NH_2), 2.35 (ddd, $J = 11.1, 9.1, 4.1$ Hz, 1 H, CHNH_2), 1.77 - 1.84 (m, 1 H, CHHCHOH), 1.69 - 1.76 (m, 1 H, CHHCHNH_2), 1.56 - 1.66 (m, 1 H, $\text{CHHCH}_2\text{CHOH}$), 1.45 - 1.56 (m, 1 H, $\text{CHHCH}_2\text{CHNH}_2$), 1.07 - 1.19 (m, 3 H, $\text{CHHCH}_2\text{CHOH}$, $\text{CHHCH}_2\text{CHNH}_2$ and CHHCHOH), 0.94 - 1.05 (m, 1 H, CHHCHNH_2)

^{13}C NMR (101 MHz, CDCl_3) $\delta / \text{ppm} = 75.4$ (CHOH), 56.6 (CHN_2), 33.8 (CH_2CHOH and CH_2CHN_2), 24.7 ($\text{CH}_2\text{CH}_2\text{CHN}_2$), 24.6 ($\text{CH}_2\text{CH}_2\text{CHOH}$)

HRMS (ESI^+) $m/z / \text{Da} = 116.1070$, $[\text{M}+\text{H}]^+$ found, $[\text{C}_6\text{H}_{14}\text{NO}]^+$ requires 116.1070

1.63 4-Chloro-*N*-((*trans*)-2-hydroxycyclohexyl)butanamide **168**



(*Trans*)-2-aminocyclohexan-1-ol **167** (1.04 g, 9.03 mmol, 1 eq.), TEA (1.65 ml, 1.20 g, 11.8 mmol, 1.3 eq.) and CH_2Cl_2 (50 ml) were stirred at 0°C . 4-Chlorobutyryl chloride **185** (1.22 ml, 1.54 g, 10.9 mmol, 1.2 eq.) was added dropwise over 5 min. The mixture was stirred at 0°C for 30 min, then water (50 ml) was added. The organic layer was separated off, and the aqueous layer was extracted with 10 % *i*-PrOH/ CHCl_3 (2×50 ml). The combined organic layers were dried with MgSO_4 , concentrated under reduced pressure and purified by column chromatography (SiO_2 , 0-100 % EtOAc/ Et_2O). **168** was obtained as white needles (1.51 g, 6.87 mmol, 76.1 %).

TLC $R_f = 0.19$ (Et_2O)

mp $T / ^\circ\text{C} = 72.5\text{-}75.7$ (*i*-PrOH, CHCl_3)


IR (neat) $\nu_{\text{max}} / \text{cm}^{-1} = 3289.9$ (N-H), 3250.0 (O-H), 2927.6 (C-H), 2857.1 (C-H), 1629.2 (amide C=O)

^1H NMR (400 MHz, MeOD) $\delta / \text{ppm} = 3.60$ (t, $J = 6.6$ Hz, 2 H, CH_2Cl), 3.51 - 3.60 (m, 1 H, CHNH), 3.28 - 3.39 (m, 1 H, CHOH), 2.37 (td, $J = 7.4, 2.3$ Hz, 2 H, C(=O)CH_2), 2.06 (quin, $J = 7.0$ Hz, 2 H, $\text{C(=O)CH}_2\text{CH}_2$), 1.97 - 2.01 (m, 1 H, CHHCHOH), 1.85 - 1.93 (m, 1 H, CHHCHNH), 1.70 - 1.77 (m, 1 H, $\text{CHHCH}_2\text{CHOH}$), 1.64 - 1.70 (m, 1 H, $\text{CHHCH}_2\text{CHNH}$), 1.24 - 1.35 (m, 3 H, $\text{CHHCH}_2\text{CHOH}$, $\text{CHHCH}_2\text{CHNH}$ and CHHCHOH), 1.13 - 1.25 (m, 1 H, CHHCHNH_2)

^{13}C NMR (101 MHz, MeOD) $\delta / \text{ppm} = 175.0$ (C(=O)), 74.1 (CHOH), 56.3 (CHNH), 45.3 (CH_2Cl), 35.6 (CH_2CHOH), 34.5 (C(=O)CH_2), 32.7 (CH_2CHNH), 30.1 ($\text{C(=O)CH}_2\text{CH}_2$), 25.8 ($\text{CH}_2\text{CH}_2\text{CHNH}$), 25.5 ($\text{CH}_2\text{CH}_2\text{CHOH}$)

HRMS (ESI^+) $m/z / \text{Da} = 242.0925$, $[\text{M}+\text{Na}]^+$ found, $[\text{C}_{10}\text{H}_{18}\text{ClNNaO}_2]^+$ requires 242.0924

1.64 4-Azido-*N*-((*trans*)-2-hydroxycyclohexyl)butanamide **169**



4-Chloro-*N*-((*trans*)-2-hydroxycyclohexyl)butanamide **168** (345 mg, 1.57 mmol, 1 eq.) and NaN_3 (180 mg, 2.77 mmol, 1.75 eq.) were stirred in DMF (12 ml) at 50°C for 16 h. Water (50 ml) and 10 % *i*-PrOH/ CHCl_3 (50 ml) were added, and the organic layer was removed. The aqueous layer was extracted again with 10 % *i*-PrOH/ CHCl_3 (50 ml) and the combined organic fractions were dried with MgSO_4 . The solvent was evaporated under reduced pressure, and then by using a N_2 stream. **189** was obtained as large white prisms (347 mg, 1.53 mmol, 97.5 %).

TLC $R_f = 0.23$ (EtOAc)

mp $T / ^\circ\text{C} = 74.5\text{-}75.7$ (*i*-PrOH, CHCl_3)


IR (neat) $\nu_{\text{max}} / \text{cm}^{-1} = 3299.0$ (N-H), 3207.8 (O-H), 2944.3 (C-H), 2927.9 (C-H), 2859.2 (C-H), 2089.2 (azide), 1624.0 (amide C=O)

^1H NMR (400 MHz, MeOD) $\delta / \text{ppm} = 7.87$ (d, $J = 7.9$ Hz, 1 H, NH), 5.27 (d, $J = 4.3$ Hz, 1 H, OH), 3.56 (td, $J = 10.5, 4.4$ Hz, 1 H, CHNH), 3.28 - 3.41 (m, 3 H, CHOH and CH_2N_3), 2.30 (td, $J = 7.4, 2.7$ Hz, 2 H, C(=O)CH_2), 1.95 - 2.03 (m, 1 H, CHHCHOH), 1.87 (m, 3 H, $\text{C(=O)CH}_2\text{CH}_2$ and CHHCHNH), 1.70 - 1.76 (m, 1 H, $\text{CHHCH}_2\text{CHOH}$), 1.63 - 1.70 (m, 1 H, $\text{CHHCH}_2\text{CHNH}$), 1.25 - 1.38 (m, 3 H, $\text{CHHCH}_2\text{CHOH}$, $\text{CHHCH}_2\text{CHNH}$ and CHHCHOH), 1.14 - 1.24 (m, 1 H, CHHCHNH_2)

^{13}C NMR (101 MHz, MeOD) $\delta / \text{ppm} = 175.1$ (C(=O)), 74.0 (CHOH), 56.3 (CHNH), 52.0 (CH_2N_3), 35.5 (CH_2CHOH), 34.3 (C(=O)CH_2), 32.7 (CH_2CHNH), 26.3 ($\text{C(=O)CH}_2\text{CH}_2$), 25.8 ($\text{CH}_2\text{CH}_2\text{CHNH}$), 25.5 ($\text{CH}_2\text{CH}_2\text{CHOH}$)

HRMS (ESI⁺) m/z / Da = 249.1331, [M+Na]⁺ found, [C₁₀H₁₈N₄NaO₂]⁺ requires 249.1327

1.65 Methyl 1-cyclopropyl-6-fluoro-7-(4-(4-(((*trans*)-2-hydroxycyclohexyl)amino)-4-oxobutyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate 170



150 (200 mg, 0.367 mmol, 1 eq.), **167** (91.1 mg, 0.791 mmol, 2.1 eq.), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (112 mg, 0.584 mmol, 1.6 eq.), 1-hydroxybenzotriazole (96 mg, 0.710 mmol, 1.9 eq.) and DIPEA (192 μ l, 142 mg, 1.10 mmol, 3 eq.) were dissolved in DMF (5 ml) and stirred at r.t. for 16 h. The solvent was removed using a stream of N₂ and the residue was purified by preparatory HPLC (5-50 % acetonitrile/water over 10 min). The combined pure fractions were evaporated under reduced pressure and then partitioned between NaHCO₃ (aq., sat., 10 ml) and CH₂Cl₂ (10 ml). The organic layer was dried with MgSO₄ and evaporated under reduced pressure. **161** was obtained as a white amorphous solid (73.0 mg, 0.142 mmol, 38.7 %).

IR (neat) ν_{max} / cm⁻¹ = 3302.5 (N-H), 2929.8 (C-H), 2850.6 (C-H), 2832.9 (C-H), 1698.1 (ester C=O), 1646.4 (amide C=O), 1613.8 (quinolone C=O)


¹H NMR (400 MHz, MeOD) δ / ppm = 8.60 (s, 1 H, *ortho* to C(=O)OCH₃), 7.79 (d, J = 13.5 Hz, 1 H, *ortho* to F), 7.46 (d, J = 7.2 Hz, 1 H, *meta* to F), 3.84 (s, 3 H, CH₃), 3.62 - 3.68 (m, 1 H, NCH(CH₂)₂), 3.58 (td, J = 10.3, 4.2 Hz, 1 H, CHNH), 3.38 (br s, 4 H, CH₂N(CH₂CH₂)CH₂CH₂), 3.32 - 3.36 (m, 1 H, CHOH), 2.83 (br s, 4 H, CH₂N(CH₂)CH₂), 2.60 (t, J = 7.3 Hz, 2 H, C(=O)CH₂CH₂CH₂N), 2.32 (td, J = 7.1, 3.1 Hz, 2 H, C(=O)CH₂), 1.96 - 2.04 (m, 1 H, CHHCHOH), 1.87 - 1.96 (m, 3 H, CHHCHNH and C(=O)CH₂CH₂), 1.72 - 1.77 (m, 1 H, CHHCH₂CHOH), 1.66 - 1.72 (m, 1 H, CHHCH₂CHNH), 1.25 - 1.39 (m, 5 H, CHHCHOH, CHHCH₂CHOH, CHHCH₂CHNH and NCH(CHH)₂), 1.15 - 1.25 (m, 3 H, CHHCHOH and NCH(CHH)₂)

¹³C NMR (101 MHz, MeOD) δ / ppm = 175.8 (CH₂C(=O)NH), 175.3 (C(=O)CC(=O)OCH₃), 166.8 (C(=O)OCH₃), 154.9 (d, J = 248.8 Hz, *ipso* to F), 150.2 (C=CC(=O)OCH₃), 146.1 (d, J = 10.8 Hz, *ipso* to piperazine), 139.9 (*para* to F), 123.5 (d, J = 7.5 Hz, *para* to piperazine), 113.2 (d, J = 23.2 Hz, *ortho* to C=O and *ortho* to F), 110.2 (CC(=O)OCH₃), 107.2 (*meta* to C=O and *meta* to F), 74.1 (CHOH), 58.9 (C(=O)CH₂CH₂CH₂N), 56.4 (CHNH), 54.0 (C(=O)CH₂CH₂CH₂N(CH₂)CH₂), 52.3 (CH₃), 50.5 (d, J = 5.0 Hz, C(=O)CH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂), 36.4 (NCH(CH₂)₂), 35.7 (CH₂CHOH), 35.1 (C(=O)CH₂), 32.8 (CH₂CHNH), 25.9 (CH₂CH₂CHNH), 25.5 (CH₂CH₂CHOH), 23.5 (C(=O)CH₂CH₂), 8.7 (NCH(CH₂)₂)

¹⁹F NMR (376.45 MHz, MeOD) δ / ppm = -124.7 (ciprofloxacin F)

HRMS (ESI⁺) m/z / Da = 529.2827, [M+H]⁺ found, [C₂₈H₃₈N₄O₅]⁺ requires 529.2826

1.66 Methyl 1-cyclopropyl-6-fluoro-4-oxo-7-(4-(4-oxo-4-((2-oxocyclohexyl)amino)-butyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate **171**



Methyl 1-cyclopropyl-6-fluoro-7-(4-(4-(((trans)-2-hydroxycyclohexyl)amino)-4-oxobutyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate **170** (5.2 mg, 9.84 μ mol, 1 eq.) and Dess-Martin Periodane (16.4 mg, 38.7 μ mol, 4 eq.) were stirred in CH_2Cl_2 (3 ml) for 6 h. The solvent was removed under reduced pressure and the residue was purified by preparatory HPLC (5-95 % acetonitrile/water over ??)

TLC R_f = 0.74 (30 % MeOH/ CH_2Cl_2)

IR (neat) ν_{max} / cm^{-1} = 2921.2 (C-H), 2851.6 (C-H), 1721.4 (ketone C=O), 1698.0 (ester C=O), 1639.3 (amide C=O), 1620.0 (quinolone C=O)


^1H NMR (400 MHz, DMSO d_6) δ / ppm = 8.45 (s, 1 H, *ortho* to C(=O)OCH₃), 7.87 (d, J = 6.2 Hz, 1 H, NH), 7.76 (d, J = 13.4 Hz, 1 H, *ortho* to F), 7.44 (d, J = 7.5 Hz, 1 H, *meta* to F), 4.42 (dddd, J = 13.0, 7.6, 6.0, 1.0 Hz, 1 H, CHNH), 3.73 (s, 3 H, CH₃), 3.65 (tt, J = 7.1, 3.9 Hz, 1 H, NCH(CH₂)₂), 3.25 (br s, 4 H, CH₂N(CH₂CH₂)CH₂CH₂), 2.58 (br s, 4 H, CH₂N(CH₂)CH₂), 2.45 - 2.53 (m, 1 H, CHHC(=O)CHNH), 2.36 (br s, 2 H, C(=O)CH₂CH₂CH₂N), 2.26 (dt, J = 13.4, 2.6, 2.6, 1.6, 1.6 Hz, 1 H, CHHC(=O)CHNH), 2.16 - 2.22 (m, 2 H, C(=O)CH₂CH₂CH₂N), 2.12 (ddq, J = 12.7, 6.0, 2.8, 2.8, 2.8 Hz, 1 H, CHHCHNH), 2.00 (ddquin, J = 13.2, 6.0, 2.9, 2.9, 2.9, 2.9 Hz, 1 H, CHHCH₂C(=O)), 1.65 - 1.83 (m, 4 H, CH₂CH₂CHNH), 1.41 - 1.56 (m, 2 H, CHHCHNH and CHHCH₂C(=O)), 1.20 - 1.30 (m, 2 H, NCH(CH₂)₂), 1.05 - 1.13 (m, 2 H, NCH(CH₂)₂)

^{13}C NMR (101 MHz, DMSO d_6) δ / ppm = 207.5 (C(=O)CHNH), 171.7 (C(=O)CC(=O)OCH₃), 171.6 (CH₂C(=O)NH), 165.0 (C(=O)OCH₃), 152.6 (d, J = 247.6 Hz, *ipso* to F), 148.3 (C=CC(=O)OCH₃), 143.9 (br s, *ipso* to piperazine), 138.1 (*para* to F), 121.8 (d, J = 6.4 Hz, *para* to piperazine), 111.5 (d, J = 22.4 Hz, *ortho* to C=O and *ortho* to F), 109.0 (CC(=O)OCH₃), 106.3 (*meta* to C=O and *meta* to F), 57.0 (CHNH and C(=O)CH₂CH₂CH₂N), 52.3 (br s, C(=O)CH₂CH₂CH₂N(CH₂)CH₂), 51.3 (CH₃), 49.5 (br s, C(=O)CH₂CH₂CH₂N(CH₂)CH₂CH₂), 40.6 (CH₂C(=O)CHNH), 34.8 (NCH(CH₂)₂), 33.9 (CH₂CHNH), 32.9 (C(=O)CH₂CH₂CH₂N), 27.2 (CH₂CH₂C(=O)CHNH), 23.8 (CH₂CH₂CHNH), 22.4 (br s, C(=O)CH₂CH₂CH₂N), 7.6 (NCH(CH₂)₂)

^{19}F NMR (376.45 MHz, DMSO d_6) δ / ppm = -124.3 (ciprofloxacin F)

HRMS (ESI⁺) m/z / Da = 527.2654, [M+H]⁺ found, [C₂₈H₃₆FN₄O₅]⁺ requires 527.2670

1.67 1-Cyclopropyl-6-fluoro-7-(4-(4-(1-(4-(((*trans*)-2-hydroxycyclohexyl)amino)-4-oxobutyl)-1H-1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid **172**



1-Cyclopropyl-6-fluoro-7-(4-(hex-5-yn-1-yl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid **176** (40 mg, 97.2 μ mol, 1 eq.) and 4-azido-*N*-((*trans*)-2-hydroxycyclohexyl)butanamide **169** (22.0 mg, 97.2 μ mol, 1 eq.) were dissolved in 10 % water/*t*-BuOH (3 ml), and the mixture was degassed by bubbling N₂ through it. A solution of CuSO₄ and THPTA (97.2 μ l, 9.72 μ mol, 0.1 eq. 100 mM, aq.) was added, followed by a solution of sodium ascorbate (194 μ l, 19.4 μ mol, 0.2 eq., 100 mM, aq.). The mixture was stirred at r.t. under argon for 16 h. Water (50 ml) and 10 % *i*-PrOH/CHCl₃ (50 ml) were added, then the organic layer was separated and dried with MgSO₄ and evaporated under reduced pressure. The residue was purified by preparatory HPLC (5-70 % acetonitrile/water over 15 min). The combined pure fractions were evaporated under reduced pressure and then partitioned between NaHCO₃ (aq., sat., 50 ml) and 10 % *i*-PrOH/CHCl₃ (50 ml). The organic layer was dried with MgSO₄ and evaporated under reduced pressure. **172** was obtained as a white amorphous solid (30.3 mg, 47.5 μ mol, 48.9 %).

IR (neat) ν_{max} / cm⁻¹ = 3345.4 (N-H), 2927.6 (C-H), 2859.6 (C-H), 2814.7 (C-H), 1727.0 (carboxylic acid C=O), 1641.7 (amide C=O), 1625.8 (quinolone C=O), 1619.0 (triazole)

¹H NMR (400 MHz, DMSO d₆) δ / ppm = 8.64 (s, 1 H, *ortho* to C(=O)OH), 7.86 (d, *J* = 13.9 Hz, 1 H, *ortho* to F), 7.84 (s, 1 H, CH=CCH₂), 7.64 (d, *J* = 8.1 Hz, 1 H, NH), 7.54 (d, *J* = 7.5 Hz, 1 H, *meta* to F), 4.54 (d, *J* = 4.7 Hz, 1 H, OH), 4.30 (t, *J* = 6.8 Hz, 2 H, C(=O)CH₂CH₂CH₂N), 3.77 - 3.86 (m, 1 H, NCH(CH₂)₂), 3.33 - 3.40 (m, 1 H, CHNH), 3.31 (br t, *J* = 4.8, 4.8 Hz, 4 H, CH=CCH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂), 3.14 - 3.24 (m, 1 H, CHOH), 2.63 (t, *J* = 7.4 Hz, 2 H, CH=CCH₂), 2.56 (br t, *J* = 4.6, 4.6 Hz, 4 H, CH=CCH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂), 2.38 (t, *J* = 6.9 Hz, 2 H, CH=CCH₂CH₂CH₂CH₂N), 2.04 - 2.08 (m, 2 H, C(=O)CH₂CH₂CH₂N), 1.96 - 2.04 (m, 2 H, C(=O)CH₂CH₂CH₂N), 1.78 - 1.87 (m, 1 H, CHHCHOH), 1.69 - 1.78 (m, 1 H, CHHCHNH), 1.63 (quin, *J* = 7.5 Hz, 2 H, CH=CCH₂CH₂CH₂CH₂N), 1.54 - 1.60 (m, 1 H, CHHCH₂OH), 1.51 (quin, *J* = 7.4 Hz, 2 H, CH=CCH₂CH₂CH₂CH₂N), 1.28 - 1.35 (m, 1 H, NCH(CH₂)₂), 1.11 - 1.22 (m, 5 H, NCH(CH₂)₂, CHHCHOH, CHHCH₂CHOH and CH₂CH₂CHNH), 1.04 - 1.13 (m, 1 H, CHHCHNH)


¹³C NMR (101 MHz, DMSO d₆) δ / ppm = 176.4 (C(=O)CC(=O)OH), 170.9 (CH₂C(=O)NH), 166.0 (C(=O)OH), 153.1 (d, *J* = 252.1 Hz, *ipso* to F), 148.0 (C=CC(=O)OH), 146.9 (CH=CCH₂), 145.3 (d, *J* = 10.0 Hz, *ipso* to piperazine), 139.2 (*para* to F), 121.8 (NCH=CCH₂), 118.5 (d, *J* = 8.3 Hz, *para* to piperazine), 110.9 (d, *J* = 23.2 Hz, *ortho* to C=O and *ortho* to F), 106.7 (CC(=O)OH), 106.3 (d, *J* = 3.3 Hz, *meta* to C=O and *meta* to F), 71.4 (CHOH), 57.4 (CH=CCH₂CH₂CH₂CH₂N), 54.2 (CHNH), 52.4 (CH=CCH₂CH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂), 49.5 (CH=CCH₂CH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂), 48.8 (C(=O)CH₂CH₂CH₂NCH=C), 35.9 (NCH(CH₂)₂), 34.1 (CH₂CHOH), 32.3 (C(=O)CH₂CH₂CH₂NCH=C), 31.1

(CH₂CHNH), 26.9 (CH=CCH₂CH₂CH₂CH₂N), 26.1 (C(=O)CH₂CH₂CH₂NCH=C), 25.8 (CH=CCH₂CH₂CH₂CH₂N), 25.0 (CH=CCH₂CH₂CH₂CH₂N), 24.2 (CH₂CH₂CHNH), 23.8 (CH₂CH₂CHOH), 7.6 (NCH(CH₂)₂)

¹⁹F NMR (376.45 MHz, DMSO d₆) δ / ppm = -121.4 (ciprofloxacin F)

HRMS (ESI⁺) *m/z* / Da = 638.3480, [M+H]⁺ found, [C₃₃H₄₅FN₇O₅]⁺ requires 638.3466

1.68 1-Cyclopropyl-6-fluoro-4-oxo-7-(4-(4-(1-(4-oxo-4-((2-oxocyclohexyl)amino)butyl)-1H-1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid **173**



1-Cyclopropyl-6-fluoro-7-(4-(4-(1-(4-(((trans)-2-hydroxycyclohexyl)amino)-4-oxobutyl)-1H-1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid **172** (15.0 mg, 23.6 μmol, 1 eq.) and Dess-Martin Periodane (35.0 mg, 82.5 μmol, 3.5 eq.) were stirred in CH₂Cl₂ (3 ml) for 4 h. The solvent was removed under reduced pressure and the residue was purified by preparatory HPLC (5-70 % acetonitrile/water over 15 min). The combined pure fractions were evaporated under reduced pressure clear gum (11.7 mg, 18.4 μmol, 78.0 %).

IR (neat) ν_{max} / cm⁻¹ = 2941.2 (C-H), 2859.8 (C-H), 1719.8 (carboxylic acid C=O and ketone C=O), 1656.8 (amide C=O), 1625.6 (quinolone C=O), 1613.5 (triazole)

¹H NMR (500 MHz, DMSO d₆) δ / ppm = 8.65 (s, 1 H, *ortho* to C(=O)OH), 7.94 (d, J=7.7 Hz, 1 H, NH), 7.88 (d, J=13.4 Hz, 1 H, *ortho* to F), 7.85 (s, 1 H, CH=CCH₂), 7.55 (d, J=7.3 Hz, 1 H, *meta* to F), 4.40 (dddd, J=12.8, 7.6, 6.1, 1.1 Hz, 1 H), 4.31 (t, J=7.0 Hz, 1 H, C(=O)CH₂CH₂CHNH), 4.31 (t, J=6.9 Hz, 1 H, C(=O)CH₂CH₂CH₂N), 3.74 - 3.84 (m, 1 H, NCH(CH₂)₂), 3.31 (br. s, 4 H, CH=CCH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂), 2.64 (t, J=7.5 Hz, 2 H, CH=CCH₂), 2.56 (br t, J=5.0, 5.0 Hz, 4 H, CH=CCH₂CH₂CH₂N(CH₂)CH₂), 2.45 - 2.52 (m, 1 H, CHHC(=O)), 2.38 (t, J=7.1 Hz, 2 H, CH=CCH₂CH₂CH₂CH₂N), 2.25 (dtt, J=13.4, 2.6, 2.6, 1.6, 1.6 Hz, 1 H, CHHC(=O)), 2.07 - 2.17 (m, 3 H, C(=O)CH₂CH₂CH₂N and CHHCNH), 1.96 - 2.05 (m, 3 H, C(=O)CH₂CH₂CH₂N and CHHCCH₂C(=O)), 1.68 - 1.81 (m, 2 H, CHHCCH₂CHNH), 1.64 (quin, J=7.5 Hz, 2 H, CH=CCH₂CH₂CH₂CH₂N), 1.40 - 1.56 (m, 5 H, CHHCCH₂C(=O), CHHCNH and CH=CCH₂CH₂CH₂CH₂N), 1.27 - 1.34 (m, 2 H, NCH(CH₂)₂), 1.13 - 1.20 (m, 2 H, NCH(CH₂)₂)

¹³C NMR (126 MHz, DMSO d₆) δ / ppm = 207.4 (C(=O)CHNH), 176.3 (C(=O)CC(=O)OH), 170.8 (CH₂C(=O)NH), 166.0 (C(=O)OH), 153.0 (d, J=246.4 Hz, *ipso* to F), 147.9 (C=CC(=O)OH), 146.8 (CH=CCH₂), 145.1 (d, J=10.1 Hz, *ipso* to piperazine), 139.1 (*para* to F), 121.7 (NCH=CCH₂), 118.7 (d, J=6.9 Hz, *para* to piperazine), 110.9 (d, J=23.0 Hz, *ortho* to C=O and *ortho* to F), 106.3 (CC(=O)OH, and *meta* to C=O and *meta* to F), 57.3 (CH=CCH₂CH₂CH₂CH₂N), 57.0 (CHNH), 52.4 (CH=CCH₂CH₂CH₂CH₂N(CH₂)CH₂), 49.5 (CH=CCH₂CH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂), 48.7 (C(=O)CH₂CH₂C(=O)OH)

40.5 (CH₂C(=O)), 35.8 (NCH(CH₂)₂), 33.7 (CH₂CHNH), 31.8 (C(=O)CH₂CH₂CH₂NCH=C), 27.1 (CH₂CH₂C(=O)), 26.9 (CH=CCH₂CH₂CH₂CH₂N), 26.0 (C(=O)CH₂CH₂CH₂CH₂NCH=C), 25.7 (CH=CCH₂CH₂CH₂CH₂N), 24.9 (CH=CCH₂CH₂CH₂CH₂N), 23.8 (CH₂CH₂CHNH), 7.6 (NCH(CH₂)₂)

¹⁹F NMR (376 MHz, DMSO d₆) δ / ppm = -121.67 (s, ciprofloxacin F)

some
TFA

HRMS (ESI⁺) *m/z* / Da = 636.3303, [M+H]⁺ found, [C₃₃H₄₃FN₇O₅]⁺ requires 636.3310

2 References

- [1] Y. Baker. Novel Affinity Based Probes for Use in Chemical Proteomic Studies. 2012.
- [2] J. D. Scribner, D. L. Smith and J. A. McCloskey. Meldrum's Acid in Organic Synthesis. 2. A General and Versatile Synthesis of β -Keto Esters. *The Journal of Organic Chemistry*, 43(10):2087–2088. 1978.
- [3] J. T. Hodgkinson. The synthesis of Pseudomonas Quinolone Signal analogues and their effects on quinolone signalling in *Pseudomonas aeruginosa*. PhD thesis, University of Cambridge. 2011.
- [4] D. M. Stacy, S. T. Le Quement, C. L. Hansen, J. W. Clausen, T. Tolker-Nielsen, J. W. Brummond, M. Givskov, T. E. Nielsen and H. E. Blackwell. Synthesis and biological evaluation of triazole-containing N-acyl homoserine lactones as quorum sensing modulators. *Organic & Biomolecular Chemistry*, 11(6):938–954. 2013.
- [5] T. Persson, T. H. Hansen, T. B. Rasmussen, M. E. Skindersø, M. Givskov and J. Nielsen. Rational design and synthesis of new quorum-sensing inhibitors derived from acylated homoserine lactones and natural products from garlic. 38:253–262. 2005.
- [6] L. S. Kocsis, E. Benedetti and K. M. Brummond. LETTERS A Thermal Dehydrogenative Diels À Alder Reaction of Styrenes for the Concise Synthesis of Functionalized Naphthalenes. *Organic Letters*, 14(17):4430–4433. 2012.
- [7] S. Information, F. Tmp, H. Signal, B. Intracellular, L. Cell, I. Chaoran, V. W. Cornish, N. W. C. Building, N. York, C. Molecular, S. Chemistry, D. Mutagenesis, C. B. Methods, F. Characterization and C. Jing. A fluorogenic TMP-tag for high signal-to-background intracellular live cell imaging. *ACS chemical biology*, 8(8):1704–12. 2013.
- [8] K. Sachin, E.-M. Kim, S.-J. Cheong, H.-J. Jeong, S. T. Lim, M.-H. Sohn and D. W. Kim. Synthesis of N₄'-[¹⁸F]fluoroalkylated ciprofloxacin as a potential bacterial infection imaging agent for PET study. *Bioconjugate chemistry*, 21(12):2282–2288. 2010.
- [9] K. Ganguly, R. Wu, M. Ollivault-Shiflett, P. M. Goodwin, L. A. Silks and R. Iyer. Design, synthesis, and a novel application of quorum-sensing agonists as potential drug-delivery vehicles. *Journal of drug targeting*, 19(7):528–539. 2011.
- [10] R. Iyer, K. Ganguly and L. A. Silks. Synthetic analogs of bacterial quorum sensors. 2012.
- [11] R. Srinivasan, L. P. Tan, H. Wu, P.-Y. Yang, K. A. Kalesh and S. Q. Yao. High-throughput synthesis of azide libraries suitable for direct "click" chemistry and in situ screening. *Organic & Biomolecular Chemistry*, 7(9):1821. 2009.
- [12] J. Aubé, Michael S. Wolfe, R. K. Yantiss, S. M. Cook, F. Takusagawa, M. S. Wolfe, R. K. Yantiss, S. M. Cook and F. Takusagawa. Synthesis of Enantiopure N-tert-Butoxycarbonyl-2- aminocycloalkanones. *Synthetic Communications*, 22(20):3003–3012. 1992.
- [13] L. E. Overman, S. Sugai, L. E. Overman and S. Sugai. A Convenient Method for Obtaining trans -2-Aminocyclohexanol and trans -2-Aminocyclopentanol in Enantiomerically Pure Form. *The Journal of Organic Chemistry*, 50:4154–4155. 1985.
- [14] L. E. Overman and S. Sugai. Total Synthesis of (-)-Crinine. Use of Tandem Cationic Aza-Cope Rearrangement/Mannich Cyclizations for the Synthesis of Enantiomerically Pure Amaryllidaceae Alkaloids. *Helvetica Chimica Acta*, 68(3):745–749. 1985.

- [15] I. Schiffrers, T. Rantanen, F. Schmidt, W. Bergmans, L. Zani and C. Bolm. Resolution of racemic 2-aminocyclohexanol derivatives and their application as ligands in asymmetric catalysis. *The Journal of organic chemistry*, 71(1):2320–2331. 2006.